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Abstract 
Innate immunity utilises a series of pathogen associated molecular pattern receptors 
such as the Toll-like receptors (TLRs) to detect and respond to invading 
microorganisms. The different TLRs play a pivotal role in the first line of defence by 
recognising the type of pathogenic threat encountered and by responding in kind. 
TLR pathogen interaction triggers the production of a number of pro-inflammatory 
cytokines and anti-viral mediators to initiate the process of microbial elimination. 
However, if left unregulated, such immunostimulatory and cytotoxic factors have the 
potential to cause grievous harm to the host and can facilitate and propagate 
autoimmune disease. Therefore, the TLR signalling response is under the control of 
stringent regulatory mechanisms to prevent self-harm. In this thesis, the generation 
and characterisation of a genetically deficient Pellino3 mouse is described. Pellino3 
is a member of the highly evolutionary conserved Pellino family of E3 ubiquitin 
ligases. Using this model, the physiological role of Pellino3 in TLR signalling is 
delineated. Peli3-deficient mice display no obvious abnormalities in cytokine 
production in response to pathogenic bacterial and fungal ligands. Pellino3 functions 
as a specific regulator of anti-viral type 1 interferon production in response to double 
stranded viral RNA recognition by TLR3. Pellino3-deficient mice are more resistant 
to the pathogenic and lethal effects of encephalomycarditis virus (EMCV) infection. 
Pellino3 functions in a novel auto-regulatory mechanism to specifically prevent 
excessive TLR3 induced expression of type 1 IFNs but leaves pro-inflammatory 
cytokine production intact. TLR3 signalling induces Pellino3 expression which in 
turn interacts with TRAF6 and facilitates its polyubiquitination. This modification of 
TRAF6 suppresses its ability to bind and ubiquitinate a key anti-viral transcription 
factor IRF7, thereby down regulating the type 1 IFN response. The findings outlined 
in this thesis define for the first time, a physiological role for Pellino3. 
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1.1 The Immune System 
Since the initial discoveries of Robert Koch and Louis Pasteur in the late 19
th
 century 
that microorganisms acted as the agents of infectious disease, the search for the 
mechanisms of protection to pathogens such as bacteria, viruses, fungi and protozoa 
have been sought. An overarching multicomponent defence organisation known as 
the immune system is now known to confer such host protection. The immune 
system is comprised of a plethora of cells, tissues and molecules that can respond to 
and defend the body against pathogenic infection. The initiation of the immune 
response is a complex, highly regulated and ordered process that tailors a selective 
protective reaction to specific microbial insult. The immune system is broadly 
categorised into two independent but fundamentally linked branches known as innate 
and adaptive immunity. This distinction is largely based upon the speed and 
longevity of the initial response, the central effector cell type functions and their 
specificity for individual microbial epitopes. Both are vitally important in 
maintaining host pathogen homeostasis as evidenced by the severe pathology 
witnessed in subjects with genetic abnormalities or acquired deficiencies in either 
component. For example, patients with inherited deficiencies in a key innate immune 
cell known as the neutrophil, result in a disorder known as Severe Congenital 
Neutropenia (SCN). SCN is characterised by severe, chronic and recurrent infections 
initially manifesting in one month old infants, and if left untreated, the infections 
often prove lethal by the second year of life (Kostmann, 1956). Conversely, T cells 
play a central role in the adaptive immune response and deficiencies in a subset 
known as CD4
+ 
helper T cells caused by Human Immunodeficiency Virus (HIV) 
lead to a major increase in susceptibility to life threatening infections and diseases 
(Hirschtick et al., 1995). It is clear from above that both innate and adaptive 
immunity must play fundamental roles in mediating host protection. However, it is 
both the division of labour and interplay between these very different systems that 
allows efficient recognition and elimination of invading pathogens. 
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1.2 Innate Immunity  
The innate immune system represents the first line of defence to pathogenic infection. 
It plays a fundamental role in the initial detection and establishment of the pro-
inflammatory and anti-viral response upon pathogenic infiltration of the host. This in 
turn drives the activation and polarisation of adaptive immunity leading to the 
efficient, antigen-specific elimination of the invading microorganism and the 
subsequent development of adaptive immunological memory to quickly combat re-
infection.  
Initially, physical and chemical barriers function in tandem to prevent pathogenic 
microorganism establishment in the host. Mechanical blockage is achieved by the 
tight junctions formed between cells of the epidermis and epithelial cells lining the 
internal mucosal layers (Guttman and Finlay, 2009). Specialised cells in 
anatomically distinct regions are aided in pathogen clearance by physiological 
functions such as cilial action, motility, desquamation and mucus secretion which all 
inhibit microbial adherence to host surfaces (Basset et al., 2003). Chemical defence 
mechanisms include the release of anti-microbial enzymes such as lysozyme which 
degrades bacterial peptidoglycan, a vital component of bacterial cell membranes 
(Dajani et al., 2005). The release of growth sequestering agents such as lactoferrin, a 
chelating enzyme that binds iron with high affinity, also acts as an effective deterrent 
to microbial survival (Arnold et al., 1980). In addition to such broad spectrum 
defence tactics, the innate immune system can also initiate immunological protection 
with a degree of relative specificity. The complement system is comprised of a 
number of soluble serum and membrane bound proteins that participate in a tightly 
regulated network to initiate an inflammatory cytolytic cascade in response to 
invading microorganisms (Dunkelberger and Song, 2010). During lectin-mediated 
complement activation, mannose-binding lectin (MBL) recognises and binds to 
carbohydrate moieties (N-acetylglucosamine, mannose, fucose or glucose) located 
on the surface of pathogens (Ikeda et al., 1987). Upon MBL pathogen binding, MBL 
undergoes a conformational change allowing the recruitment of the MBL-associated 
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serine proteases (MASPs) which cleave key downstream complement proteins C4 
and C2 facilitating complement cascade activation (Matsushita and Fujita, 1992, Ji et 
al., 1993, Thiel et al., 1997).  This allows for the formation of the membrane attack 
complex which can result in damage to pathogen cellular integrity and direct cell 
death (Esser, 1994). In addition, complement deposition of C3b on the surface of 
cells from pathogens results in their opsonisation and increases their potential to be 
recognised and phagocytosed by the cellular component of innate immunity 
(Ehlenberger and Nussenzweig, 1977). 
Innate immune cells comprise of phagocytic macrophages, antigen-presenting 
dendritic cells (DCs), tissue resident mast cells and granulocytes such neutrophils, 
eosinophils and basophils which all originate in the bone marrow from the myeloid 
progenitor hematopoietic stem cell (Akashi et al., 2000). Natural killer cells are also 
considered part of the innate immune system although unlike their compatriot 
leukocytes, they derive from the common lymphoid progenitor stem cell (Kondo et 
al., 1997). Although the different cells of innate immunity have their own unique 
and specialised functions, they all share a number of unifying traits. Cells of innate 
immunity are immediately ready to respond to pathogenic insult, do not form 
immunological memory and do not require selection and expansion before mediating 
their immunological function. Unlike the T and B cells of adaptive immunity, innate 
leukocytes cannot initiate a specific immune response against every possible foreign 
antigen present on the pathogen. This is because the functional genes encoding key 
subunit chains of T and B cell receptors are assembled by somatic recombination 
from a multitude of separate gene segments (Siu et al., 1984, Brack et al., 1978). 
This can therefore give rise to a potentially unlimited number of different specificity 
T and B cells receptors for virtually any pathogenic antigen. Upon recognition of a 
pathogen antigen, displayed on major histocompatibility complex (MHC) class 
receptors found on innate immune leukocytes, the adaptive immune cell undergoes 
selection and clonal expansion to allow efficient combat and elimination of cells 
displaying the pathogenic antigen. (Zinkernagel and Doherty, 1974, Langhoff and 
Steinman, 1989). Although this system is extremely efficient and specific for 
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pathogen clearance, alone it would be ineffective to maintain a healthy host. A 
mature adaptive immune response can take days to develop and requires not only 
direct pathogenic antigen presentation by innate immune cells, but it is also 
completely reliant on innate immune derived cytokines and co-stimulatory molecules 
to direct an appropriate adaptive immune response. In contrast, cells of the innate 
immune response are fully capable of rapid induction of the immune responses 
whereby they can directly attack the invading microorganism and begin the process 
of adaptive immune activation. This near instant response is facilitated by their 
‘innate’ ability to detect and distinguish between different types of pathogen and 
orchestrate the appropriate immunological response to that given infection. 
1.3 Pattern Recognition Receptors (PRRs) and Pathogen 
Associated Molecular Patterns (PAMPs) 
Central to innate immune cell functionality is a series of germline encoded pattern-
recognition receptor (PRRs) families (Janeway and Medzhitov, 2002). The PRRs can 
detect and differentiate between a vast array of microorganisms by sensing 
evolutionary conserved structures that are vital for pathogen viability but not found 
in host physiology and have been termed pathogen associated molecular patterns 
(PAMPs) (Janeway, 1989). Bacterial PAMPs are often displayed on their cell surface 
allowing innate immune PPRs to recognise them extracellularly. They include 
peptidoglycan which is found on nearly all bacterial surfaces, a key component of 
the gram negative bacterial cell wall lipopolysaccharide (LPS) and flagellin, the 
major constituent protein of the motile bacterial flagella (Schwandner et al., 1999, 
Poltorak et al., 1998, Hayashi et al., 2001). Like bacteria, fungal pathogens also have 
the ability to trigger a PRR response due to the many PAMPs displayed on their 
cellular exteriors. Their cell walls are commonly constructed of chitin, glucan, 
mannan and mannoproteins and all have the ability to trigger an innate immune 
response (Reese et al., 2007, Kataoka et al., 2002, Tada et al., 2002, Bozza et al., 
2009). In contrast, viral PAMPs are often only evident during their replication cycle 
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which is predominantly inside the host cell. In accordance, PRRs for viral PAMPs 
are often located inside the host cytoplasm or on endosomal membranes. Depending 
on the viral infection, these PAMPs include single stranded (ss) and double stranded 
(ds) viral RNA and DNA, which on their own or acting in unison with other viral 
characteristics (such as unmethylated DNA CpG motifs or tri-phosphate caps on 
dsRNA), alert innate immunity to infection (Lund et al., 2004, Stetson and 
Medzhitov, 2006, Hemmi et al., 2000, Hornung et al., 2006, Alexopoulou et al., 
2001). It is clear from the above that a multitude of very diverse PAMPs exist to 
alert the immune system to infectious microorganisms. Therefore it is not surprising 
that a multitude of PRRs have also co-evolved to detect and direct a relatively 
specific innate immune response to that infection. To date, 4 families of PRRs have 
been characterised. They include the transmembrane Toll-like Receptors (TLRs), C-
type Lectin Receptors (CLRs), cytosolic Retinoic acid-inducible gene (RIG)-I-like 
receptors (RLRs) and nucleotide-binding oligomerisation domain receptors (NOD)-
like receptors (NLRs). Differential PRR activation can lead to diverse signalling 
cascades culminating in the activation of distinct transcription factors and the 
alteration of gene expression. PRR signalling can trigger the upregulation of genes 
encoding pro-inflammatory cytokines, type 1 interferons (IFNs), chemokines, 
antimicrobial proteins, costimulatory molecules and proteins involved in the 
modulation and regulation of PRR signalling. Together, these mediators initiate and 
control the innate immune response and can create an inflammatory 
microenvironment to direct and dictate the adaptive immune response. Therefore, the 
initial correct recognition of the invading pathogen is absolutely essential for overall 
host protection.  
1.4 Toll-like Receptors (TLRs) 
The identification of the mammalian PRR system began with the discovery of Toll, a 
transmembrane receptor expressed in the insect Drosophila melanogaster that 
functions in dorsal-ventral embryonic polarity (Hashimoto et al., 1988). Toll was 
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subsequently shown to act as the key receptor for the insect immune response to 
fungal pathogens. It was required for the upregulation of anti-microbial mediators 
through a signalling pathway that was homologous to mammalian cytokine 
activation by Nuclear Factor-kappa B (NF-қB) (Lemaitre et al., 1996). The first 
mammalian Toll homologue cloned (originally annotated human Toll (hToll) now 
known as TLR4) showed that like its ancestrally linked insect protein, it too 
functioned in the induction of an anti-microbial response (Medzhitov et al., 1997a). 
Further characterisation showed that the mammalian TLR4 was a bona fide PRR and 
functioned by detecting the bacterial PAMP LPS to initiate the innate immune 
response (Hoshino et al., 1999, Poltorak et al., 1998, Shimazu et al., 1999). Taken 
together these data provided experimental evidence for the theory that PRRs detect 
PAMPs to initiate the innate immune response as first hypothesised by Charles 
Janeway Jr. in 1989 (Janeway, 1989). Such studies lead to an intense period of 
research into TLRs and the elucidation of their complex signalling pathways. 
To date, using sequence homology, genetic and biochemical approaches, 10 human 
and 12 murine functional TLR genes have been identified. TLR1-9 are conserved 
and functional in both species. TLR10 has lost functionality in the mouse due to an 
inactivating retroviral insertion while TLR11-13 are absent in the human genome 
(Kawai and Akira, 2009). TLRs are type 1 transmembrane receptor glycoproteins. 
Their location within the cell is dependent on the PAMPs in which they are designed 
to detect. TLRs responsible for recognition of extracellular pathogens are located on 
the cell surface, while others remain sequestered on intracellular endosomes to 
mediate viral replication surveillance. Consequently, the TLR N-terminus is located 
on the exterior of the cell or inside the lumen of an intracellular compartment. This 
TLR ectodomain is responsible for PAMP recognition and ligand binding and 
specificity. The presence of a varying number (19-25) of tandem Leucine Rich 
Repeat (LRR) motifs, each of which is 24–29 amino acids in length mediates 
specific ligand binding by the different TLRs (Bell et al., 2003). Upon TLR-LRR 
recognition of its associated ligand(s) (see table 1.1), TLR hetero/homo-dimerisation, 
or in the case of weakly pre-associated complexes, a conformational change occurs 
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triggering the association and activation of the cytoplasmic signalling domain. This 
domain is homologous to that of the interleukin 1 receptor (IL-1R) and is termed the 
Toll/IL-1R homology (TIR) domain (Slack et al., 2000, Medzhitov et al., 1998b).  
The close association of the TLRs TIR domains allows for the recruitment of key 
signalling TIR adaptor molecules, myeloid differentiation primary response protein 
88 (Myd88), TIR doman containing adaptor protein (TIRAP), TIR domain contain 
adaptor protein inducing interferon-β (IFN-β) (TRIF) and TRIF related adaptor 
molecule (TRAM) (Feng et al., 2003, Fitzgerald et al., 2001, Medzhitov et al., 
1998b, Fitzgerald et al., 2003b, Yamamoto et al., 2002c). The TIR adaptor proteins 
play a critical and non-redundant role in TLR signalling and it has recently been 
proposed that differential recruitment and activation of the TIR adaptors by different 
TLRs plays a fundamental role in the specificity of the innate immune response 
(Akira et al., 2006). The TLRs family can therefore be subdivided into groups based 
on their ligand specificity (West et al., 2006). 
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Receptor Ligands Origin of ligands 
TLR1 
 
Tri-acyl lipopeptides (Pam3CSK4) 
Soluble factors 
Bacteria, mycobacteria  
Neisseria meningitides  
TLR2 
 
 
 
 
 
 
 
 
 
 
 
Lipoprotein/lipopeptides 
Di-acyl lipopeptides (Pam2CSK4) 
Tri-acyl lipopeptides (Pam3CSK4) 
Peptidoglycan 
Lipoteichoic acid 
Lipoarabinomannan 
A phenol-soluble modulin 
Glycoinositolphospholipids 
Glycolipids 
Porins 
Zymosan 
Atypical LPS 
Atypical LPS 
LPS 
HSP70 
A variety of pathogens  
Mycoplasma 
Bacteria, mycobacteria  
Gram-positive bacteria  
Gram-positive bacteria   
Mycobacteria   
Staphylococcus epidermidis   
Trypanosoma cruzi  
Treponema maltophilum  
Neisseria   
Fungi   
Leptospira interrogans  
Porphyromonas gingivalis 
Porphyromonas gingivalis  
Host  
TLR3 Double-stranded RNA 
Polyinosinic-polycytidylic acid (Poly(I:C)) 
Polyadenylic–polyuridylic acid (Poly(I:U)) 
Virus 
Synthetic dsRNA  
Synthetic dsRNA 
TLR4 LPS 
Taxol 
Fusion protein 
Envelope proteins 
HSP60 
HSP60 
HSP70 
Type III repeat extra domain A of fibronectin 
Oligosaccharides of hyaluronic acid 
Polysaccharide fragments of heparan sulfate 
Fibrinogen 
Fetuin-A 
Gram-negative bacteria   
Plant   
RSV   
MMTV  
Chlamydia pneumoniae   
Host   
Host   
Host   
Host  
Host  
Host 
Host  
TLR5 Flagellin Bacteria  
TLR6 Di-acyl lipopeptides (Pam2CSK4) Mycoplasma  
TLR7 Imidazoquinoline 
Loxoribine 
Bropirimine 
Single-stranded RNA 
Synthetic compounds  
Synthetic compounds   
Synthetic compounds  
Virus 
TLR8 Imidazoquinoline 
Single-stranded RNA 
Synthetic compounds 
Virus 
TLR9 CpG DNA Viruses, Bacteria and Protozoa 
Table 1.1 Toll-like receptors and their ligands.                                                     
Adapted from Akira and Takeda, 2004. 
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1.4.1 TLR1/2/6 Heterodimers Recognise a Broad Spectrum 
of Microbial Products 
Unlike the other members of the TLR family, TLR1/2/6 are unique in that they do 
not preferentially form homodimers. Instead, TLR1/2 and TLR2/6 form 
heterodimers allowing the recognition of a diverse array of microbial PAMPs at the 
cell surface (Ozinsky et al., 2000a, Wyllie et al., 2000). Interestingly, the genetic 
makeup of TLR1/2/6 shares a high degree of sequence homology (~66%) and a 
similar genomic structure. Furthermore, the genes are all located in tandem on the 
same chromosome suggesting the 3 individual genes evolved and diverged from a 
single common ancestor to allow these TLRs to attain a greater diversity in ligand 
specificity (Farhat et al., 2008, Takeda et al., 2003, Du et al., 2000). Therefore, it is 
not surprising that TLR2 has the greatest repertoire of ligands of all the TLRs and 
has been implicated in the direct molecular discrimination of different pathogens 
(Underhill et al., 1999). 
Although TLR2 was originally thought to confer host recognition to LPS, it was 
found contaminating lipoproteins in the LPS preparations were the actual detected 
ligands (Hirschfeld et al., 2000, Yang et al., 1998). In addition TLR2-deficient mice 
were shown to be highly susceptible to infection by the Gram positive bacteria 
Staphylococcus aureus (Takeuchi et al., 2000b). TLR2 recognizes lipopeptides that 
are anchored to the bacterial membrane by lipid chains covalently attached to the N-
terminal cysteine (Manavalan et al., 2011). It has recently been shown that 
lipoproteins from Gram positive and negative bacteria differ in their specificity for 
the TLR2 heterodimer. Lipopeptides from Gram-negative bacteria have three lipid 
chains, while lipoproteins from Gram-positive bacteria and mycoplasm have only 
two such chains. Two of these chains are attached to the lipopeptide glycerol through 
an ester bond, which is in turn connected to the sulfur atom of the N-terminal 
cysteine and is said to be di-acylated. The third lipid chain of the Gram-negative 
bacteria is attached to the N-terminal of the lipopeptides via an amide bond causing 
the cysteine to become tri-acylated, a modification absent in Gram-positive bacteria. 
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(Muhlradt et al., 1997, Shibata et al., 2000). Such distinctions in the lipoprotein 
composition allowed for the generation of specific synthetic analogues for TLR1/2 
and TLR2/6 activation. The synthetic di-acylated cysteine group analogue 
Pam2CSK4 and the tri-acylated cysteine group analogue Pam3CSK4 have been shown 
to specifically induce TLR2/6 and TLR1/2 heterodimers respectively, both in 
functional proinflammatory cytokine production and at the crystal structure level (Jin 
et al., 2007, Kang et al., 2009, Takeuchi et al., 2002, Takeuchi et al., 2001). This 
strict paradigm of TLR2/6 recognition of di-acyalted bacterial components has been 
somewhat complicated with the discovery of the role of CD36 in TLR signalling. 
CD36 acts an accessory receptor for R-enantiomer of macrophage-activating 
lipopeptide 2 (MALP2) from Mycoplasma pneumonia, a di-acylated lipoprotein, but 
has no effect on TLR2/6 recognition of Pam2CSK4
 
highlighting the complexity and 
specificity of ligand recognition exhibited during TLR2 signalling. (Hoebe et al., 
2005). 
TLR2 also facilitates recognition of the mycobacterial glycolipid lipoarabinomannan, 
the phenol-soluble modulin of Staphylococcus epidermidis, the Meningococcal porin 
PorB from Neisseria meningitidis and lipoteichoic acids from Staphylococcus 
aureus and Bacillus subtilis (Means et al., 1999, Hajjar et al., 2001, Opitz et al., 
2001, Massari et al., 2006).  
In addition to bacterial recognition, TLR2 also participates in the detection of fungal 
pathogens. TLR2/6 heterodimers are also required for the recognition of the cell wall 
component zymosan of Saccharomyces cerevisiae (Ozinsky et al., 2000b).  
Interestingly, TLR2 participates with the C-type lectin receptor Dectin-1 to modulate 
independent but synergistic signalling in response to zymosan. While Dectin-1 
induces reactive oxygen species and phagocytosis, TLR2/6 and Dectin-1 cooperate 
in NF-қB activation of pro-inflammatory cytokines (Gantner et al., 2003). In 
addition, the ability of TLR2 to cooperate with not just TLR1/6 but other families of 
PRRs suggest that the vast array of ligands recognised and distinguished by TLR2 
may only be one facet of its function. It may play a role in the fine tuning of the 
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innate immune response during the complex signalling cascades exhibited during 
pathogenic infection.  
1.4.2 TLR3 Detects Viral dsRNA 
In contrast to the heterogeneity of ligands that the TLR2 complex recognises, TLR3 
is highly specific for dsRNA. TLR3 ligand binding is dependent on the formation of 
a TLR3 homodimerisation complex in which the receptors themselves interact 
weakly but share a high affinity interaction with their dsRNA ligand (Wang et al., 
2010). Interestingly, more than one TLR3 dimer can bind a single dsRNA molecule 
allowing the number of participating receptors and signalling complexes to increase 
as dsRNA strand length increases (Leonard et al., 2008). Upon TLR3 dimersiation 
the formation of a specialised TIR domain containing platform is created. Unlike the 
other TLRs, TLR3 does not require Myd88 to initiate downstream signalling and 
instead solely relies on a TRIF-mediated signalling cascade. (Yamamoto et al., 
2003a, Hoebe et al., 2003). TRIF-dependent signalling results in the production of 
both pro-inflammatory and anti-viral mediators in order to combat the viral infection 
detected. 
The discovery that dsRNA was detected by TLR3 was inferred from TLR3-deficient 
animal studies in which the TLR3 knockout animals displayed reduced cytokine 
production and were resistant to experimentally lethal dsRNA administration 
(Alexopoulou et al., 2001). Furthermore, evidence for TLR3 detection of naturally 
occurring viral RNA was also appreciated. The rotavirus has a dsRNA genome and 
is responsible for common infectious gastroenteritis in children. It has been shown 
that the intestinal epithelium of neonatal mice has a low expression of TLR3 and this 
is attributed to increases in susceptibility to rotaviral infection. TLR3 levels increase 
dramatically after weaning and are associated with increased protection from the 
disease. Importantly, mice deficient in TLR3 do not show this decrease in rotavirus 
susceptibility indicating the protective role of TLR3 in sensing dsRNA viruses (Pott 
et al., 2012). Although only 8 families of viruses have dsRNA genomes, TLR3 is not 
limited to their detection alone (Mertens, 2004). dsRNA is often a key intermediate 
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in viral replication of positive strand ssRNA virus, such as the encephalomyocarditis 
virus (EMCV) and DNA viruses, such as the herpes simplex virus 1 (HSV) (Weber 
et al., 2006). Interestingly, TLR3 does not detect or respond to dsRNA 
indiscriminately. Host dsRNA is highly modified with a large number of methyl-
modified nucleosides and such methylated dsRNA exhibit an abrogated TLR 
response (Karikó et al., 2005). Furthermore, polyinosinic:polycytidylic acid 
(Poly(I:C)) is a synthetic analogue of dsRNA routinely used to activated TLR3 
experimentally. The unmodified nature of the Poly(I:C) is highly recognisable by 
TLR3 which preferentially detects this structure and differs largely from those 
recognised by the other dsRNA-binding proteins (Okahira et al., 2005). Although a 
number of other dsRNA detection mechanisms exist, such as the RIG-I and MDA-5 
pathways, the role of TLR3 in sensing extracellular and cell associated dsRNA on 
necrotic and virally infected cells is paramount (Schulz et al., 2005, McBride et al., 
2006).   
Central to TLR3 functionality is its expression profile and subcellular location. 
TLR3 is expressed in a wide variety of cells including professional innate immune 
cells such as macrophages, dendritc cells and granulocytes (excluding neutrophils 
that sense dsRNA by RLRs) (Alexopoulou et al., 2001, Tamassia et al., 2008) 
(Visintin et al., 2001, Yang et al., 2009a). In addition, TLR3 is expressed on 
epithelial cells, fibroblasts and endothelial cells as well as astrocytes, microgial and 
neuronal cells of the central nervous system (Guillot et al., 2005, Tissari et al., 2005, 
Matsumoto et al., 2002, Town et al., 2006, Jack et al., 2005, Lafon et al., 2006). In 
contrast to the other dsRNA sensors which have strict cytosolic localisation, TLR3 
localisation has been shown to be somewhat promiscuous depending on the cell type 
and stage of viral infection. Classically, TLR3 is thought to be an intracellular 
receptor residing on the membrane of endosomes and this is the case for the majority 
of cell types such as macrophages and dendritic cells (Matsumoto et al., 2003). A 26 
amino acid cytoplasmic linkage domain between the intracellular TIR domain and 
the transmembrane portion of the receptor has been discovered. This domain 
contains an intracellular localisation motif that restricts TLR3 to the endosome and 
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site directed mutagenesis targeting this region was found to result in cell surface 
TLR3 expression (Funami et al., 2004). Interestingly, although dendritic cells do not 
express cell surface TLR3 they are still capable of recognising exogenously added 
extracellular dsRNA via TLR3. Recently it has been shown that exogenous Poly(I:C) 
exposure to dendritic cells results in the Clathyrin-mediated endocytic internalisation 
of the dsRNA and   its preferential sensing is by endosomal TLR3 and not that of the 
RLR (Itoh et al., 2008). In addition, endosome/phagolysosome maturation has been 
shown to be critical for exogenous Poly(I:C) detection as the inhibitors of 
acidification, bafilomycin and chloroquine, prevent TLR3 dimerisation and 
subsequent type 1 interferon production (de Bouteiller et al., 2005).   
In contrast to dendritic cells, naturally expressing cell surface TLR3 has been 
demonstrated on fibroblasts, astrocytes and epithelial cells (Matsumoto et al., 2002, 
Jack et al., 2005, Sajjan et al., 2006). Cell surface TLR3 is also a functional antiviral 
sensor as pre-treatment with an monoclonal antibody against human TLR3 inhibited 
Poly(I:C) activation of the antiviral signalling pathway in fibroblasts (Matsumoto et 
al., 2002). Interestingly, live viral infection has the ability to not only upregulate 
TLR3 expression but also influence its subcellular location. Prior to respiratory 
syncytial virus (RSV) infection, human tracheobronchial epithelial cells have no cell 
surface expression of TLR3. After exposure to the virus, cell surface TLR3 is highly 
upregulated and extracellular membrane localisation is achieved (Groskreutz et al., 
2006). This is thought to prime and sensitise the host to subsequent viral challenge 
and highlights the key role TLR3 plays in anti-viral immunity (Groskreutz et al., 
2006).  
Although great strides into the function of TLR3 in innate immune detection of viral 
pathogens have been made, its precise role still remains elusive. Its place in viral 
sensing in the context of the other dsRNA sensors remains to be fully characterised. 
Additionally, its role in viral detection and induction of a protective innate immune 
response is somewhat controversial in many circles, a problem confounded by 
TLR3s apparent protective and detrimental roles during different viral infection. For 
example, murine TLR3 plays a critical role in protection against EMCV-induced 
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cardiac damage and host lethality, while TLR3-induced inflammation and the 
resulting breakdown of the blood brain barrier plays a major role in West Nile virus 
(WNV) pathogenesis and encephalitis (Wang et al., 2004, Hardarson et al., 2007b). 
Despite such contrasting observations, there is no doubt that in the case of some viral 
infections, TLR3 is vitally important for human anti-viral defence. A dominant 
negative allele in TLR3 discovered in children has recently linked the PRR to 
protection from HSV-1-mediated encephalitis indicating TLR3 plays a non-
redundant and crucial role in host protection (Zhang et al., 2007). Therefore further 
study into TLR3s activation and regulation are vital in order to understand its core 
biological function in dsRNA sensing and innate immunity. 
1.4.3 TLR4, the LPS Receptor and Beyond 
The search for the receptor of LPS, the causative agent in endotoxin-induced septic 
shock, proved to be a massive undertaking culminating in the discovery of the first 
PRR and the awarding of the 2011 Nobel Prize to Jules Hoffmann and Bruce Beutler. 
The outer wall of Gram negative bacteria is an asymmetrical membrane which serves 
as a protective barrier from antimicrobial peptides released by the host immune 
system (Papo and Shai, 2005, Nikaido, 1989). Approximately 90% of the bacterial 
cell surface is covered in LPS and differences in the LPS structural composition 
confers varying susceptibility of the bacteria to different cationic anti-microbial 
peptides (Rosenfeld and Shai, 2006). LPS typically consists of an evolutionary 
conserved hydrophobic domain known as lipid A (or endotoxin), a non-repeating 
core oligosaccharide, and a highly variant distal polysaccharide (or O-antigen) 
(Rietschel et al., 1994, Zahringer et al., 1994). Lipid A is a phosphoglycolipid with a 
chemically unique architecture and represents the most highly conserved structural 
component of LPS and is an absolute requirement for all Gram negative bacterial 
cell walls (Zahringer et al., 1994). It is therefore not surprising that lipid A was 
found to be the toxic and immunostimulatory constituent of LPS and that LPS served 
as the ligand for mammalian TLR4 detection (Westphal and Lüderitz, 1954, Poltorak 
et al., 1998, Hoshino et al., 1999).  
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Interestingly, TLR4 detection of LPS is not as simple as receptor ligand recognition. 
Instead a series of sequential interactions with a number of proteins is required to 
achieve TLR4 activation. Initially LPS is directly bound to the soluble shuttling 
protein, LPS-binding protein proteins (LBP), which facilitates the conversion of the 
oligomeric micelles of LPS to a monomer and its subsequent delivery of the ligand 
to a glycosylphosphatidylinositol-anchored protein known as CD14 (Wright et al., 
1989, Wright et al., 1990). CD14 then associates with TLR4 and an extracellular 
accessory protein MD2 (Shimazu et al., 1999). MD2 is thought to directly bind the 
LPS molecule allowing TLR4 to bind the LPS/MD2 complex to trigger TLR4-
mediated downstream signalling (Visintin et al., 2003, Nagai et al., 2002).   
As TLR4 was the first mammalian PRR to be identified, it has been subjected to 
almost 15 years of intensive investigation. Interestingly, it has become clear that 
TLR4 not only detects a diverse array of bacterial ligands but also motifs on 
pathogenic viruses. Soon after TLR4 was identified as the PRR for Gram negative 
bacteria, reports emerged that some viral genomes encoded proteins that could 
negatively regulate TLR4 signalling (Bowie et al., 2000). These reports were closely 
followed with the discovery that TLR4 and CD14 could identify the fusion protein 
(F protein) of RSV and mount an appropriate immunological response to infection 
(Kurt-Jones et al., 2000). Furthermore, TLR4 can recognise the retroviral 
glycoproteins on the envelope of both the mouse mammary tumour virus and the 
murine leukemia virus and trigger NF-қB activation (Rassa et al., 2002). Recently, 
TLR4 was shown to be able to bind glycoproteins from viruses that cause serious 
pathology in humans. The Ebola virus glycoprotein present on the VP40 matrix 
protein of viral like particles, a structure critical for Ebola viral infection, was shown 
to interact with and modulate TLR4 signalling (Okumura et al., 2010). Lipo-viro-
particles (LVP, triglyceride-rich lipoprotein like particles containing viral RNA and 
proteins) from Hepatits C have been also shown to interact with TLR4 and induce 
activation and maturation of dendritic cells leading to a viral-induced bias in the 
subsequent T cell subset response (Agaugue et al., 2007). TLR4 is therefore a key 
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receptor for the recognition of viral proteins and particles during the initial stage in 
viral infection before intracellular replication and nucleic acid exposure to the host.  
An extremely important and compelling finding in PRR biology was again 
discovered during investigation of TLR4. The belief that PRRs could only detect 
molecular patterns from pathogens began to be questioned, as TLR4 was shown to 
recognise Heath-shock protein 60 (HSP60) of both human and microorganism origin 
(Ohashi et al., 2000, Costa et al., 2002). Endogenous HSP60 is usually present 
within the mitochondria where it acts as a chaperone protein facilitating the correct 
folding of oligomeric proteins (Cheng et al., 1989). Interestingly, during periods of 
cellular stress, damage or cell death, HSP60 can localise to the cell surface and it is 
proposed that TLR4 can recognise this danger signal and initiate innate immunity 
(Lehnardt et al., 2008). 
Other endogenous ligands have also been shown to mediate TLR4 initiation of 
innate immunity. During tissue injury, cellular fibronectin, which contains an 
alternatively spliced exon encoding type III repeat extra domain A (EDA) is released 
from the cell and potently activates TLR4 signalling (Okamura et al., 2001). The role 
of TLR4 in autoimmunity and the onset of insulin resistance by inflammatory free 
fatty acids have recently been highlighted (Shi et al., 2006). Feutin-A a secretory 
liver glycoprotein has been proposed as the endogenous TLR4 ligand responsible for 
insulin resistance in mice on high fat diets, as knockout of either gene results in a 
rescue of pathology (Pal et al., 2012). Therefore, the first mammalian PRR/TLR 
discovered not only provided direct evidence of recognition of PAMPs, but has 
expanded our understanding of the initiation of inflammation by endogenous 
molecules in injury and autoimmune disease. 
1.4.4 TLR5 Senses Extracellular Flagellin 
TLR5 was the first PRR to be shown to bind a protein ligand. TLR5 recognises the 
monomeric form of flagellin, the major component of the whip-like flagellar 
filament responsible for bacterial locomotion (Smith et al., 2003, Hayashi et al., 
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2001). Flagella are part of the sensory/motility system of bacteria and are 
upregulated and transported to the membrane during times of stress such as those 
exhibited in a nutrient depleted microenvironment or during extreme pH or saline 
alterations (Macnab, 2003). Flagella are critical for bacterial growth, host cellular 
adhesion and pathogenesis and over 50 genes under the control of a number of 
operons such as the master operon flhDC have been shown to be involved in 
flagellum production, transport and regulation (Chilcott and Hughes, 2000, 
Kutsukake et al., 1990). Such findings highlight the important role motility has on 
the microorganisms survival (Salazar-Gonzalez and McSorley, 2005). Therefore it is 
not surprising that many important human pathogenic bacteria are flagellated, 
including agents of gastroenteritis (Salmonella, Escherichia coli and Campylobacter), 
pneumonia (Pseudomonas, Burkholderia and Legionella) and invasive infections 
(Proteus, Escherichia coli and Clostridium) (Steiner, 2007).  
Although Flagellin is currently the only known TLR5 ligand, due to its protein 
nature, it has been amenable to genetic manipulation and therefore a lot is known 
about the TLR5-flagellin recognition. fliC, the main flagellin gene in Salmonella 
typhimurium, has been subject to the most rigorous study. The flagellar filament of 
fliC is composed of over 20,000 subunits of a 494 amino acid flagellin and is 
organised into 2 domains (Ramos et al., 2004, McClelland et al., 2001). fliC has a 
highly conserved 140 amino-terminal and 90 carboxy terminal residues which 
govern polymerisation and motility and flanks a central region that is highly variable 
in both residue composition and size (Beatson et al., 2006). This conserved region is 
critical for flagellum motility and therefore has not undergone significant 
evolutionary change without deleterious effect on bacterial motility and experimental 
mutations in this region lead to a severe abrogation in mobility and survival 
(Andersen-Nissen et al., 2005). 
This conserved region of flagellin serves as the PAMP for TLR5 recognition and 
pro-inflammatory cytokine production (Eaves-Pyles et al., 2001b, Smith et al., 2003). 
Conversely, the hypervariant region of flagellin elicits no TLR5 immunomodulation, 
and neither experimental mutation nor its physiological absence in Listeria 
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monocytogenes adversely affects its innate immune recognition (Hayashi et al., 2001, 
Smith et al., 2003). As flagellin is a protein, the exact sites of TLR5-mediated 
detection have been divulged using mutagenesis and structural studies. Although 
separated in primary sequence, the D1 domain of flagellin relates to the conserved 
residues of the C and N termini and forms a tertiary structure vital for TLR5-
mediated detection (Yoon et al., 2012, Donnelly and Steiner, 2002, Murthy et al., 
2004). Interestingly, this recognition site is not exposed on the flagellin surface when 
in the filamentous form and TLR5 can only detect monomeric flagellin (Smith et al., 
2003). Although the exact mechanism for this recognition is still under investigation, 
it has been suggested that monomeric flagellin may be released during the hostile 
microenvironment of the innate immune response, during bacterial replication or 
during bacterial cell death (Ciacci-Woolwine et al., 1997, Eaves-Pyles et al., 2001a, 
Salazar-Gonzalez and McSorley, 2005). Despite the ambiguity of how TLR5 comes 
in contact with monomeric flagellin, it is known that TLR5 must form a homodimer 
to signal and the exact stoichiometry has now been uncovered (Hayashi et al., 2001). 
Structural and functional studies suggest that TLR5 forms a asymetrical inactive 
dimer in the absence of flagellin and upon binding of two flagellin molecules (in a 
2:2 receptor:monomer ratio) TLR signalling and proinflammatory cytokine 
activation is achieved (Ivičak-Kocjan et al., 2013, Yoon et al., 2012, Zhou et al., 
2012).  
Although further effort is required to delineate how the precise physiological 
conditions occur to instigate TLR5 signalling in vivo, there is no doubt that TLR5 
plays a fundamental role in host protection. This claim is exemplified by the recent 
discovery that a natural polymorphism in human ligand recognition domain of TLR5 
results in an inability to respond to bacterial flagellin and results in an increased risk 
of serious legionnaires' disease (Hawn et al., 2003). 
1.4.5 TLR7/8/9 the Intracellular TLRs 
Intracellular TLR7/8/9 in humans and TLR7/9 in mice have evolved to detect and 
respond to bacterial and viral nucleic acids present inside host innate immune cells. 
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To a certain degree, the intracellular TLRs specificity for their natural ligands is 
achieved by their restricted localisation in an internal compartment from which the 
majority of self-nucleic acids are excluded but microorganism genetic material often 
frequent (Krieg and Vollmer, 2007). In addition, the transport of TLR7/9 to the 
endosome from the endoplasmic reticulum by UNC93B1 prevents cytosolic 
localisation and the requirement of endolysosome acidification for appropriated 
TLR7/9 responses minimise self-nucleic acid recognition in non-infected resting 
cells (Kim et al., 2008, Hacker et al., 1998).   
Human TLR7 and TLR8 share a high level of sequence homology and are both 
located on the X chromosome (Akira et al., 2006). The first indication that TLR7/8 
pathways may function in anti-viral defence came about from studies using small 
type 1 IFN modulating ribonucleoside analogues known as imidazoquinolines 
(which include imiquimod, R848 and CLO97). It was shown that TLR7 and Myd88-
deficient mice exhibited a complete abrogation in imidazoquinoline-induced IFN-α 
and pro-inflammatory cytokine production (Hemmi et al., 2002). In an additional 
study, it was also found that human TLR8 could also respond to the 
imidazoquinolines R848 while murine TLR8 was non-responsive (Jurk et al., 2002). 
The natural ligands for TLR7/8 were discovered two years later to be ssRNAs in two 
independent reports. TLR7 was shown to be critical for the recognition of endosomal 
genomic ssRNA from the influenza virus by Plasmacytoid dendritic cells (pDCs) and 
the induction of Myd88 dependent type 1 IFN production (Diebold et al., 2004). In 
addition, they also showed that ssRNA from a non-viral origin (polyuridine) but not 
oligomeric RNAs could also facilitate TLR7 activation highlighting ssRNA as a 
natural TLR7 ligand (Diebold et al., 2004).  In the second study, guanosine (G)- and 
uridine (U)-rich ssRNA oligonucleotides derived from HIV-1 was shown to 
stimulate dendritic cell and macrophage production of IFN-α and pro-inflammatory 
cytokines (Heil et al., 2004). Interestingly, they demonstrated that murine TLR7 and 
human TLR8 recognised GU-rich ssRNA specifically indicating a species specific 
recognition axis exists for GU-rich ssRNA detection.  
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Although TLR7 is fully functional in mouse models, murine TLR8 was thought to be 
inactive until very recently and controversies still remain about its actual role 
(Martinez et al., 2010, Bauer et al., 2010). Initial observations that murine TLR8 
may have functionality were made when primary murine peripheral blood 
mononuclear cells (PBMCs) from TLR8-deficient animals were treated with the 
selective imidazoquinoline CLO75 in combination with polyT oligonucleotides and 
enhanced TLR8 activation was observed, in conjunction with a suppression of TLR7 
activity (Gorden et al., 2006). This suggested a possible antagonist relationship 
between the two closely related receptors. More recently, TLR7 expression was 
observed to be overexpressed in TLR8-deficient dendritic cells and TLR7 signalling 
was hyper-reactive to various TLR7 ligands (Demaria et al., 2010). Furthermore, 
TLR8
–/– 
mice displayed increased serum levels of autoantibodies against small 
nuclear ribonucleoproteins and ribonucleoprotein, and developed glomerulonephritis, 
whereas neither TLR7
–/–
 nor TLR7
–/–
TLR8
–/–
 mice showed any of the phenotypic 
pathologies. This indicates that TLR8 has a functional role in innate immune 
signalling by specifically regulating aberrant TLR7-induced autoimmunity (Demaria 
et al., 2010).  
Classically, TLR9 is thought to recognise unmethylated 2′-deoxyribo(cytidine-
phosphate-guanosine) (CpG) DNA islands, motifs that are highly abundant in 
bacterial and viral genomes but rare in mammals (Blasius and Beutler, 2010). TLR9 
was originally shown to detect bacterial CpG and this was later expanded to DNA 
from viruses and protozoa (Hemmi et al., 2000, Lund et al., 2003, Bafica et al., 
2006). Investigations into TLR9 biology is often conducted using two different 
synthetic oligonucleotides types. Type A CpG oligonucleotides are characterised by 
a phosphorothioate-modified poly G stretch at the 5′ and 3′ ends and a 
phosphodiester CpG motif in the central portion of the molecule and are potent 
activators of the type 1 IFN responses in pDCs (Krug et al., 2001, Verthelyi et al., 
2001). In contrast, conventional phosphorothioate-modified CpG-DNAs, termed B 
type CpG-DNAs, do not stimulate pDCs to produce type 1 IFNs, but can activate the 
anti-viral cytokines in myeloid derived DC and macrophages (Schmitz et al., 2007b). 
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It is thought that the CpG A and CpG B localise to both early and late endosomes, 
respectively, and it is this distinction that plays a key role in the signalling pathway 
that is triggered (Guiducci et al., 2006).  
Recently the dogma that TLR9 recognised the CpG motif itself was called into 
question, and it is now thought that TLR9 actually detects the 2′ deoxyribose 
phosphate backbone of the molecule and that phosphorothioate linkages nor specific 
sequences of the CpG motifs are required to induce a response (Haas et al., 2008). It 
is now suggested that the phosphorothioate linkages and the sequence of the CpG 
motifs of the synthetic ligands likely increase and influence the stability, aggregation, 
uptake and endosomal targeting of the DNA to mediate their variant responses 
(Blasius and Beutler, 2010). Finally, in addition to TLR9 recognition of pathogenic 
DNA, it has also been show to bind the insoluble crystal hemozoin, a by-product 
from the malarial heme-detoxification process that is generated after digestion of 
host hemoglobin by Plasmodium falciparum (Coban et al., 2010).  
Consequently, the intracellular TLRs play a vital role in mediating host defence 
against pathogenic infection. Interestingly however, although TLR7/9 uses Myd88 to 
facilitate downstream signalling, the pathways employed by pDCs are very different 
to that employed by the TIR adaptor in TLR1/2/4/5/6 activation and therefore, in 
depth knowledge into these signalling cascade is vital in understanding TLR innate 
immune biology.  
1.5 TLR Signalling Pathways 
1.5.1 The TIR Adaptor Proteins 
Upon recognition of their cognate PAMPs, TLRs undergo receptor dimerisation or if 
a low affinity pre-assembled dimer already exists, ligand binding will induce a 
conformational change in the receptors (Latz et al., 2007, Ozinsky et al., 2000b).  
Such a conformational changes facilitate the reorganisation of the cytoplasmic 
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domain responsible for intracellular signalling, the TIR domain (O'Neill and Bowie, 
2007). The TIR domains of the TLRs undergo oligomerisation and allow the 
recruitment of the TIR domain containing adaptor proteins to propagate downstream 
intracellular signalling (Gay et al., 2006). Specific and preferential adaptor 
recruitment by the different TLRs, their subcellular localisations and their individual 
affinities for interacting proteins allow the TIR adaptors to orchestrate a non-linear 
innate immune response to the combinations of stimuli which constitute pathogenic 
infection (Jenkins and Mansell, 2010).  
Myd88 was originally described as a protein involved in the terminal differentiation 
of murine myeloid precursors cells in response to IL-6 stimulation (Lord et al., 1990). 
Soon afterwards it became clear that a conserved sequence of cytoplasmic amino 
acids existed between the invertebrate Toll receptor, the mammalian IL-1R and the 
newly defined Myd88 protein and it was proposed to function in a conserved signal 
transduction pathway (Yamagata et al., 1994). This proved to be the case for not 
only IL-1R signalling but also for TLR inflammatory responses (Medzhitov et al., 
1998b, Hultmark, 1994). The generation of Myd88-deficient mice proved that the 
adaptor protein played a fundamental physiological role in TLR4 responsiveness to 
LPS (Kawai et al., 1999). However, although Myd88-dependent signalling is 
critically important for most TLR-induced NF-қB activation, a Myd88-independent 
signalling pathway had also been observed during TLR3- and TLR4-induced pro-
inflammatory and antiviral responses (Kawai et al., 2001, Alexopoulou et al., 2001).  
The identification of the TIR domain containing protein TRIF as a key adaptor 
linking TLR4 signalling to both interferon regulator factor 3 (IRF3) and NF-қB 
activation provided a direct mechanism to explain these Myd88-independent 
cytokine responses (Yamamoto et al., 2002b, Oshiumi et al., 2003a). TRIF was 
independently shown to be the only TIR adaptor that bound TLR3 after dsRNA 
recognition and was required for induction of interferon-β (IFN-β), a potent anti-
viral cytokine (Yamamoto et al., 2002b, Oshiumi et al., 2003a). Furthermore, 
genetic disruption of the murine gene encoding TRIF provided physiological 
evidence for its role in TLR3 and TLR4 induction of pro-inflammatory and anti-viral 
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mediators in response to infection (Yamamoto et al., 2003a). Recently a splice 
variant of TRIF missing its TIR domain named TRIS has been identified. Upon 
TLR3 stimulation TRIF and TRIS form a heterotrimeric complex. Surprisingly, this 
oligomerisation is essential for both NF-қB and IRF3/7 signalling pathways and 
knockdown of TRIS results in reduced transcriptional activity of these transcription 
factors (Han et al., 2010). Although the exact mechanism of TRIS-dependent 
signalling is still unknown, this represents a unique complexity to the TRIF 
dependent signalling cascade not shared with the Myd88 pathway. In addition to 
TRIFs role in TLR3 and TLR4 signalling, it has also been implicated as a key 
adaptor for TLR5 signalling in intestinal epithelial cells. Flagellin stimulation allows 
recruitment of TRIF to TLR5 whereby in conjunction with Myd88 it mediates pro-
inflammatory cytokine production (Choi et al., 2010). Recently, a role for TRIF in 
TLR1/2 recognition of Borrelia burgdorferi, the bacteria vector of Lymes disease, 
has been uncovered (Petnicki-Ocwieja et al., 2012). As in TLR5 signalling, TRIF 
dependent pro-inflammatory cytokine production is again reliant on Myd88 
signalling. These findings indicate that the TIR adaptors may play cell type, infection 
specific and temporal roles in innate immunity beyond what is currently accepted. 
In addition to Myd88 and TRIF, TLR4 also utilises two other TIR adaptors, TIRAP 
and TRAM. Although TIRAP was originally proposed to play a role in the Myd88 
independent pathway, functional investigation into the adaptor showed it acted as a 
key signalling intermediate in TLR2 and TLR4 signalling by acting as a bridge 
between the TLR and Myd88 (Horng et al., 2001, Fitzgerald et al., 2001, Kagan and 
Medzhitov, 2006, Horng et al., 2002). Generation of TIRAP-deficient mice showed 
that the adaptor protein was not required for TLR3/5/7/9 or IL-1 and IL-18 signalling 
(Horng et al., 2002, Yamamoto et al., 2002a).  To date, the role of TRAM in TLR 
signalling is unique as it is the only adaptor to be used by a single TLR. TRAM was 
initially discovered as a TIR adaptor using bioinformatical approaches (Bin et al., 
2003). The first definitive description of TRAMs role in TLR signalling came 
shortly after with the observation that TRAM interacted with TLR4 and TRIF and 
facilitated TLR4-induced activation of IRF3 and Myd88-independent NF-қB 
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(Fitzgerald et al., 2003a). It was proposed that TRAM acted similarly to TIRAP in 
that it could bridge TLR4 signalling to another TIR adaptor (Oshiumi et al., 2003b).  
TRAM-deficient mice generation provided genetic evidence for its specific role in 
TLR4 and TRIF-dependent signal transduction (Yamamoto et al., 2003b). More 
recently, TRAM was shown to facilitate TLR4-mediated activation of anti-viral 
cytokine production by controlling TLR4 relocalisation from the plasma membrane 
(where it signals through the Myd88 dependent pathway) to an early endosome to 
facilitate TRIF-dependent signalling (Kagan et al., 2008). 
Although great advances have been made in TIR adaptor-mediated signalling the 
roles of TIRAP and TRAM require further investigation to fully elucidate their roles 
in innate immune signalling. Recently, TIRAP has been shown to have independent 
roles to Myd88 during TLR2 and TLR4 signalling and can drive the activation of 
anti-inflammatory IL-10 indicating the TIR adaptors can play subtle and regulatory 
roles in controlling the innate immune response (Mellett et al., 2011). In addition, 
TRAM has recently been implicated as a TIR adaptor during IL-18 signalling, a 
receptor complex highly related to the IL-1 receptor that does not require TRAM to 
signal via the Myd88 dependent pathway (Ohnishi et al., 2012). The requirement of 
the additional TIR adaptor in IL-18 signalling is still unknown. 
 Although the elucidation of complexities of TIRAP and TRAM-mediated signalling 
is on-going, our knowledge of Myd88-dependent and TRIF-dependent signalling is 
extensive (illustrated in Fig. 1.1). 
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Fig. 1.1 Myd88 and TRIF-dependent TLR signalling 
See section 1.5.2 for detailed Myd88 dependent signalling and section 3.1 for 
detailed TRIF dependent signalling pathway description. Yellow circles marked with 
a “p” inside represent phosphorylation events, green circles with “Ub” represents 
K63-linked ubiquitination while red circles with “Ub” represent K48-linked 
ubiquitination. Straight Blue arrows represent My88 signalling and straight red 
arrows represent TRIF signalling. Straight green arrows represent nuclear 
translocation and gene promoter binding. Curved red arrows indicate initiation of 
gene transcription.   
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1.5.2 Myd88-dependent Signalling 
It is now clear that Myd88 is the critical TIR adaptor protein for all the TLRs with 
the exception of TLR3 (Takeuchi et al., 2000a, Hayashi et al., 2001, Heil et al., 2004, 
Hacker et al., 2000, Alexopoulou et al., 2001). Upon TLR4 
dimerisation/conformational alteration, Myd88 is recruited to the proximal surface of 
the membrane receptor via homotypic TIR-TIR interactions with its bridging partner 
TIRAP (Kagan and Medzhitov, 2006). Myd88 can then in turn recruit members of 
the IL-1 receptor-associated kinase (IRAK) family via homophilic death domain 
(DD) interactions (Wesche et al., 1997, Burns et al., 1998, Medzhitov et al., 1998b, 
Muzio et al., 1997). Structural studies have recently uncovered the stoichiometry of 
these interactions. Myd88 undergoes oligomerisation into a hexameric form allowing 
the ordered modular recruitment of four IRAK4 molecules and four IRAK2 (or 
IRAK1) kinases, a complex termed the Myddosome (Suzuki et al., 2002, Motshwene 
et al., 2009, Lin et al., 2010). Formation of these complexes brings the kinase 
domains into close proximity for phosphorylation and activation. It is thought that 
IRAK4 and IRAK1 participate in the early and transient activation of NF-қB while 
IRAK2 is responsible for the long term sustainment of the signal (Kawagoe et al., 
2008). While IRAK1 undergoes rapid ubiquitination and degradation upon 
stimulation, IRAK2 levels and activity are sustained, albeit with delayed kinetics 
(Yamin and Miller, 1997, Kawagoe et al., 2008). IRAK4 promotes the 
phosphorylation of IRAK1, which triggers IRAK1 auto-phosphorylation (Li et al., 
2002, Kollewe et al., 2004). This triggers the phosphorylation of the E3 ubiquitin 
ligase Pellino1, which in turn mediates K63-linked polyubiquitination of IRAK1 
enhancing its catalytic activity (Ordureau et al., 2008). The activated IRAK 
molecules are vital in linking Myd88-dependent signalling to TRAF6 activation, a 
key event in TLR/IL-1R functionality (Cao et al., 1996). TRAF6, a really interesting 
new gene (RING) domain containing ubiquitin ligase, acts in combination with a 
dimeric E2 ubiquitin conjugating enzyme known as Ubc13/Uev1A, which serves to 
further polyubiquitinate IRAK1 and indeed itself (Deng et al., 2000, Lamothe et al., 
2007a). In addition, TRAF6 can produce unanchored free polyubiquitin chains to 
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activate downstream kinases to further enhance TLR-mediated signalling (Xia et al., 
2009). IRAK-activated TRAF6 allows the dissociation of the signalling complex 
from the membrane to the cytosol to facilitate further downstream signalling (Qian et 
al., 2001). Polyubiquitylated TRAF6 can then in turn induce direct or indirect (via 
free chain formation) recruitment of the transforming growth factor-β (TGF-β)-
activated kinase 1 (TAK1) regulatory components, TAK-1 binding protein 2 (TAB2) 
and TAB3 (Takaesu et al., 2000, Kanayama et al., 2004). This ubiquitin dependent 
modification allows for the activation of the kinase potential of TAK1 (Wang et al., 
2001).  Another critical event for TLR signal transduction is the polyubiquitination 
of NF-қB essential modulator (NEMO) (Zhou et al., 2004). A number of E3 ligases 
have been put forward to facilitate this modification including TRAF6 and linear 
ubiquitin chain assembly complex (LUBAC). However, the precise mode of NEMO 
ubiquitination during TLR signalling remains uncertain (Sun et al., 2004, Tokunaga 
et al., 2009, Ni et al., 2008). TAK1 and NEMO are both required for the activation 
of the inhibitor of қB (IқB) kinases (IKKs) IKKα and IKKβ (Wang et al., 2001, 
Mercurio et al., 1997, Yamaoka et al., 1998). As NEMO contains no catalytic 
domain and may act as a scaffold for IKK recruitment, it is TAK1 which mediates 
IKK phosphorylation (Wang et al., 2001, Ninomiya-Tsuji et al., 1999, Harhaj and 
Sun, 1999, Rothwarf et al., 1998). Phosphorylated IKKβ in turn is recruited to the 
IқB proteins such as IқBα which sequester NF-қB in the cytosol (Mercurio et al., 
1997, Haskill et al., 1991). Upon IқBα phosphorylation, it undergoes K48-linked 
ubiquitination by the F-box protein Slimb/β-TrCP (β-TrCP) and subsequent 
proteasomal-dependent degradation (Alkalay et al., 1995). Liberated from its 
inhibitor, members of the NF-қB transcription factor family, such as p65, can in turn 
become phosphorylated and translocate to the nucleus to mediate direct alterations in 
gene expression (Sakurai et al., 1999, Baeuerle and Baltimore, 1988). 
Myd88 dependent signalling also has the ability to activate the mitogen and stress 
activated protein kinase (MAPK) pathways. In addition to IKK activation, TAK1 
also functions as a MAPK kinase kinase (MAPKKK) and can phosphorylate 
MAPKK6 which can in turn directly activates the MAPKs c-Jun N-terminal kinases 
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(JNK) and p38 (Wang et al., 2001). TRAF6 ubiquitination also recruits a number of 
other MAPKKs such as MEKK3, Tpl-2 and ASK1 (apoptosis signal-regulating 
kinase 1) which result in the eventual phosphorylation of JNK, p38 and extracellular 
signal-regulated kinase 1/2 (ERK1/2) (Banerjee et al., 2006, Huang et al., 2004, 
Matsuzawa et al., 2005). MAPK phosphorylation can lead to the direct activation of 
transcription factors such as is the case for JNK activation of c-JUN, or via 
downstream kinases as is the case for p38-MSK1/2 activation of cAMP response 
element binding protein (CREB) (Ananieva et al., 2008, Morton et al., 2003). In 
addition to transcription factor activation, MAPKs can have profound effects on the 
level of stability of transcripts containing adenylate/uridylate (AU)-rich elements 
(AREs) with p38 playing a major role in expression of mRNAs encoding pro-
inflammatory cytokines (Brook et al., 2000, Frevel et al., 2003).  
Myd88-dependent signalling also has the capability to activate members of the IRF 
family of transcription factors and mediate production of anti-viral cytokines. During 
TLR3 and TLR4 signalling by LPS and Poly(I:C) respectively, TRIF is an absolute 
requirement for IFN-β induction, a process mediated by IRF3 and IRF7 (see section 
3.1). However, in pDCs Myd88 acts as the sole adaptor for the activation of IRF7 in 
response to TLR7/9 signalling (Hemmi et al., 2003b, Diebold et al., 2004). It is 
thought that autophagy, a conserved process involving lysosomal degradation and 
recycling of cellular organelles, is involved in delivery of cytoplasmic viral/bacterial 
nucleic acid to the endosomal TLR7/9 (Lee et al., 2007). Upon TLR7/9 activation, 
Myd88 is recruited to the endosome and initiates the assembly of a specialised 
signalling complex containing IRAK4, IRAK1, TRAF6 and IRF7 (Kawai et al., 
2004). TRAF6 E3 ligases activity and IRF7 polyubiquitination is a critical event in 
IRF7 induction of IFN-α (Kawai et al., 2004). Another essential modification for 
IRF7-induced gene transcription is phosphorylation, which allows IRF7 to dimerise 
and expose its transactivation domain (Marie et al., 2000). In Myd88-dependent 
signalling IRF7 phosphorylation is mediated by IRAK4, IRAK1 and IKKα as 
deficiency in any of the kinases results in ablated IFNα upregulation  (Yang et al., 
2005, Uematsu et al., 2005, Kim et al., 2007a, Hoshino et al., 2006). In addition to 
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type 1 IFN production, pDCs also activate pro-inflammatory cytokines upon 
infection. This is thought to be facilitated by TRAF6 activation of TAK1 in a similar 
manner to that displayed in TLR4 and IL-1β signalling (Gilliet et al., 2008). It would 
therefore be easy to speculate that TLR9-Myd88 signalling in other cell types would 
signal through a similar pathway.  However, a surprising observation was discovered 
when TLR9 activation of type 1 IFNs was dissected in myeloid/conventional DCs 
(mDCs) and macrophages. Unlike TLR7/9 signalling in pDCs (and TLR3/4 
signalling in mDCs), TLR9 activation of antiviral cytokines was independent of 
IRF7 (and IRF3) in mDCs (Schmitz et al., 2007a). Instead TLR9 drives type 1 IFN 
production through a new signalling axis involving Myd88 and IRF1 highlighting 
the complexities of Myd88-dependent signalling in both different cell types and 
different receptor engagements (Negishi et al., 2006).  In addition, Myd88 facilitates 
activation of IRF5 in both mDC and pDCs to mediate proinflammatory cytokine 
production (Takaoka et al., 2005).   
Taken together, Myd88 dependent signalling is a complex process that is still not 
completely understood. The ability of the adaptor to recruit differential signalling 
components to diverse stimuli in different cell populations is only beginning to be 
uncovered while its place in combination with the other PRRs and the IL-1/18R is 
still in its infancy. What is known however is that Myd88 is a critical and potent 
mediator of both pro-inflammatory and anti-viral cytokine production. Given its vital 
role in host defence signalling, it is not surprising that rare naturally occurring 
polymorphisms that interfere with TIR adaptor recruitment of the Myddosme confer 
susceptibility to reoccurring and life-threatening infections (von Bernuth et al., 2008, 
George et al., 2011).  
1.5.3 Negative Regulation of TLR Signalling 
Although TLR detection of infectious microorganisms is essential for host survival, 
the powerful pro-inflammatory and anti-viral mediators that enable pathogenic 
elimination can have a profound adverse effect on host homeostasis. As such, TLRs 
can also be directly involved in the pathogenesis of chronic inflammatory and 
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autoimmune disease. One of the most serious examples of an inflammatory damage 
to the host is sepsis. TLR4 recognition of endotoxin from Gram negative bacteria is a 
major driving force in septic shock (Poltorak et al., 1998). This often lethal condition 
is characterised by an excessive pro-inflammatory cytokine response and the over-
production of IL-1β and tumour necrosis factor-α (TNF-α) directly contribute to 
disease pathology (Remick et al., 1990, Hultgren et al., 2002, Dinarello, 1997). 
Recently, it has been found that TLR3 is highly upregulated in the synovium of 
patients with rheumatoid arthritis (RA) and can detect RNA released from necrotic 
synovial fluid during disease progression and the subsequent upregulation of 
cytokines by TLR3 may be a key factor in the inflammatory condition (Brentano et 
al., 2005, Roelofs et al., 2005). In addition, raised levels of type 1 IFNs have been 
observed in systemic lupus erythematosus (SLE) patients and it has been shown to 
correlate with disease severity (Bengtsson et al., 2000).  Recently it has been 
proposed that TLR7/9 activated pDCs are the source of the pathogenic IFN-α in SLE 
(Blanco et al., 2001, Barrat et al., 2005, Baccala et al., 2013). Taken together, 
aberrant TLR activation can lead to serious and life threatening conditions and 
therefore must be subject to tight regulatory control mechanisms after pathogen 
elimination.  In order to control the complex signalling triggered by TLR activation, 
a number of distinct mechanisms have evolved to limit harmful inflammation 
(overviewed in Fig. 1.2). Such regulatory mechanisms are often directly activated or 
transcriptionally upregulated by the signal they function to inhibit.  
1.5.3.1 Splice Variants Negatively Regulate TLR signalling 
The first line of regulation of TLRs can be seen at the level of the receptors 
themselves. An alternatively spliced variant of murine TLR4 has been identified as a 
soluble decoy receptor which contains the ligand binding LRR domain but lacks the 
intracellular signalling domain and functions as an inhibitor of LPS-mediated pro-
inflammatory cytokine production (Iwami et al., 2000). Subsequently a similar splice 
variant has been discovered in humans. The upregulation of this splice variant is 
deficient in cystic fibrosis patients and is associated with increased NF-қB-induced 
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TNF-α production, highlighting its potential role in preventing autoimmune disease 
(Jarešová et al., 2007). In addition to TLR4 soluble decoys, a short splice variant of 
its partner MD-2 has also been discovered and termed MD-2s. MD-2s has been 
shown to be secreted from the cell and bind TLR4 and compete with full length MD-
2 to prevent TLR4 signal transduction (Gray et al., 2010, Ohta et al., 2004). This 
method of splice variant decoy inhibition is not restricted to TLR4 signalling as a 
naturally occurring splice variant of TLR2 (TLR2s) has also been described 
(LeBouder et al., 2003). TLR2s consists of the majority of the extracellular domain 
of TLR2 and inhibits the receptors functionality by interfering with the recognition 
of Gram-positive bacteria and supresses pro-inflammatory cytokine induction (Raby 
et al., 2009).   
Splice variants of the TIR adaptor proteins have also been discovered. Myd88 short 
(Myd88s) lacks exon 2 which encodes the inter-domain between the DD and the TIR 
domain, and can be upregulated by LPS stimulation (Janssens et al., 2002). 
Importantly, Myd88s was shown to negatively regulate IL-1 and TLR4 signalling 
but not TNF-α induced NF-қB activation. The formation of a Myd88 and Myd88s 
heterodimer prevents TLR-induced activation of IRAK1 and IRAK4 (Janssens et al., 
2003, Burns et al., 2003). An alternatively spliced form of TRAM which contains 
TRAMs TIR domain fused to a Golgi dynamics (GOLD) domain termed TRAM 
adaptor with GOLD domain (TAG) has been shown to specially inhibit TLR4 
Myd88 independent signalling. It mediates this function by displacing TRIF from 
full length TRAM specifically disrupting the TLR4/IRF3 activation pathway 
(Palsson-McDermott et al., 2009). A number of splice variants of the IRAK family 
members have been discovered. Two splice variants of murine IRAK2, IRAK2c and 
IRAK2d, have been revealed to lack a DD and function to inhibit TLR activation of 
NF-қB (Hardy and O'Neill, 2004). In addition, a human splice variant of IRAK1, 
IRAK1c, also has the ability to block TLR signalling. IRAK1c cannot be 
phosphorylated by IRAK4, and lacks its catalytic domain but can still associate with 
Myd88 to prevent downstream signalling. Interestingly, after LPS stimulation, 
IRAK1 is subject to ubiquitin-dependent degradation while IRAK1c is up regulated 
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highlighting an auto-inhibitory loop exists for IRAK1 signalling (Rao et al., 2005). 
Splice variants of the TLRs, the TIR adaptors and key signalling intermediates are 
often upregulated to compete with their full length counterparts to protect the host 
from excessive inflammation. 
1.5.3.2 Transmembrane Receptors as Negative Regulators 
In addition to splice variant TLR inhibition, a number of transmembrane proteins 
have been characterised that negatively regulate inflammatory signalling. A novel 
member of the IL-1R superfamily, single Ig IL-1R-related molecule (SIGIRR) or 
TIR-8 is a single transmembrane TIR domain containing protein that cannot activate 
NF-қB (Thomassen et al., 1999).  It was found that SIGIRR acts as a negative 
regulator of Myd88-dependent induction of pro-inflammatory cytokines (Wald et al., 
2003). SIGIRRs mechanism of inhibition has only been partially elucidated. While 
SIGIRRs attenuation of IL-1R signalling requires both extracellular and intracellular 
domains to be intact, its intracellular TIR domain alone is sufficient to inhibit TLR4 
activity and it has been proposed to act as a molecular trap to prevent IRAK and 
TRAF6 downstream signalling (Qin et al., 2005). Interestingly, although its 
expression is not readily upregulated by pro-inflammatory stimuli, it is highly 
restricted to cells of the epithelium and may act to prevent excessive inflammation in 
the gastrointestinal tract, a major interface between the host and microorganisms 
(Garlanda et al., 2004).  
The TNF-related apoptosis-inducing ligand (TRAIL) receptor (TRAILR) also 
functions as a negative regulator of TLR signalling. Unlike SIGIRR, TRAILR does 
not contain a TIR domain and as the name implies is a member of the TNFR 
superfamily (Wu et al., 1999). TRAILR-deficient cells displayed increased cytokine 
expression upon TLR3 and TLR4 stimulation, stimuli which also induced TRAILR 
expression. TRAIL was showed to play a physiological role in regulating the 
immune response as TRAIL-deficient mice were more resistant to and showed 
enhanced clearance of mouse cytomegalovirus infection, which correlated with 
increased levels of pro-inflammatory cytokines and IFN-. Mechanistically, 
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TRAILR signalling inhibits IқBα degradation preventing sustained NF-қB nuclear 
translocation (Diehl et al., 2004). Furthermore, TRAILR has been shown to directly 
protect against chronic inflammation and tumorigenesis in mouse models 
highlighting the key role transmembrane negative regulators of TLR signalling exert 
on host protection (Finnberg et al., 2008).  
1.5.3.3 TIR Domain Containing Proteins Regulate TLR 
Signalling 
There is no doubt that TIR adaptor containing proteins play fundamental roles in the 
instigation of TLR signalling pathways. However the discovery of independent TIR 
domain containing proteins that negatively regulate TLR signalling led to a re-
evaluation of their respective roles in innate immunity. 
The fifth TIR adaptor protein discovered was Sterile-α and Armadillo motif 
containing protein (SARM) (Mink et al., 2001). SARM is the most ancient of the 
TIR adaptors and has a direct orthologue in Caenorhabditis elegans termed TIR-1 
(Couillault et al., 2004). TIR-1 was shown to play a vital role in anti-fungal defence 
by acting upstream of the worm orthologue of p38. Surprisingly however, unlike the 
other adaptor proteins, overexpressed human SARM is incapable of activating NF-
қB (Liberati et al., 2004). In human cells, SARM has been shown to acts as a 
specific inhibitor of TLR3 and TLR4 activation of TRIF dependent cytokine 
induction in a TIR domain dependent manner. LPS induces SARM protein 
expression and SARM directly interacts with TRIF suggesting SARMs involvement 
in a negative feed-back loop. Interestingly, generation of SARM-deficient mice 
showed no phenotypic differences to wild type animals upon TLR stimulation, with 
SARM expression being restricted to the central nervous system (CNS) (Kim et al., 
2007b). In addition, a recent study concluded that Bunyavirus infection, a major 
cause of encephalitis, results in a RIG-I and mitochondrial antiviral signalling 
protein (MAVS) signalling pathway leading to the upregulation and induction of 
SARM-mediated neuronal cell death (Mukherjee et al., 2013). Therefore, it is still 
unclear the exact role of SARM in TLR signalling and further investigation into 
Chapter 1: Introduction 
35 
 
 
redundancy and species specific roles of the TIR adaptor are required to elucidate its 
innate immune functionality. 
Recently, B-cell adapter for PI3K (BCAP) has been discovered to contain a 
previously unknown TIR domain (Troutman et al., 2012). As the name implies 
BCAP was originally discovered to link B cell receptor engagement to PI3K 
pathway induction (Okada et al., 2000, Inabe and Kurosaki, 2002). Two groups 
simultaneously discovered its similar role in TLR signalling (Troutman et al., 2012, 
Ni et al., 2012). Troutman et al. ascribed its ability to link TLR signalling to PI3K 
induction as being TIR dependent. Genetic disruption of BCAP leads to enhanced 
production of pro-inflammatory cytokines but has no effect on NF-қB and MAPK 
pathway activation (Ni et al., 2012, Troutman et al., 2012). Instead, BCAP is a 
critical factor in TLR phosphorylation of protein kinase B (also known as AKT) 
which in turn negatively regulates pro-inflammatory cytokine production. Although 
this process is still incompletely understood, phosphorylated AKT has been shown to 
upregulate the microRNA let-7e which decreases TLR4 transcript stability and 
downregulate miR-155 that targets suppressor of cytokine signalling 1 (SOCS1), a 
known TLR inhibiting protein (Androulidaki et al., 2009). In addition, AKT can 
phosphorylate glycogen synthase kinase 3b (GSK3b) inducing its degradation to 
suppress optimal pro-inflammatory IL-12 production (Ohtani et al., 2008). Although 
the exact mechanism remains to be defined, the TIR containing protein is a novel 
and potent inhibitor of TLR signalling.  
As outlined above, Myd88 is the key TIR adaptor for all TLR signalling pathways 
with the exception of TLR3. It was therefore surprising that Myd88 was shown to 
play a negative regulatory role in TLR3-induced corneal inflammation in a murine 
disease model (Johnson et al., 2008). In another murine model, Myd88-deficiency 
during viral myocarditis by Coxsackievirus B3 proved to be protective. This 
correlated with increased type 1 IFNs present in the cardiac tissue of the infected 
Myd88-deficient animals in conjunction with increased IRF3 activation (Fuse et al., 
2005). Investigation into the mechanism by which the adaptor negatively regulated 
TLR3 signalling revealed that Myd88 specifically targeted the activation of IRF3 by 
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IKKε but not TBK1 (Siednienko et al., 2011). Similar to Myd88, TIRAP has also 
been shown to have regulatory functions in TRIF-dependent signalling pathways. 
Initial observations made in TIRAP-deficient cells showed an increase in TLR3-
induced expression of IL-6 (Kenny et al., 2009). Furthermore, TLR3 activation of 
IFN-β by IRF7 was found to be inhibited by TIRAP associating with IRF7 and 
blocking its activation of the positive regulatory domain I/III of the IFN-β promoter 
(Siednienko et al., 2010). Interestingly, TRIF has recently been shown to potentially 
act as a negative regulator of Myd88-dependent induction of IL-12p70 and IL-6 in 
the TLR4 and TLR7 pathways of murine dendritic cells (Seregin et al., 2011). 
Although no mechanistic investigation has yet been conducted, it raises the 
interesting possibility of the TIR adaptors antagonising differential TLR cascades in 
order to fine tune and regulate the innate immune response. 
1.5.3.4 Negative Regulation of TLR Signalling by Post 
Translational Modifications 
Although splice variants, membrane domain proteins and the TIR adaptors 
themselves can regulate TLR signalling, vast arrays of enzymatic intracellular 
proteins have also been discovered to curtail excessive inflammatory signals by 
direct post-translational modifications. It is clear from the above that 
phosphorylation represents a critical step in the activation of the innate immune 
response and it is not surprising therefore that dephosphorylation events are often 
vital in inflammatory resolution. 
Recessive mutations in the murine gene Hcph
me
 (or Ptpn6
me
) that encodes the 
tyrosine kinase phosphatase Src homology protein tyrosine phosphatase (SHP-1) 
exhibit a condition known as “moth-eaten (me/me)” (Shultz et al., 1993). These mice 
are characterised by severe defects in hematopoiesis resulting in autoimmune 
symptoms, including immune complex deposition and auto-antibody production, 
with early mortality due to pneumonitis and other inflammatory disorders (Sidman et 
al., 1984, Greiner et al., 1986). Interestingly, another mutation in the Ptpn6 gene 
known as spin, also elicits a chronic inflammatory condition that can be rescued if 
Chapter 1: Introduction 
37 
 
 
mice are kept in a germfree environment. In addition, individual deficiencies in 
Myd88, IRAK4 and IL-1R also prevent the autoimmune disorders associated with 
this mutation indicating that SHP-1 plays an essential role in control of TLR-
mediated inflammation (Croker et al., 2008). SHP-1 was found to bind to the 
immunoreceptor tyrosine-based inhibition motif (ITIM) in the IRAK1 kinase domain 
whereby it prevents IRAK1 phosphorylation and its catalytic activity (An et al., 
2008).  
Members of the MAPK family can also be regulated by reversible phosphorylation 
events of conserved threonine and tyrosine residues in their tripeptide TXY signature 
motifs (Robinson and Cobb, 1997). A key mediator of MAPK dephosphorylation is 
the dual specificity (phosphor-tyrosine and phospho-serine/phospho-threonine) 
phosphatase MAP kinase phosphatase-1 (MKP-1) (Sun et al., 1993). TLR activation 
of MAPKs leads to the transcriptional upregualtion of MKP-1 and protein stability is 
maintained by ERK activity (Chen et al., 2002, Chi et al., 2006). Mice genetically 
deficient in MKP-1 are characterised by enhanced TLR4 induction of pro-
inflammatory cytokines and increased susceptibility to endotoxic shock. The 
increases in TNF-α and IL-6 are associated with prolonged p38 and JNK 
phosphorylation and AP-1 transcriptional activity (Chi et al., 2006, Zhao et al., 2006, 
Salojin et al., 2006). Interestingly, acetylation of MKP-1 during TLR signalling has 
been shown to increase MKP-1 interaction with p38 and increase p38 
dephosphorylation (Cao et al., 2008).  Therefore, MAPK regulation by 
dephosphorylation is vital to defend against an excessive pro-inflammatory response.  
Studies revealing MKP-1 acetylation were surprising as acetylation by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) has generally been 
associated with regulating gene expression by modifying histone proteins (Allfrey et 
al., 1964, Peterson, 2002). TLR4 activation leads to the recruitment of HDAC1 by 
the CREB related transcription factor activating transcription factor-3 (ATF-3) to 
NF-қB responsive genes and this causes deactelyation of associated histones 
resulting in the closure of chromatin and repression of gene expression (Gilchrist et 
al., 2006). Interestingly however, an increasing body of evidence has placed 
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acetylation as an important mediator of NF-қB regulation. Phosphorylation of the 
NF-қB family subunit p65 allows the recruitment of the nuclear cofactors p300/CBP 
and P/CAF that enable histone modification to allow gene transcription (Sheppard et 
al., 1999, Zhong et al., 1998, Sterner and Berger, 2000). Furthermore, p65 is the 
direct substrate for acetylation, and this post-translational modification prevents 
nuclear p65 from re-associating with de vovo IқBα. Upon deacetylation by HDAC3, 
p65 binds to IқBα and is exported from the nucleus via a chromosomal region 
maintenance-1 (CRM-1) dependent motif thereby limiting p65 transcriptional 
activity (Chen et al., 2001).  
A recent study has highlighted the complexity of acetylation events in pro-
inflammatory gene expression. During LPS-induced tolerance, a number of pro-
inflammatory genes but not antimicrobial mediators are desensitised to further gene 
transcription upon subsequent exposure to signal (Foster et al., 2007). This is 
mediated in part by the p50 subunit of NF-қB (that alone lacks transactivation 
potential) undergoing homo-dimerisation and subsequent blockage of transcriptional 
active NF-қB dimers to their shared gene responsive promoter sites (Ziegler-
Heitbrock et al., 1994, Schmitz and Baeuerle, 1991, Carmody et al., 2007). Upon 
TLR4 activation, p50 undergoes deacetylation and forms a repressorsome complex 
with nuclear receptor corepressor (NcoR), HDAC1, and HDAC3. This stable 
complex occupies genes containing an NF-қB binding motif (termed tolerisable 
genes) and renders them unresponsive to further LPS stimulation while allowing 
genes not containing this motif to be reactivated by subsequent stimulation (Yan et 
al., 2012). Taken together, alterations in phosphorylation and acetylation represent 
significant regulatory mechanisms in TLR signalling. 
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1.6 Ubiquitination and TLR Regulation 
1.6.1 The Ubiquitination Pathway 
Ubiquitination represents one of the most important regulatory systems in biology 
and is extensively used to orchestrate and regulate the complex signalling proteins 
utilised in the innate immune response (Bhoj and Chen, 2009). Ubiquitin is a highly 
conserved 76 amino-acid polypeptide that is ubiquitously expressed in eukaryotic 
cells (Goldstein et al., 1975, Wilkinson and Audhya, 1981). The ubiquitination 
process involves a 3 step enzymatic cascade involving a ubiquitin activating enzyme 
(E1), a ubiquitin conjugating enzyme (E2) and a ubiquitin ligase protein (E3) 
(Hershko et al., 1983). In humans there are two ubiquitin E1 enzymes, 
approximately forty to fifty E2 enzymes and hundreds of E3 ubiquitin ligases (Jiang 
and Chen, 2012). The E1 enzyme initiates the cascade by using ATP to adenylate 
ubiquitin at its C-terminal glycine residue. The sulfhydryl group of the catalytic 
cysteine in the active site of the E1 then attacks the adenylate to form a thioester 
bond between E1 and ubiquitin allowing AMP to be released. The ubiquitin bound 
E1 can then readily transfer the activated ubiquitin to the active cysteine site of the 
E2 enzyme through a transthioesterification. The cascade is complete when an E3 
ubiquitin ligase binds to the E2-ubiquitin complex and a substrate protein to 
facilitate the transfer of ubiquitin via a covalent isopeptide linkage between the 
carboxyl-terminal glycine of ubiquitin and the ε-amino group of a lysine residue on 
the target protein (Strieter and Korasick, 2011, Herrmann et al., 2007, Pickart and 
Eddins, 2004). The E3 ligases mediate substrate specificity and have been a major 
focus of research in TLR signalling. Two distinct groups of E3 ligases have been 
distinguished. The RING domain E3 ligases are characterised by an octet of cysteine 
and histidine residues that constitute a zinc binding domain (Lorick et al., 1999). 
Mutations of these cysteine residues interfere with the zinc binding domain and E2 
ligase interaction and often result in a loss in E3 ligase activity (Itahana et al., 2007, 
Deshaies and Joazeiro, 2009). RING domain E3 ligases are not thought to transfer 
the ubiquitin from E2 onto an active site on themselves and instead function by 
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positioning the reactive ubiquitin-E2 thioester bond in close proximity to the 
nucleophilic lysine residue of the substrate protein and may initiate conformation 
changes to aid ubiquitin substrate transfer (Deshaies and Joazeiro, 2009). The other 
group of E3 ligases are known as the homologous to E6-activating protein (E6-AP) 
carboxy terminus (HECT) domain containing enzymes. These E3 ligases contain an 
invariant cysteine residue that accepts the ubiquitin molecule directly from the E2 
enzyme in which ubiquitin is thioesterified to the HECT domain, as is the case for 
the archetypical member E6-AP (Scheffner et al., 1995). The ubiquitin is then 
transferred from this intermediate to the substrate by the HECT E3 directly.  
Ubiquitination of a protein can occur at a single lysine in a process known as 
monoubiquitination or ubiquitin chains can be formed as E2 and E3 enzymes 
catalyse the formation of a covalent isopeptide bond between a carboxyl group of 
one ubiquitin glycine to the amino group of another ubiquitin's lysine residue, a 
process known as polyubiquitination (Terrell et al., 1998, Chau et al., 1989).  In 
addition, a protein may be subjected to multiple ubiquitination events on different 
lysine residues simultaneously a process termed multi-ubiquitination (Petroski and 
Deshaies, 2003). Monoubiquitin events have mainly been associated with receptor 
internalisation and endocytosis, trafficking and gene silencing (Terrell et al., 1998, 
Endoh et al., 2012, Wu et al., 2011).  In regards to polyubiquitin chain formation, 
the ubiquitin molecule contains 7 lysine residues (K6, K11, K27, K29, K33, K48, 
and K63) and an N-terminal methionine residue (M1) all of which can act as a 
ubiquitin acceptor site (Xu et al., 2009, Kirisako et al., 2006). While K48-linked 
polyubiquitination targets proteins for proteasomal degradation, K63-linked chains 
function in non-proteolytic events that modify the proteins signalling functionality.  
The roles of the other lysine linkages (K6, K11, K27, K29 and K33) and linear 
ubiquitination (M1) remain to be fully elucidated but are thought to function in both 
proteasomal dependent and independent processes. Like phosphorylation, 
ubiquitination is a reversible modification and serves as a key regulatory 
consequence of signal transduction. This process is facilitated by approximately 100 
deubiquitinating (DUB) enzymes, cysteine metalloproteases that cleave ubiquitin 
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chains from protein substrates or their degradation remnants (Sun, 2008). Ubiquitin-
specific proteases (USPs) are the largest family of DUBs and contain two short well 
conserved motifs, Cys and His boxes that include residues critical for catalysis. The 
different USPs also contain motifs and sequences outside this domain which may 
confer substrate specificity (Nijman et al., 2005). As the E3 ubiquitin ligases and 
their antagonising DUB enzymes represent a major regulatory control mechanism, it 
is not surprising they have been heavily implicated in the control of TLR signalling 
pathways. 
1.6.2 Polyubiquitination, a Key Regulator of TLR 
Signalling 
The critical nature of polyubiquitin chain formation in facilitating TLR signalling is 
self-evident. TRAF6 dependent K63-linked ubiquitination mediates IKK-induced 
phosphorylation of IқBα and triggers its K48-linked degradation, allowing NF-қB to 
translocate to the nucleus and induce gene transcription. However, in conjugation 
with its positive role in TLR signal propagation, polyubiquintation events play key 
roles in the negative regulation of the inflammatory response.    
TLR4 and TLR9 activation potently upregulates the expression of the SOCS box 
containing protein SOCS1, a protein thought to possess E3 ligase like activity 
(Crespo et al., 2000, Dalpke et al., 2001). The SOCS box is characterised by its 
ability to bind elongin B, elongin C, cullin-5 and RING-box-2 (RBX2), which 
recruits E2 ubiquitin transferase to mediate ubiquitin conjugation activity (Kamura et 
al., 2004). Interestingly, SOCS1-deficient mice display hyper-responsive LPS-
induced cytokine production and increased susceptibility to endotoxin-mediated 
septic shock (Kinjyo et al., 2002, Nakagawa et al., 2002b). SOCS1 mediates its 
negative regulation of TLR4 during a negative feedback loop that is thought to 
involve the ubquitination and proteasomal degradation of a number of key signalling 
components of the pathway. During TLR4 signalling Bruton's tyrosine kinase (Btk) 
phosphorylates TIRAP facilitating the recruitment of SOCS1 triggering TIRAP 
polyubiquintation on lysines 15 and 16. This modification then targets the TIR 
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adaptor for proteasome-mediated degradation (Mansell et al., 2006). As SOCS1 can 
also inhibit TLR9 signalling, a TLR that does not utilise TIRAP, it must target other 
proteins in this signalling cascade (Nakagawa et al., 2002a). Recently, SOCS1 has 
also been implicated in the direct polyubiquintation of the NF-қB subunit p65 
(Strebovsky et al., 2011). In this model, SOCS1 translocates to the nucleus and 
interacts with p65 via the former’s SH2 domain. SOCS1 was shown to preferentially 
bind p65 but not a transcriptionally inactive mutant form. In turn, SOCS1 p65 
interaction leads to SOCS box dependent ubiquitination and degradation of p65 to 
curtail pro-inflammatory cytokine production.  
Ubiquitin dependent proteasomal regulation of the innate immune response is not 
restricted to NF-қB and pro-inflammatory signalling. Recently, RTA-associated 
ubiquitin ligase (RAUL) has been implicated in the direct catalysis of K48-linked 
polyubiquitination of the antiviral transcription factors IRF3 and IRF7 leading to 
their proteasomal degradation (Yu and Hayward, 2010). RAUL is a HECT domain 
containing E3 ligases that under resting conditions is thought to undergo auto-
ubiquitination-mediated self-degradation. Interestingly, during antiviral signalling by 
TLR3 or RIG-I, RAUL associates with a DUB enzyme known as USP7 leading to 
the removal of K48-linked chains from the E3 ligase. This newly stabilised protein 
can then in turn mediated polyubiquitination of its target transcription factors thereby 
limiting a potentially harmful type 1 IFN response. This mechanism of action 
highlights the complex dynamics of ubiquitin events that control the innate immune 
response. Furthermore, as IRF7 requires K63- linked ubiquitination for activation 
and induction of gene expression, an interplay between the different ubiquitin 
linkages possibly mediated by additional DUBs and/or E3 ligases is crucial in the 
type 1 IFN response (Ning et al., 2008a). USP7 has also recently been shown to 
regulate NF-қB-mediated transcriptional events. RNA interference (RNAi) studies 
specifically targeting USP7 revealed it had a functional role in maintaining TLR-
induced pro-inflammatory cytokine production. USP7 however had no effect on 
upstream NF-қB signalling intermediates or on p65 nuclear translocation. USP7 
functions by deubiquitinating promoter bound p65, preventing its proteasomal 
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degradation and therefore allowing maintained pro-inflammatory gene expression 
(Colleran et al., 2013). These two studies highlight an intriguing scenario whereby a 
single DUB enzyme can function as a positive regulator of the pro-inflammatory but 
negatively regulator of the anti-viral response, indicating it may play a key 
determining role in the innate immune response mounted to a specific pathogen 
threat.  
A20 is a zinc RING domain containing E3 ligase that can also be classed as a 
cysteine protease DUB due to a catalytic deubiquitination domain at its N-terminus 
(Opipari et al., 1990, Wertz et al., 2004). A20 is rapidly upregulated during LPS 
signalling and in turn negatively regulates TLR activation of pro-inflammatory 
cytokine production (Cooper et al., 1996, Boone et al., 2004, O’Reilly and Moynagh, 
2003). Upon TLR4 activation, A20 is recruited to TRAF6 and facilitates the removal 
of K63-linked chains preventing its ability to bind the TAK1 TAB complex (Boone 
et al., 2004, Heyninck and Beyaert, 1999). A20 also has the ability to potently inhibit 
IRF3 transcriptional activity (Saitoh et al., 2005). It is thought that A20 in 
combination with its adaptor protein Tax1-binding protein 1 (TAX1BP1) binds the 
non-canonical IKKs, TBK1 and IKKε, and removes K63-linked ubiquitin chains that 
aid in IRF3 phosphorylation to restrict the antiviral response (Parvatiyar et al., 2010).  
A20 has also been implicated in the negative regulation of IRF7 during Epstein-Barr 
virus (EBV) oncoprotein latent membrane protein (LMP) 1-mediated activation. A20 
binds to IRF7 via its DUB domain and mediates K63-linked deubiquitination of the 
transcription factor correlating with decreased antiviral transcriptional activity (Ning 
and Pagano, 2010).  
Conceptually, it would be easy to say that K63 ubiquitination propagates TLR 
downstream inflammatory signalling and deubiquitination serves as a key regulator 
in curtailing this response. Emerging evidence in the field however is highlighting a 
more complex regulatory system is at play. TRAF6, in addition to conjugating K63-
linked ubiquitin chains to activate the NF-қB pathway, has also been shown to 
directly polyubiquitinate AKT of the PI3K pathway. K63 modified AKT can then 
relocate to the plasma membrane whereby it becomes phosphorylated and activated 
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(Yang et al., 2009b). Although the authors of this study did not examine its effect on 
the inflammatory response, it is known that the TIR domain containing protein 
BCAP negatively regulates TLR signalling at the membrane via AKT recruitment 
and downstream signal activation and one could speculate that this may represent a 
novel regulatory mechanism at play in TLR signalling. In any case, as the sheer 
number of E3 ligases identified in eukaryotic signalling has now outpaced that of the 
kinase family, further work is warranted and required to fully access the role 
polyubiquitination plays in the innate immune response (Deshaies and Joazeiro, 
2009).  
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Fig. 1.2 Negative regulation of TLR signalling 
See section 1.5.3 for detailed description of negative regulation of TLR signalling by 
splice variant, transmembrane receptors, the TIR adaptors, phosphatases and 
acetylation modifications. See section 1.6.2 for detailed description of negative 
regulation by ubiquitination. White circles with red labels identify negative 
regulators of TLR signalling. Red Xs represent where in the pathway is targeted for 
regulation. 
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1.7 The Pellino Family  
It is clear from the above that ubiquitination is a central regulator of TLR signalling. 
The recent discovery of a mammalian family of closely related E3 ubiquitin ligases 
known as the Pellino proteins, that show strong homology to the Pelle (IRAK) 
interacting protein in the Drosphila Toll pathway, has focused research effort on 
their roles in TLR signalling. Pellino was first identified in 1999 in a yeast two-
hybrid screen and shortly afterwards 3 mammalian family members were uncovered, 
genetically annotated Peli1, Peli2 and Peli3 (Grosshans et al., 1999, Rich et al., 2000, 
Resch et al., 2001, Jensen and Whitehead, 2003c). The human Pellino proteins, 
Pellino1, Pellino2 and two splice variants of Pellino3 known as Pellino3a and 
Pellino3b are highly conserved and encoded on chromosomes 2, 14 and 11 
respectively. Pellino1 and Pellino2 are most similar in size and identity as the 
Pellino3 proteins have an additional 27 amino acid leader sequence n their N 
terminus. Pellino3a consists of 7 exons however Pellino3b is missing exon2 leading 
to an in frame deletion of 24 amino acids.  Similarly, murine Pellino1, Pellino2 and 
Pellino3 are also highly conserved; one noticeable difference however is that 
Pellino3 only has one isoform and no splice variants in the mouse genome. In 
addition murine Pellino1, Pellino2 and Pellino3 are mapped to chromosomes 11, 14 
and 19 respectively. Pellino proteins have also been highly selected throughout 
evolution with human Pellino1 sharing 40% aa homology to Caenorhabditis elegans 
Pellino (Schauvliege et al., 2007). This high degree of conservation between the 
different species and the selection of 3 isoforms in most mammals suggests the 
Pellino proteins serve an important biological purpose(s) (see Fig. 1.3 for sequence 
alignments and Table 1.2 for percentage sequence identity). 
At the time of their discovery in mammals, the Pellino proteins were shown to be 
able to bind IRAK1, IRAK4, TAK1 and TRAF6 suggesting that Pellino proteins 
may function in TLR signal transduction (Butler et al., 2005, Jiang et al., 2003a, 
Strelow et al., 2003b). As no functional or catalytic domains had been ascribed for 
the Pellino proteins, they were thought to act as mere signalling scaffolds (Jensen 
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and Whitehead, 2003c).  However the presence of a RING-like domain 
(CHC2CHC2) in the Pellino proteins C terminus indicated that they may possess E3 
ubiquitin ligase activity. Overexpression studies showed that all Pellino proteins 
could bind to IRAK1 and facilitate its polyubiquitination (Schauvliege et al., 2006).  
Subsequent studies showed that the Pellino proteins could directly catalyse K63-
linked polyubiquitin chains of IRAK1 in vitro and that they are in fact E3 ubiquitin 
ligases (Butler et al., 2007). Furthermore, the Pellino proteins E3 ligase activity was 
shown to be under direct control of IRAK1 and IRAK4 phosphorylation. In addition, 
Pellino1 was shown to be able to associate with a number of E2 ubiquitin 
conjugating enzymes and mediate not only K63, but also K48 and K11-linked chain 
formation in vitro suggesting Pellino proteins can mediate diverse cellular signalling 
events (Ordureau et al., 2008). Intriguingly, the RING-like domain of the Pellino 
proteins does not mediate IRAK binding. Resolution of the X-ray crystal structure of 
Pellino2 lacking its RING-like domain revealed the presence of a cryptic N terminal 
forkhead associated (FHA) domain (Lin et al., 2008), a module known to confer 
recognition and binding of phosphor-serine-theronine residues on interacting 
proteins. The Pellino2 FHA domain was found to be responsible for interaction with 
phosphorylated IRAK. Interestingly, this FHA domain is flanked by two atypical 
wing appendages, the function of which are still unknown (Lin et al., 2008). A viral 
form of Pellino has been identified in the genome of a member of the 
Entomopoxvirinae (poxviruses of insects) family, specifically, Melanoplus 
sanguinipes entomopoxvirus (MsEPV), a virus that infects the North American 
grasshopper (Rich et al., 2000, Afonso et al., 1999). Viral Pellino (vPellino) does not 
contain a RING-like domain or the wing appendages around its FHA domain. 
Interestingly vPellino was shown to be able to bind to phosphorylated IRAK but not 
induce its polyubiquitination and inhibit both Toll and TLR-mediated anti-
microbial/inflammatory responses (Griffin et al., 2011). As viruses have evolved to 
target key innate immune signalling complexes and only advantageous viral proteins 
are retained, the selection of a viral Pellino protein highlights the potential 
importance the Pellino proteins must play in the innate immune response. 
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hPeli1      1 ---------------------------MFSPDQENH--PSKAPVKYGELIVLG------- 
mPeli1      1 ---------------------------MFSPDQENH--PSKAPVKYGELIVLG------- 
hPeli2      1 ---------------------------MFSPGQEEHCAPNKEPVKYGELVVLG------- 
mPeli2      1 ---------------------------MFSPGQEEPSAPNKEPVKYGELVVLG------- 
hPeli3a     1 MVLEGNPEVGSPRTSDLQHRGNKGSCVLSSPGEDAQ--PGEEPIKYGELIVLGCCEEGGE 
hPeli3b     1 MVLEGNPEVGSPRTSDLQHRGNKGSCVLSSPGEDAQ--PGEEPIKYGELIVLG------- 
mPeli3      1 MVLEGNPDVGSPRTSDLQHPGSQGSCILSCPGEEAL--AGEEPIKYGELIVLG------- 
dPellino    1 ---------------MVKRTDGTESPILAEDGGDGH---DKPRLRYGELVILG------- 
 
 
hPeli1     25 -----------------YNGSLPNGDRGRRKSRFALFKRPKANGVKPSTVHIACTPQAAK 
mPeli1     25 -----------------YNGSLPNGDRGRRKSRFALFKRPKANGVKPSTVHIACTPQAAK 
hPeli2     27 -----------------YNGALPNGDRGRRKSRFALYKRPKANGVKPSTVHVISTPQASK 
mPeli2     27 -----------------YNGALPNGDRGRRKSRFALYKRTYASGVKPSTIHMVSTPQASK 
hPeli3a    59 ETEAQRGEVTGPRAHSCYNGCLASGDKGRRRSRLALSRRSHANGVKPDVMHHISTPLVSK 
hPeli3b    52 -----------------YNGCLASGDKGRRRSRLALSRRSHANGVKPDVMHHISTPLVSK 
mPeli3     25 -----------------YNGCLASGDKGRRRSRLALSRRPHANGVKPDVMHHISTPLVSK 
dPellino   36 -----------------YNGYLPQGDRGRRRSKFVLHKRTEASGVKRSKHYIVQSPQTSK 
 
hPeli1     68 AISNKDQHSISYTLSRAQTVVVEYTHDSNTDMFQIGRSTESPIDFVVTDTVPGSQSNSDT 
mPeli1     68 AISNKDQHSISYTLSRAQTVVVEYTHDSNTDMFQIGRSTESPIDFVVTDTVPGSQSNSDT 
hPeli2     70 AISCKGQHSISYTLSRNQTVVVEYTHDKDTDMFQVGRSTESPIDFVVTDTISGSQNTDEA 
mPeli2     70 AISSRGHHSISYTLSRSQTVVVEYTHDKDTDMFQVGRSTESPIDFVVTDTVSGGQNE-DA 
hPeli3a   119 ALSNRGQHSISYTLSRSHSVIVEYTHDSDTDMFQIGRSTENMIDFVVTDTSPGGGAA-EG 
hPeli3b    95 ALSNRGQHSISYTLSRSHSVIVEYTHDSDTDMFQIGRSTENMIDFVVTDTSPGGGAA-EG 
mPeli3     68 ALSNRGQHSISFTLSRSHSVIVEYTHDSDKDMFQIGRSTENMIDFVVTDTSPGGGAT-EG 
dPellino   79 AILDANQHSISYTLSRNQAVIVEYKEDTETDMFQVGRSSESPIDFVVMDTLPGDKK--DA 
 
hPeli1    128 QSVQSTISRFACRIICERNPPFTARIYAAGFDSSKNIFLGEKAAKWKTSDGQMDGLTTNG 
mPeli1    128 QSVQSTISRFACRIICERSPPFTARIYAAGFDSSKNIFLGEKAAKWKTSDGQMDGLTTNG 
hPeli2    130 QITQSTISRFACRIVCDRNEPYTARIFAAGFDSSKNIFLGEKAAKWKNPDGHMDGLTTNG 
mPeli2    129 QITQSTISRFACRIVCDRNEPYTARIFAAGFDSSKNIFLGEKAAKWKNPDGHMDGLTTNG 
hPeli3a   178 PSAQSTISRYACRILCDRRPPYTARIYAAGFDASSNIFLGERAAKWRTPDGLMDGLTTNG 
hPeli3b   154 PSAQSTISRYACRILCDRRPPYTARIYAAGFDASSNIFLGERAAKWRTPDGLMDGLTTNG 
mPeli3    127 PSAQSTISRYACRILCDRRPPYTARIYAAGFDASSNIFLGERAAKWRTPDGLMDGLTTNG 
dPellino  137 KVMQSTISRFACRILVNRCEPAKARIFAAGFDSSRNIFLGEKATKWQDN-VEIDGLTTNG 
 
hPeli1    188 VLVMHPRNGFTED-SKPGIWREISVCGNVFSLRETRSAQQRGKMVEIETNQLQDGSLIDL 
mPeli1    188 VLVMHPRNGFTED-SKPGIWREISVCGNVFSLRETRSAQQRGKMVEIETNQLQDGSLIDL 
hPeli2    190 VLVMHPRGGFTEE-SQPGVWREISVCGDVYTLRETRSAQQRGKLVESETNVLQDGSLIDL 
mPeli2    189 VLVMHPQGGFTEE-SQPGVWREISVCGDVYTLRETRSAQQRGKLVESETNVLQDGSLIDL 
hPeli3a   238 VLVMHPAGGFSED-SAPGVWREISVCGNVYTLRDSRSAQQRGKLVENESNVLQDGSLIDL 
hPeli3b   214 VLVMHPAGGFSED-SAPGVWREISVCGNVYTLRDSRSAQQRGKLVENESNVLQDGSLIDL 
mPeli3    187 VLVMHPAGGFSED-SAPGVWREISVCGNVYTLRDSRSAQQRGKLVENESNVLQDGSLIDL 
dPellino  196 VLIMHPKGSFCGGNAKCGLWRECSVGGDVFSLRESRSAQQKGQPIYDECNILQDGTLIDL 
 
hPeli1    247 CGATLLWRTAEGLSHTPTVKHLEALRQEINAARPQCPVGFNTLAFPSMKRKD-VVDEKQP 
mPeli1    247 CGATLLWRTAEGLSHTPTVKHLEALRQEINAARPQCPVGFNTLAFPSMKRKD-VVDEKQP 
hPeli2    249 CGATLLWRTADGLFHTPTQKHIEALRQEINAARPQCPVGLNTLAFPSINRKE-VVEEKQP 
mPeli2    248 CGATLLWRTADGLFHAPTQKHIEALRQEINAARPQCPVGLNTLAFPSINRKE-VVEEKQP 
hPeli3a   297 CGATLLWRTPAGLLRAPTLKQLEAQRQEANAARPQCPVGLSTLAFPSPARGRTAPDKQQP 
hPeli3b   273 CGATLLWRTPAGLLRAPTLKQLEAQRQEANAARPQCPVGLSTLAFPSPARGRTAPDKQQP 
mPeli3    246 CGATLLWRTPAGLLRAPTLKQLEAQRQEANAARPQCPVGLSTLAFPSPARGRTAPDKQQP 
dPellino  256 CGATLLWRSAEGLQHSPTKHDLEKLIDAINAGRPQCPVGLNTLVIPRKVNI--GDQVNQP 
 
hPeli1    306 WVYLNCGHVHGYHNWGNKEERDGKDRECPMCRSVGPYVPLWLGCEAGFYVDAGPPTHAFS 
mPeli1    306 WVYLNCGHVHGYHNWGNKEERDGKDRECPMCRSVGPYVPLWLGCEAGFYVDAGPPTHAFS 
hPeli2    308 WAYLSCGHVHGYHNWGHRSDTEANERECPMCRTVGPYVPLWLGCEAGFYVDAGPPTHAFT 
mPeli2    307 WAYLSCGHVHGYHSWGHRSDTEANERECPMCRTVGPYVPLWLGCEAGFYVDAGPPTHAFT 
hPeli3a   357 WVYVRCGHVHGYHGWGCRRERGPQERECPLCRLVGPYVPLWLGQEAGLCLDPGPPSHAFA 
hPeli3b   333 WVYVRCGHVHGYHGWGCRRERGPQERECPLCRLVGPYVPLWLGQEAGLCLDPGPPSHAFA 
mPeli3    306 WVYVRCGHVHGYHGWGCRREQGPQERECPLCRLVGPYVPLWLGQEAGLCLDPGPPSHAFA 
dPellino  314 YVYLNCGHVQGHHDWGQDENTG--ARRCPMCLELGPVVTLCMGLEPAFYVDVGAPTYAFN 
 
hPeli1    366 PCGHVCSEKTTAYWSQIPLPHGTHTFHAACPFCAHQLAGEQGYIRLIFQGPLD 
mPeli1    366 PCGHVCSEKTTAYWSQIPLPHGTHTFHAACPFCAHQLAGEQGYIRLIFQGPLD 
hPeli2    368 PCGHVCSEKSAKYWSQIPLPHGTHAFHAACPFCATQLVGEQNCIKLIFQGPID 
mPeli2    367 PCGHVCSEKSAKYWSQIPLPHGTHAFHAACPFCATQLVGEQNCIKLIFQGPVD 
hPeli3a   417 PCGHVCSEKTARYWAQTPLPHGTHAFHAACPFCGAWLTGEHGCVRLIFQGPLD 
hPeli3b   393 PCGHVCSEKTARYWAQTPLPHGTHAFHAACPFCGAWLTGEHGCVRLIFQGPLD 
mPeli3    366 PCGHVCSEKTARYWAQTPLPHGTHAFHAACPFCGAWLTGELGCVRLIFQGPLD 
dPellino  372 PCGHMATEKTVKYWANVEIPHGTNGFQAVCPFCATPLDGATGYIKLIFQDNLD 
 
Fig. 1.3 Amino Acid Sequence Alignment of the Pellino proteins  
Amino acid (aa) sequence alignment for human (h), murine (m) and drosophila (d) 
Pellino (Peli) proteins. Black shading indicates identical aa and grey indicates similar 
aa. Analysis conducted with CLUSTALW and Boxshade software. 
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     Table 1.2 Pellino Proteins Percentage Sequence Identity 
Table shows the percentage sequence identity between human (h), mouse (m) and fly 
(d) Pellino (Peli) proteins. Analysis conducted with CLUSTALW software. 
 
 
 
 
 hPeli1 mPeli1 hPeli2 mPeli2 hPeli3a hPeli3b mPeli3 dPellino 
hPeli1 100.00    99.76    81.82    79.86    70.50    70.50    69.78    60.49 
mPeli1 99.76   100.00    81.58    79.62    70.50    70.50    69.78    60.49 
hPeli2 81.82    81.58   100.00    95.23    71.22    71.22    70.74    60.24 
mPeli2 79.86    79.62    95.23   71.22    71.22    100.00    70.50    60.49 
hPeli3a 70.50    70.50    71.22    71.22   100.00   100.00   96.63    52.25 
hPeli3b 70.50    70.50    71.22    71.22   100.00   100.00   96.63    52.25 
mPeli3 69.78    69.78    70.74    70.50    96.63    96.63   100.00    51.77 
dPellino 60.49    60.49    60.24    60.49    52.25    52.25    51.77   100.00 
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1.7.1 Pellino1 
Initial investigations into the role of Pellino1 during the immune response were 
solely based on overexpression and RNAi approaches. Such studies concluded that 
Pellino1 played an important role in both IL-1R and TLR signalling cascades by the 
formation of polyubiquitin chains on IRAK molecules to facilitate downstream 
activation of the NF-қB pathway (Jiang et al., 2003a, Schauvliege et al., 2006, 
Butler et al., 2007). Such studies were further complemented by the finding that the 
inhibitory properties of TGF-β and the TGF-β family member Bone morphogenetic 
protein-4 (BMP-4) on IL-1R and TLR signalling were mediated at the Pellino1 level. 
TGF-β signalling was shown to activate SMAD6 which could associate with 
Pellino1 and prevent the formation of the Pellino1-IRAK1-IRAK4-TRAF6 
signalling complex thereby abrogating NF-қB activation (Choi et al., 2006, Lee et al., 
2010).  
Although such approaches all indicated that Pellino1 functions at the level of IRAK 
signalling, the generation of Pellino1-deficient mice proved otherwise as Pellino1 
was not required to propagate IL-1R signalling. Instead, Pellino1 was essential for 
TRIF dependent activation of the IKKs and NF-қB and the subsequent pro-
inflammatory cytokine response. Importantly, this investigation revealed that 
Pellino1 interacted with and facilitated RIP1 polyubiquitination, a modification 
crucial for TRIF-dependent signalling (Chang et al., 2009). Interestingly however, 
Pellino1 was also required for TLR9 signalling in B cells, a pathway that does not 
require TRIF and RIP1 activity indicating other functional roles for the Pellino 
during TLR signalling (Zhang et al., 2011, Hoebe et al., 2003). A number of years 
later the same group discovered that Pellino1 was required to prevent autoimmunity 
by inhibiting T cell activation as Pellino1-deficient mice spontaneously develop 
multi-organ inflammation and auto-antibody production due to hyper active T cells 
that are refractory to regulatory T cell suppression (Chang et al., 2011). Surprisingly, 
Pellino1 was found to function in the K48-linked polyubiquitination and proteasomal 
degradation of c-REL, a late phase induced NF-қB family subunit in T cells 
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responsible for transcription of genes required for T cell activation, differentiation 
and prevention of anergy (Chang et al., 2011). More recently, a third study from this 
group demonstrated that Pellino1 also played important roles in CNS inflammation. 
Pellino1 was required for MAPK activation in microglial cells. Pellino1 was shown 
to bind to TRAF3, a potent inhibitor of MAPK activation, leading to its K48-linked 
ubquitination and degradation allowing optimal induction of pro-inflammatory and 
chemoattractant cytokines. Furthermore, this had striking physiological 
consequences in experimental autoimmune encephalomyelitis whereby Pellino1-
deficient mice do not display recruitment of pathogenic T cells into the CNS and are 
highly protected from disease onset and progression (Xiao et al., 2013). 
The generation of a specific knock-in mouse model in which the wild type Pellino1 
protein was replaced with a Pellino1
F397A
 mutant thought to be devoid of E3 ligase 
activity revealed a further role for Pellino1 in innate immunity (Enesa et al., 2012). 
Pellino1
F397A 
mice display a reduction in type 1 IFN production in response to 
dsRNA viruses and ligands with reduced binding of IRF3 to the IFN-β (Enesa et al., 
2012). Interestingly, TLR3 induction of RIP1 polyubiquitination and MAPK 
activation is not unaffected in this mouse model. Although the reason for this is 
unclear, it is possible that the single aa substitution in the knock-in mouse may not 
fully abolish the proteins E3 ligase activity or the protein may aid in the recruitment 
of another catalytically active mediator.  
In addition to the functional roles Pellino1 plays in the innate immune response, 
recent investigations into the upstream activators of Pellino1 that govern its 
downstream activities have been explored using newly synthesised pharmacological 
kinase inhibitors. During Il-1R signalling IRAK1 is the major kinase responsible for 
Pellino1 phosphorylation, while during TLR signalling the IKK related kinases, 
TBK1 and IKKε, mediate phosphorylation (Goh et al., 2012, Smith et al., 2011).  
Although additional insight is required to fully delineate Pellino1 functionality, the 
generation of Pellino1-deficient mice was highly informative in understanding the 
importance of this proteins role in the complexities of the immune response. 
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1.7.2 Pellino2 
Although the role of Pellino1 in the innate immune response has been extensively 
investigated, the functional role of Pellino2 in innate immunity remains ambiguous. 
As was the case for Pellino1, Pellino2 was first reported to interact with and be 
phosphorylated by IRAK1 and IRAK4 (Strelow et al., 2003b). However, unlike 
Pellino1, overexpression of Pellino2 does not induce the transcriptional activity of 
the NF-қB reporter construct (Strelow et al., 2003a). In contrast, overexpression and 
RNAi knockdown of murine Pellino2 indicated that the protein may function in IL-
1R and TLR4 but not TNF-α activation of the IL-8 promoter (Yu et al., 2002). 
Further overexpression studies demonstrated that Pellino2 could also interact with 
TRAF6 and TAK1 and stimulate the kinase activity of JNK, culminating in 
increased activity of the transcription factors AP-1 and Elk-1 (Jensen and Whitehead, 
2003a). However, another study concluded that Pellino2 acted as a bridging partner 
for Bcl-10 in a LPS-induced signalling complex including Bcl-10-MALT1-TRAF6-
TAK1 for NF-қB activation and had no role in AP-1 or Elk-1 activity (Liu et al., 
2004, Dong et al., 2006). To date, the most comprehensive report into the function of 
Pellino2 in innate immunity indicates that the E3 ligase may be required for 
phosphorylation of the MAPKs JNK and ERK to maintain pro-inflammatory 
transcript stability (Kim et al., 2012). Although the role of Pellino2 in innate 
immune signalling is somewhat controversial, a few reports indicating it may play a 
role in human health are emerging. Recently, a microarray analyses of 128 genes 
involved in the TLR signalling pathway were performed in nephrectomy samples of 
patients with chronic allograft nephropathy and acute rejection. Of all the genes 
screened Pellino2, IL-8 and the E2 ubiquitin conjugating enzyme E2-UBE2V1 were 
the only significantly upregulated genes indicating a potential role in inflammation 
induced transplant damage and rejection (Nogueira et al., 2009). A genome wide 
association study also mapped a number of single nucleotide polymorphisms (SNP) 
to chromosome 14q21 that correlated with decreased susceptibility to bladder cancer. 
One SNP, rs398652 was found to occur in the intergenic space just before Peli2 and 
the authors of the study suggested that a SNP in Peli2 may be associated with 
Chapter 1: Introduction 
53 
 
 
decreased inflammation and decreased cancer risk (Gu et al., 2011). However, like 
the basic research into Pellino2’s functionality in vitro these clinical observations 
require more effort in order to define Pellino2’s role in inflammation. The generation 
of a Pellino2-deficient animal will no doubt aid in delineation of the E3 ligases 
physiological role in the immune response. 
1.7.3 Pellino3 
Pellino3 transcript is present in most human tissue with highest expression levels in 
the heart, brain and testes (Jensen and Whitehead, 2003b). Furthermore, it was 
shown that Pellino3 could also interact with IRAK1, TRAF6 and TAK1 upon IL-1R 
signalling but its overexpression failed to activate NF-қB reporter constructs. Instead, 
Pellino3 was thought to activate MAPK kinase activity and trigger increased 
transcriptional activity of c-JUN and Elk-1 (Jensen and Whitehead, 2003b). However, 
as was the case for Pellino2, there have been contrasting reports on the function of 
Pellino3. An additional study indicated that knockdown of Pellino3 by siRNA 
augments TAK1 dependent signalling and IL-8 production (Xiao et al., 2008). In 
support of the initial finding that Pellino3 may act in the MAPK pathways, 
overexpression of Pellino3 was shown to induce p38 phosphorylation. In addition, 
knockdown of Pellino3 with siRNA led to a decrease in Il-1β activation of p38. The 
ability of Pellino3 to activate p38 was reliant on TRAF6 and TAK1 functionality 
(Butler et al., 2005). Further studies into Pellino3’s role in p38 activation revealed 
that Pellino3 was required in a signalling axis for TLR4 activation of the 
transcription factor CREB in a TRAF6 and p38 dependent manner. Interestingly, 
mutation of cysteine residues in the Pellino3 RING-like domain rendered Pellino3 
signal transduction ineffective (Mellett et al., 2011). The most current report on 
Pellino3’s function indicates that Pellino3 and IRAK1 are activated by oxidized low-
density lipoprotein (oxLDL) that accumulates in atherosclerotic lesions. Upon 
macrophage ingestion of oxLDL, they transform into lipid laden foam cells (Conway 
and Kinter, 2006). It was recently shown that oxLDL treated macrophages have a 
reduced capacity to trigger IFN-β upon LPS stimulation. Mechanistically, it has been 
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proposed that oxLDL activated IRAK1 and Pellino3 induce TANK modification 
leading to inactivation of TBK1 and reduced phosphorylation of IRF3 (Tzieply et al., 
2012).  
Taken together, Pellino3 has been implicated in NF-қB, MAPK/AP-1 and the IRF 
signalling pathways. However, an exact mechanistic understanding of how Pellino3 
functions in TLR signalling and what physiologically relevant role it holds is still 
largely unknown. In order to address this deficit in innate immune signalling 
knowledge, this studies aims to elucidate the physiological role of Pellino3 in TLR 
signalling. 
1.8 Project Aims 
The aims of this thesis were: 
 To employ Pellino3-deficient mice and RNAi knockdown approaches to 
define the function of Pellino3 in TLR signalling.  
 To delineate the mechanistic basis underlying the regulatory role(s) of 
Pellino3 in TLR signalling.  
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2.1 Materials 
2.1.1 Reagents 
Reagents Supplier 
7-AAD Viability Staining Solution eBiosciences 
Agar Sigma 
Agarose Promega 
Ampicillin Sigma 
APS Sigma 
Bovine serum albumin (BSA) Sigma 
TRAF6 siRNA Ambion 
GAPDH siRNA Ambion 
Pellino3 shRNA Sigma 
Control shRNA Sigma 
Bradford reagent dye Bio-Rad 
Bromophenol blue Sigma 
CHAPS Sigma 
Chloroform Sigma 
CLO97 Invivogen 
Coomassie Blue (G250) Sigma 
CpG type A ODN 1585  Invivogen 
CpG type B ODN 1666 Invivogen 
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DirectPCR Lysis Reagent (Tail) Viagen Biotech 
DMEM (Dulbecco's Modified Eagle's medium) Invitrogen 
DMSO (dimethyl  sulfoxid) Sigma 
DNA ladder & Loading dye Promega 
dNTPs (deoxyribonucleotide triphosphates) Promega 
DTT (dithiothreitol) Sigma 
E.coli-TOP10 competent cells Invitrogen 
EDTA (ethylenediaminetetra-acetic acid) Sigma 
Ethanol Sigma 
Ethidium bromide Sigma 
FBS (fetal bovine serum) Invitrogen 
Flagellin Invivogen 
Glycerol Sigma 
Glycine Sigma 
GoTaq®
 
polymerase Promega 
GoTaq® Green Master Mix Promega 
HEPES Sigma 
Hydrochloric acid (HCl) Merck 
Hydrogen peroxide solution (H2O2) Sigma 
Igepal Sigma 
Isopropanol Sigma 
Kanamycin Sigma 
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Lipofectamine 2000 Invitrogen 
LPS Enzo Life Sciences 
Lysogeny broth (LB) Sigma 
Magnesium Chloride Sigma 
Methanol BDH 
Molecular Biology Grade Water (RNase and DNase Free) Sigma 
NF-κB IRDye Labelled Oligonucleotides Licor Biosciences  
NF-κB non-labelled Oligonucleotides MWG 
OptiMEM Invitrogen 
Pam2CSK4 Invivogen 
Pam3CSK4 Invivogen 
PBS (Phosphate buffered saline) Oxoid 
Penicillin / Streptomycin / Glutamine Invitrogen 
PMSF (phenylmethylsulfonyl fluoride) Sigma 
Poly(I:C) Invivogen 
PRD I/III  non-labelled Oligonucleotides MWG 
PRD I/III IRDye Labelled Oligonucleotides MWG 
Prestained molecular weight marker  Invitrogen 
Protease inhibitor cocktail Roche 
Protein A/G-agarose Santa Cruz 
Proteinase K Qiagen 
Protogel National Diagnostics 
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Random primers Invitrogen 
Recombinant murine FLT3L Miltenyi Biotec 
Recombinant murine GM-CSF Immunotools 
Recombinant murine IFN-α4 PBL Interferon 
Source 
Recombinant murine IFN-β Peprotech 
RNase Zap Ambion 
SDS (sodium dodecyl sulphate) Sigma 
siRNA Scrambled Control Ambion 
siRNA TRAF6 specific Ambion 
Skim milk powder Sigma 
Sodium chloride (NaCl) Sigma 
Sodium hydroxide (NaOH) Sigma 
Sodium orthovanadate (Na3VO4) Sigma 
Sodium Phosphate (Na3PO4) Sigma 
Sulphuric acid (H2SO4) Sigma 
Synthetic oligonucleotides MWG Biotech 
TEMED (N, N, N′, N′-tetramethylethylenediamine) Sigma 
TMB (3, 3’, 5, 5’-Tetramethylbenzidine liquid substrate) Sigma 
Tris-base Sigma 
Tris-HCl Sigma 
Trition-X-100 Sigma 
Trypsin/EDTA Invitrogen 
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Tween-20 Sigma 
Zymosan Invivogen 
pMSCV (Murine STEM Cell Virus) Clotech 
Blasticidin Invivogen 
Zeocin Invivogen 
2-Mercaptoethanol Gibeco 
Ponceau s Sigma 
Acetic Acid Fisher 
WesternBright ECL HRP Substrate Advansta 
2.1.2 Kits 
Kits Supplier 
BioScript  (Reverse Transcriptase) 1st-Strand cDNA 
Synthesis Kit 
Bioline 
EMSA (Electophoretic Mobility Shift Assay) Buffer Kit Licor Biosciences 
Mouse IFN-α Platinum ELISA Kit Ebiosciences 
Mouse IL-6 ELISA Kit R&D Systems 
Mouse IP-10 ELISA Kit Peprotech 
Mouse TNF-α ELISA Kit R&D Systems 
Plasmacytoid Dendritic Cell Isolation Kit II, mouse Miltenyi Biotec 
Plasmid Plus Midi Kit Qiagen 
SensiMix SYBR No-ROX Kit Bioline 
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2.1.3 Antibodies 
2.1.3.1 Antibodies for Immunoblotting 
Primary 
Antibodies  
Dilution 
Factor 
Diluent Supplier 
ERK 1:1000 5% BSA TBST Cell Signalling 
Fibrillarin 1:1000 5% Milk TBST Cell Signalling 
FLAG M2 1:1000 5% Milk TBST Sigma 
IKK-β 1:1000 5% BSA TBST Cell Signalling 
IRF3 1:500 5% Milk TBST Santa Cruz 
IRF7 (Mouse) 1:200 5% Milk TBST Santa Cruz 
IRF7 (Rabbit) 1:1000 5% Milk TBST Abcam 
IκB-α 1:1000 5% BSA TBST Santa Cruz 
JNK 1:1000 5% BSA TBST Cell Signalling 
Myc-Tag (9B11) 1:2000 5% Milk TBST Cell Signalling 
p38 1:1000 5% BSA TBST Cell Signalling 
p65 1:200 5% Milk TBST Santa Cruz 
Peli3 1:200 5% Milk TBST GenScript 
Phosho-p38 1:1000 5% BSA TBST Cell Signalling 
Phospho-ERK 1:1000 5% BSA TBST Cell Signalling 
Phospho-IκB-α 1:500 5% Milk TBST Cell Signalling 
Phospho-JNK 1:1000 5% BSA TBST Cell Signalling 
Phospho-cJUN 1:1000 5% BSA TBST Cell Signalling 
Phospho-IKK-α/β 1:750 5% BSA TBST Cell Signalling 
Phospho-IRF3 1:1000 5% BSA TBST Cell Signalling 
Phospho-p65 1:1000 5% BSA TBST Cell Signalling 
Phospho-Serine 1:500 5% BSA TBST Millipore 
Phospho-STAT1 1:1000 5% BSA TBST Cell Signalling 
Phospho-STAT3 1:1000 5% BSA TBST Cell Signalling 
Phospho-TBK1 1:1000 5% BSA TBST Cell Signalling 
TBK1 1:1000 5% Milk TBST Cell Signalling 
TRAF6 1:200 5% Milk TBST Santa Cruz 
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Ubiquitin 1:200 5% Milk TBST Santa Cruz 
β-actin 1:5000 5% Milk TBST Sigma 
    
Secondary 
Licor Antibodies 
Dilution 
Factor 
Diluent Supplier 
IRDye 680 Goat  
Anti-Mouse 
1:5000 5% Milk TBST Licor Biosciences 
IRDye 800CW  
Goat Anti-Rabbit 
1:5000 5% Milk TBST Licor Biosciences 
 
 
   
 Secondary ECL 
Antibodies 
Dilution 
Factor 
Diluent Supplier 
Anti-mouse HRP 1:1000 5% Milk TBST Cell Signalling 
Anti-rabbit HRP 1:4000 5% Milk TBST Promega 
2.1.3.2 Antibodies for IFN-β ELISA 
Antibody Function Dilution Factor Supplier 
Rat anti-Mouse IFN-β Capture 1:1000 Santa Cruz 
Rabbit anti-Mouse IFN-β Detection 1:2000 PBL Interferon Source 
anti-Rabbit HRP Reporter 1:2000 Promega 
2.1.3.3 Antibodies for Flow Cytometry 
Flow Cytometry Antibodies Isotype Controls Supplier 
anti-Mouse CD11c-APC anti-Armenian Hamster IgG-APC Ebiosciences 
anti-Mouse CD11b-PE anti-Rat IgG2bκ-PE Ebiosciences 
Anti-Mouse/Human CD45R-FITC anti-Rat IgG2aκ-FITC Ebiosciences 
2.1.4 Cell Lines 
Cells Description 
HEK293-TLR3 Human embryonic kidney cells, stably expressing human 
Toll-like Receptor 3 
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U373-MG Human glioblastoma-astrocytoma, epithelial-like cell line 
B16-Blue
TM
 IFN-α/β Cells Cells allow the quantitative detection of bioactive murine 
type 1 IFNs via measurement of the IFNAR activation of 
JAK/STAT/ISGF3 pathway. 
WT iBMDM Immortalised BMDM derived from WT mice 
TRIF
–/– 
iBMDM Immortalised BMDM derived from TRIF
–/– 
mice 
TBK1
–/– 
iBMDM Immortalised BMDM derived from TBK1
–/– 
mice 
MAVS
–/– 
iBMDM Immortalised BMDM derived from MAVS
–/–
 mice 
  
2.1.5 Buffers 
Buffer  Composition  
Blocking Buffer for 
Immunoblotting 
TBS, 0.1% (v/v) Tween-20 with 5 % (w/v) non-fat 
dry 
Milk 
Blocking Buffer for ELISA PBS, 1% (w/v) BSA, Filtered Sterile 0.02μm 
Cell Lysis Buffer 
and  
CoIP Lysis Buffer 
50 mM HEPES pH 7.5, 10% (v/v) Glycerol, 0.5% 
(w/v) 
CHAPS, 0.5% (v/v) Triton-X-100, 250 mM NaCl, 
1 mM Na3VO4, 1 mM PMSF, 1 mM EDTA and 
protease inhibitor mixture cocktail 
Laemmli sample buffer  
 
62.5 mM Tris-HCl, pH 6.8, 10% (w/v) glycerol, 
2% (w/v) SDS, 0.7 M β-mercaptoethanol and 
0.001% 
(w/v) bromophenol blue 
Nuclear Fraction Buffer-A  10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM 
MgCl2, 
0.1% (v/v) Igepal , 0.5 mM DTT and 0.5 mM 
PMSF 
Nuclear Fraction Buffer-B  20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM 
MgCl2, 
0.2 mM EDTA, 25% (w/v) glycerol and 0.5 mM 
PMSF 
Nuclear Fraction Buffer-C 10 mM HEPES pH 7.9, 50 mM KCl, 0.2 mM 
EDTA, 
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20% (w/v) glycerol, 0.5 mM PMSF and 0.5 mM 
DTT 
PBS (Phosphate buffered 
saline) 
2.7 mM KCl, 1.5mM KH2PO4, 137 mM NaCl and 
8 mM Na2HPO4, pH 7.4 
Reagent diluent for  ELISA 0.1% (w/v) BSA, 0.05% (v/v) Tween in TBS 
RIPA Lysis Buffer 50 mM Tris-HCl pH 7.4, 1% (v/v) Igepal, 150 mM 
NaCl, 0.5% (w/v) Sodium Deoxycholate, 1 mM 
EDTA, 
0.1% (w/v) SDS 1 mM Na3VO4, 1 mM PMSF and 
protease inhibitor cocktail 
SDS running Buffer 25 mM Tris, 192 mM glycine, 0.1% SDS. 
TAE (Tris-acetate-EDTA)   
Buffer 
40 mM Tris base, 0.1% (v/v) glacial acetic acid, 1 
mM 
EDTA 
TBE (Tris-Borate-EDTA) 
Buffer 
90 mM Tris Base, 90 mM Boric Acid, 2 mM 
EDTA 
TBS (Tris buffered saline) 25 mM Tris, pH7.4, containing 0.14M NaCl. 
TE (Tris-EDTA) Buffer 10 mM Tris-HCl, 1 mM EDTA pH 8.0 
Transfer Buffer 25 mM Tris, 192 mM glycine, 20% (v/v) methanol 
Ponceau Stain 0.1% (w/v) Ponceau S in 5% (v/v) acetic acid 
2.1.6 Primer Sequences 
2.1.6.1 Primers for Quantitative Real-Time PCR 
Targeted Gene Sense Primer Sequence 5’-3’ 
Antisense Primer Sequence 5’-3’ 
Human HPRT AGCTTGCTGGTGAAAAGGAC 
TTATAGTCAAGGGCATATCC 
Human IFN-β AACTGCAACCTTTCGAAGCC 
TGTCGCCTACTACCTGTTGTGC 
Human IL-6 AGCCACTCACCTCTTCAGAACGAA 
CAGTGCCTCTTTGCTGCTTTCACA 
Murine HPRT GCTTGCTGGTGAAAAGGACCTCTCGAAG 
CCCTGAAGTACTCATTATAGTCAAGGGCAT 
Murine IFN-α4 GGCTTGACACTCCTGGTACAAATGAG 
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 CAGCACATTGGCAGAGGAAGACAG 
Murine IFN-β GGAGATGACGGAGAAGATGC 
CCCAGTGCTGGAGAAATTGT 
Murine IL-6 ACAACCACGGCCTTCCCTAC 
TCCACGATTTCCCGAGAACA 
Murine IP-10 GACGGTCCGCTGCAACTG 
GCTTCCCTATGGCCCTCATT 
Murine 
Pellino3 
ACATGCCAACGGAGTGAAGC 
AGCGGCCAATCTGGAACAT 
Murine TNF-α CATCTTCTCAAAATTCGAGTGACAA 
TGGGAGTAGACAAGGTACAACCC 
2.1.6.2 Primers for PCR targeting Genomic DNA for 
genotyping 
Allele Targeted 
 
Sense Primer Sequence 5’-3’ 
Antisense Primer Sequence 5’-3’ 
HPRT 
 
GCTTGCTGGTGAAAAGGACCTCTCGAAG 
CCCTGAAGTACTCATTATAGTCAAGGGCAT 
WT and Recombined Peli3 Allele 
Primers a + b 
CCCAACATAGGTGTTTCCTCTCC 
GTGCATACACATTCATGCAAGC 
WT Peli3 Allele Only 
Primers c + d 
GACACGTGTGGAGATAATGAGG 
ACCCAGGCACAAGTCAAGC 
2.1.7 Animals 
Pellino3-deficient mice and their wild-type littermates were bred at the Bioresource 
Unit of the National University of Ireland Maynooth. Genotyping was performed by 
PCR analysis of genomic DNA from ear punches as described in 2.2.1 and 
genotypes were reconfirmed after the completion of experiments. The mice were 
housed under specific pathogen free (SPF) conditions in individually ventilated 
cages (IVC), enriched with cardboard housing and nesting material. The animals 
were kept at room temperature (22 – 24°C) in a 12hr light/dark cycle (lights on at 
8:00 a.m.) with ad libitum access to food and water. All mice were used under the 
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guidelines of the Irish Department of Health, and all procedures were approved by 
the research ethics committee of the National University of Ireland Maynooth. 
2.1.8 Gifts 
2.1.8.1 Cells 
WT and Traf6
–/– 
MEFs: Prof. Andrew Bowie (Trinity College Dublin, Dublin, 
Ireland) 
HEK293 stably expressing TLR3: Prof. Douglas Golenbock (The University of 
Massachusetts Medical School, Worcestor, Massachusettes 01605, USA) 
U373-MG: Dr. Sinead Miggin (National University of Ireland Maynooth, Co. 
Kildare, Ireland) 
WT and MAVS
–/– 
iBMDM: Dr. Sinead Miggin (National University of Ireland 
Maynooth, Co. Kildare, Ireland)  
WT, TRIF
–/–
 and TBK1
–/– 
iBMDM: Prof. Katherine Fitzgerald (The University of 
Massachusetts Medical School, Worcestor, Massachusettes 01605, USA) 
L929 cells expressing M-CSF and J558 cells expressing GM-CSF: Prof. Luke 
O’Neill (Trinity College Dublin, Dublin, Ireland) 
2.1.8.2 Constructs 
FLAG-tagged WT TRAF6, TRAF6
(C70A) 
and TRAF6
(K124A)
 : Prof. Andrew Bowie 
(Trinity College Dublin, Dublin, Ireland) 
FLAG-tagged IRF7: Dr. Marion Butler (National University of Ireland Maynooth, 
Co. Kildare, Ireland) 
Myc-tagged human WT Pellino3: Dr. Marion Butler (National University of 
Maynooth, Co. Kildare, Ireland 
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Myc-tagged human Pellino3 Ring Mutant
(C360A/C363A)
: Dr. Lisa Tang (National 
University of Maynooth, Co. Kildare, Ireland 
Myc-tagged murine WT Pellino3 and Pellino3 Ring Mutant
(C360A/C363A)
: Dr. Shuo 
Yang (National University of Maynooth, Co. Kildare, Ireland 
2.1.8.3 Live Viruses 
Encephalomyocarditis virus (EMCV): Dr. Jakub Siednienko (Polish Academy of 
Sciences, Wrocław, Poland) 
2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Culturing of Bone Marrow Derived Macrophages 
(BMDMs)  
For the generation of BMDMs, gender and age matched WT and Peli3
–/–
 mice (8– 12 
weeks) were selected and sacrificed by cervical dislocation. To prevent 
contamination, mice were placed in a laminar flow hood and sterilised using 70% 
ethanol and all further work was conducted using aseptic technique. The femur and 
tibia of the mice were removed and bone marrow was isolated by flushing the bones 
with a 27¾ gauge needle filled with Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% (v/v) heat inactivated Fetal Bovine Serum (FBS), penicillin 
G (100 μg/ml) and streptomycin (100 μg/ml). Cells were pelleted by centrifugation 
at 600 gravitation (g) for 6 minutes (min). The cell pellet was subject to red blood 
cell lysis (RBL) using 1 ml of Sigma RBL buffer for 1 min. 25 ml of DMEM was 
added to terminate lysis and cells were again centrifuged at 600 gravitation “g” for 6 
min. Bone marrow cells were resuspended in 10 ml DMDM and counted using a 
haemocytometer. Cells from WT and Peli3
–/– 
were equalised for number and seeded 
at 2x10
6 
cells/ml (25 ml) in a T175
2
 culture flask. Conditioned media (CM) from 
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L929 cells that express Macrophage Colony Stimulating Factor (M-CSF) was added 
to a final concentration of 20% (v/v). The primary cells were maintained in a 37°C 
humidified atmosphere with 5% CO2. After 3 days media was gently removed to 
avoid detachment of the adherent macrophage differentiating cells. Fresh media was 
added containing 20% (v/v) M-CSF. The removed media containing non-adhered 
cells were subjected to centrifugation at 600 g for 6 min. Cells were re-suspended in 
fresh media and placed in a new T175
2
 culture flask in the presence of 20% (v/v) M-
CSF. Cells were incubated for another 3-4 days until fully differentiated (as assessed 
by cell morphology). The highly adherent BMDMs were isolated from culture flasks 
by cell scraping and seeded in DMEM without M-CSF for experimental use. 
2.2.1.2. Culturing of Bone Marrow Derived Dendritic Cell 
(BMDC) 
For the generation of BMDCs, gender and age matched WT and Peli3
–/–
 mice (8 – 
12 weeks) were sacrificed by cervical dislocation. To prevent contamination, mice 
were placed in a laminar flow hood and sterilised using 70% ethanol and all further 
work was conducted following aseptic technique. The femur and tibia of the mice 
were removed and the bone marrow was isolated by flushing the bones with a 27¾ 
gauge needle filled with Roswell Park Memorial Institute-1640 (RPMI-1640) 
medium supplemented with 10% (v/v) heat inactivated FBS, GlutaMAX™ (200 
mM), penicillin G (100 μg/ml), streptomycin (100 μg/ml) and 2-Mercaptoethanol 
(55 μM). Cells were pelleted by centrifugation at 600 g for 6 min. The cell pellet was 
subject to RBL using 1 ml of Sigma RBL buffer for 1 min. 25 ml of DMEM was 
added to terminate lysis and cells were again centrifuged at 600 g for 6 min. Bone 
marrow cells were resuspended in 10 ml RPMI and counted using a haemocytometer. 
Cells numbers between WT and Peli3
–/– 
were equalised and seeded at 1x10
6 
cells/ml 
(40 ml) in a T175
2
 culture flask. CM from J558 cells expressing Granulocyte-
macrophage colony-stimulating factor (GM-CSF) was added to a final concentration 
of 20% (v/v). The primary cells were maintained in a 37°C humidified atmosphere 
with 5% CO2. After 3 days the media containing the non-adherent cells was removed 
and centrifuged at 600 g for 6 min. The semi-adherent cells in the T175
2
 flask were 
scrapped in PBS and also subjected to centrifugation. The cell pellets were combined 
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and counted using a haemocytometer. Cells numbers from WT and Peli3
–/– 
mice 
were equalised and seeded at 1x10
6 
cells/ml (40 ml) in 2 T175
2
 culture flasks in 
RPMI with 20% (v/v) GM-CSF. After a further 3 days, the above culture step was 
repeated. The non-adherent cells constituting the BMDCs, were isolated and seeded 
for experiments in the absence of GM-CSF or allowed to be cultured for a further 3 
days in media containing GM-CSF. 
2.2.1.3 Culturing of Bone Marrow derived Plasmacytoid 
DC (pDC) 
pDC generation was achieved by following the protocol outlined in 2.2.1.2 with 
minor modifications. The culture media used was RPMI supplemented with 10% 
(v/v) heat inactivated FBS, GlutaMAX™ (200 mM), penicillin G (100 μg/ml), 
streptomycin (100 μg/ml), 2-Mercaptoethanol (55 μM), 1% (v/v) MEM non-essential 
amino acids, Sodium pyruvate (1 mM) and HEPES (10 mM). In order to drive the 
progenitor cells to pDC lineage, recombinant murine FMS-related tyrosine kinase 3 
ligand (Flt3L) (100 μg/ml) was added at each culture step. As pDC generation 
resulted in a heterogeneous suspension cell population, pDC cells were enriched 
prior to experimental use using the Plasmacytoid Dendritic Cell Isolation Kit II from 
Miltenyi Biotech as per manufactures instructions.  
2.2.1.4 Culturing of Murine Embryonic Fibroblasts (MEFs)  
Peli3
+/–
 mice were interbred to produce
 
Peli3
+/+ 
and Peli3
–/–
 embryos. Mouse breeder 
pairs were set up in the afternoon with one male being set up with two or three 7-8 
week old females. Females were checked for copulatory plugs the following morning. 
If present, this was marked as day +0.5.  Females, with copulatory plugs, were 
removed from the male’s breeder cages.  The remaining females were checked on a 
daily basis.  
At +13.5 days, pregnant mice were euthanized by cervical dislocation. The uterus 
(containing the embryos) was cut free from the mouse and placed in a sterile petri 
dish. Embryos were removed from the uterus one at a time in sterile PBS under 
sterile conditions in a laminar flow hood. The head and all of the soft tissues from 
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each embryo were removed so that only the carcasses were left. Embryo carcasses 
were minced using small scissors or scalpel, and placed in a 50 ml sterile tube 
containing 1.5 ml PBS. Trypsin-EDTA solution (1% w/v) was added and tissue was 
mechanically agitated using a sterile 5 ml pipette. The mixture was then incubated at 
37ºC for 8 min and again mechanically agitated and returned to incubation for a 
further 8 min. DMEM (15 ml)  supplemented with 10% (v/v) heat inactivated FBS, 
penicillin G (100 μg/ml) and streptomycin (100 μg/ml) was added and cells were 
added to a T75
2
 culture vessel. The MEF cells were passaged every 3-4 days or until 
they were confluent. DNA samples were collected from discarded head or soft tissue 
for genotyping. 
2.2.1.5 Culturing of B16-Blue™ IFN-α/β Cells 
The murine type 1 IFNs sensor cell line B16-Blue IFN-α/β were cultured in RPMI-
1640 medium supplemented with 10% (v/v) heat inactivated FBS, GlutaMAX™ 
(200 mM), penicillin G (100 μg/ml) and streptomycin (100 μg/ml). Zeocin™ (100 
μg/ml) was used to select for expression of the stably integrated cassette encoding 
the Sh ble gene and embryonic alkaline phosphatase (SEAP) reporter gene under the 
control of the IFN-α/β-inducible ISG54 promoter. Cell lines were maintained in a 
37°C humidified atmosphere with 5% CO2. Cells were passaged every 2-3 days at 
approximately 80% confluence using 1% (w/v) Trypsin/EDTA solution in PBS. 
Cells were cultured for up to 25 passages before being discarded to prevent genetic 
instability accumulation. 
2.2.1.6 Culturing of HEK293-TLR3 and U373 Cells 
HEKT293 cells stably expressing TLR3 and U373 cells were cultured in DMEM 
supplemented with 10% (v/v) heat inactivated FBS, penicillin G (100 μg/ml) and 
streptomycin (100 μg/ml). Blasticidin (10 µg/ml) was used to select for expression of 
the stably integrated cassette encoding the TLR3 gene.  Cell lines were maintained in 
a 37°C humidified atmosphere with 5% CO2. Cells were passaged every 2-3 days at 
approximately 80% confluence using 1% (w/v) Trypsin/EDTA solution in PBS. 
Cells were cultured for up to 25 passages before being discarded to prevent genetic 
instability accumulation. 
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2.2.1.7 Culturing of Immortalised Bone Marrow Derived 
Macrophages 
Immortalised Bone Marrow derived Macrophages (iBMDM) from WT, TRIF
–/–
, 
TBK1
–/–
 and MAVS
–/–
 were cultured in RPMI supplemented with 10% (v/v) heat 
inactivated FBS, penicillin G (100 μg/ml) and streptomycin (100 μg/ml). Cell lines 
were maintained in a 37°C humidified atmosphere with 5% CO2. The highly 
adherent cells were passaged every 2-3 days at approximately 80% confluence using 
a cell scraper in PBS. Cells were cultured for up to 25 passages before being 
discarded to prevent genetic instability accumulation. 
2.2.1.8 Culturing of L929 Cells and M-CSF Media 
Production 
L929 cells were cultured in DMEM supplemented with 10% (v/v) heat inactivated 
FBS, penicillin G (100 μg/ml) and streptomycin (100 μg/ml). Cell lines were 
maintained in a 37°C humidified atmosphere with 5% CO2. Cells were passaged 
every 2-3 days at approximately 80% confluence using 1% (w/v) Trypsin/EDTA 
solution in PBS.  For collection of CM containing M-CSF, cells were seeded at 
5x10
5 
cells/ml (40 ml) in a T175
2
 culture flask and cultured for 7 days. CM was 
collected by centrifugation at 600 g for 6 min and supernatant collected. This 
centrifugation and supernatant collection step was repeated to ensure cell free CM. 
The supernatant was aliquoted and stored at -80°C until required. Cells were cultured 
for up to 25 passages before being discarded to prevent genetic instability 
accumulation. 
2.2.1.9 Culturing of J558 Cells and GM-CSF Media 
Production 
J558 cells were cultured in RPMI supplemented with 10% (v/v) heat inactivated FBS, 
penicillin G (100 μg/ml) and streptomycin (100 μg/ml). Blasticidin (10 µg/ml) was 
used to select for GM-CSF producing cells.  Cell lines were maintained in a 37°C 
humidified atmosphere with 5% CO2. The suspension cells were passaged every 3 
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days at approximately 80% confluence by centrifugation at 600 g for 6 min. For 
GM-CSF CM production, cells were cultured for 2 passages without Blasticidin. 
Cells were then seeded at 1x10
6
 cells/ml (40 ml) in a T75
2
 culture flask. At 80% 
confluence, CM was collected by centrifugation at 600 g for 6 min and supernatant 
collected. This centrifugation and supernatant collection step was repeated to ensure 
cell free CM. The supernatant was aliquoted and stored at -80°C until required. Cells 
were cultured for up to 25 passages before being discarded to prevent genetic 
instability accumulation. 
2.2.2 Molecular Biological Methods 
2.2.2.1 Genomic DNA Extraction 
For mouse colony genotyping, three week old mice were ear punched and tissue 
placed in sterile tubes. For genotyping MEFs, the embryo head was placed into a 
sterile tube. 100 μl of DirectPCR™ Lysis Reagent containing Proteinase K (0.4 
mg/ml) was added to each tissue sample and incubated at 55°C overnight. Crude 
DNA lysates were subjected to a Proteinase K inactivation step in which samples 
were incubated at 85°C for 45 min. This lysate was used as the template for 
genotyping PCR reactions. Ear punch DNA was used neat, while DNA from 
embryos was diluted 1:10 in DNase free water.  
2.2.2.2 Isolation of RNA and cDNA Synthesis 
2.2.2.2.1 Isolation of Total RNA 
In order to prevent RNA degradation by RNases, all working surfaces and areas were 
treated with an RNase decontamination solution. In addition, all plasticware used 
was certified RNase free. Gloves and face mask were also worn to prevent self-
introduced RNase contamination.  
For mRNA analysis experiments using BMDM and BMDCs, cells were seeded at 
1x10
6 
cells/ml (3 ml) in 6-well plates. MEFs were seeded at 5x10
5 
cells/ml (3ml) in 6 
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well plates. HEK293-TLR3 cells were initially seeded at 7.5x10
4 
cells/ml (3 ml) in 6 
well plates and subjected to genetic manipulation prior to harvesting.  Total RNA 
was extracted using 500 μl Trizol Reagent following manufacturer’s instructions. 
Briefly, cells were washed and centrifuged at 6,500 g for 7 min at 4°C. 500 μl of 
Trizol was added and pellets resuspended and left at room temperature for 5 min. 
175 μl of chloroform was added and mixtures vortexed into a uniform suspension for 
15 seconds (sec).  Phase separation of aqueous RNA was achieved by incubating the 
lysates for 10 min at room temperature followed by centrifugation at 12,000 g for 15 
min at 4°C. The clear interphase was removed and transferred to a fresh tube and an 
equal amount of isopropanol was added. After 5 min room temperature incubation, 
samples were vortexed for 5 sec and centrifuged at 12,000 g for 15 min at 4°C. The 
isopropanol was removed from the resulting RNA precipitated pellet and washed in 
900 μl of 75% (v/v) ethanol and vortexed briefly. Samples were centrifuged at 6,500 
g for 5 min at 4°C. The ethanol was removed and samples spun down again at 6,500 
g for 5 min at 4°C. Any remaining ethanol was removed and the pellets were 
allowed to air dry for 10 min. Depending on pellet size, the RNA was resuspended in 
15-50 μl RNase free water and incubated at 65°C for 10 min. The concentration of 
RNA was determined by using a Nanodrop™ spectrophotometer measuring 
absorbance at wavelengths of 260 nm and 280 nm, where absorbance of 1 unit at 260 
nm is ~40 μg/ml. Pure RNA preparations had an OD260/280 ratio of between 1.8-2.0. 
RNA was stored at -80°C until use as template for reverse transcriptase PCR. 
 2.2.2.2.2 Synthesis of First Strand cDNA from mRNA 
In order to generate full-length first-strand cDNA from total cellular RNA, 2 μg of 
RNA, diluted in nuclease free water (12 μl volume), was added to a nuclease free 
microcentrifuge PCR tube. 1 μl of random primers (0.5 μg) were added to each RNA 
sample and incubated at 70°C for 5 min to remove any secondary structure which 
could impede long cDNA strand synthesis. The mixture was then chilled on ice prior 
to addition of the following: 
Bioscript reverse transcriptase (200U/μl) 0.5μl 
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dNTPs (10mM) 1μl 
5 x Bioscript Reaction Buffer 4μl 
Nuclease-Free Water 1.5μl 
The mixture was incubated for 10 min at room temperature to allow primers to 
anneal to the RNA. The reaction was then incubated at 42°C for 45 min. The 
reaction was terminated by incubation at 85°C for 5 min. The resulting cDNA was 
stored at -20°C. 
2.2.2.3 PCR analysis 
2.2.2.3.1 PCR Amplification  
PCR products were amplified using isolated genomic or complementary DNA as 
template and using specific primers to detect the sequence of interest as outlined in 
2.1.6.1 and 2.1.6.2 using the following reaction mixture:   
Template DNA 2 μl 
GoTaq polymerase 0.15 μl 
5 x Buffer 5 μl 
MgCl2 2 μl 
Primers (100 pmol/μl) 0.25 μl of sense  
0.25 μl of anti-sense 
dNTPs (10 mM) 1 μl 
Nuclease free water 14.35 
Each sample was subjected to an initial incubation at 95°C for 5 min, followed by 29 
cycles of  95°C for 30 sec, 60°C for 30 sec and 72°C for 1 min. Samples were then 
incubated at 72°C for 10 min and stored at 4°C. 
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2.2.2.3.2 Agarose Gel Electrophoresis 
Agarose gels were prepared by adding 1.5% (w/v) agarose in TAE and heating until 
completely dissolved. The solution was then cooled to below 50°C and Ethidium 
Bromide (5 μg/ml) was added and solution poured into a gel tray. Following 
solidification, agarose gels were submerged in TAE buffer and subjected to 
electrophoresis at 90 volts. Samples were run simultaneously with a 1 kb molecular 
size marker. Nucleic acid products were visualised under ultraviolet (UV) light (254 
nm) and images acquired using a Syngene G box gel documentation system. 
 
2.2.2.3.3 Real-Time PCR 
cDNA generated as described in 2.2.2.2.2 (diluted 1:10 with nuclease free water) 
was used for quantitative real-time PCR analysis using primes specific from gene 
sequences of interest as outline in 2.1.6.1. A reaction mix was made for each 
transcript containing: 
2x SensiMix No Rox enzyme  10 μl 
Primers (4 pmol/μl) 2.5 μl of sense  
2.5 μl of anti-sense 
Nuclease free water 3 μl 
18 μl of reaction mix was added to specialised optical 96 well plates and 2 μl 
template DNA added. Each sample was subjected to an initial 95°C for 15 min, 
followed by 45 cycles of 95°C for 30 sec, 57°C for 30 sec and 72°C for 45 sec. 
Intercalation of SYBR green into the dsDNA product formed was monitored after 
each step of primer annealing and elongation. Amplification of one specific product 
was confirmed by melt curve analysis whereby one single melting peak eliminated 
the possibility of primer-dimer associations. For melting curve analysis to be 
performed the products were heated from 60°C to 95°C after the 40 cycles. The PCR 
were conducted in a Applied Biosystems Step One™ real-time PCR instrument. The 
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relative quantification of target genes expression was evaluated using the ∆CT 
method. Crossing Threshold (CT) which recorded the cycle when sample 
fluorescence exceeds a chosen threshold above background fluorescence, was 
generated by Applied Biosystems Step One™ software. The ∆CT value was 
determined by subtracting the HPRT CT value for each sample from the target CT 
value. Fold change in the relative gene expression of target were determined by 
calculating the 2
−∆CT
. 
2.2.2.4 Transformation of E.coli with Plasmid DNA 
TOP10 chemically competent E.coli was used for propagation of plasmids. 100-400 
ng (1 μl) of plasmid was added to 5 μl of TOP10 cells. DNA and the cells were 
mixed gently with a pipette and incubated on ice for 30 min. The plasmids were 
allowed to enter the bacterial cells by heat shocking the mixture at 42ºC for 40 sec. 
The cells become permeable to allow easy entry of the plasmid and cooling on ice 
for 2 min allowed the cells to once again become impermeable. The transformed 
cells were then incubated in 150 μl SOC medium at 37ºC on an Exceller E25 shaker 
at 220 revolutions per minute (rpm) for 1 hour (h). The mix was then plated out on 
LB agar plates (LB broth with 1.5% (w/v) agar) containing 100 μg/ml ampicillin. 
Plates were inverted and incubated overnight at 37ºC. Plates were then stored at 4ºC 
for up to four weeks.  
2.2.2.5 Large-Scale Preparation of DNA from E. coli 
100 ml LB broth containing ampicillin (50μg/ml) was inoculated with a single 
transformed E. coli colony from an agar plate. The culture was incubated overnight 
at 37ºC with constant shaking at 220 rpm. Large plasmid preparations were made 
using the high-speed plasmid midi kit from Qiagen. The bacterial cells were 
centrifuged at 3,000 g for 25 min. The supernatant was discarded and the plasmid 
DNA was extracted as outlined in the manufacturer’s handbook. DNA concentration 
was determined by using a Nanodrop™ spectrophotometer measuring absorbance at 
wavelengths of 260 nm and 280 nm, where absorbance of 1 unit at 260 nm is ~50 
μg/ml. 
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2.2.3 Genetic Manipulation of Mammalian Cells 
2.2.3.1 Transient Transfection of MEFs Cells 
MEFs derived from Traf6
–/– 
mice were seeded at 5x10
5 
cells/ml (3 ml) in 6-well 
plates and left overnight until approximately 70% confluency. 1 ml of media was 
removed from all wells to be transfected. 3 μg of plasmid DNA for non-protein 
coding empty vector DNA (EV), TRAF6 or TRAF6
(C70A) was diluted in 250 μl of 
OptiMEM and mixed gently. In addition, 4 μl of Lipofectamine 2000 was diluted 
into 250 μl of OptiMEM. After 5 min incubation the solutions were combined 
together and incubated for 20 min. 500 μl of the DNA-Lipofectamine complexes 
were added to each well and left for 48 h before stimulation and harvesting.  
2.2.3.2 Transient Transfection of HEKT-TLR3 Cells 
HEK293-TLR3 cells were seeded at 2x10
5 
cells/ml (3 ml) in 6-well plates and left 
overnight until approximately 70% confluency. 1 ml of media was removed from all 
wells to be transfected. 1 μg of plasmid DNA as indicated was diluted in 250 μl of 
OptiMEM and mixed gently. In addition, 4 μl of Lipofectamine2000 was diluted into 
250 μl of OptiMEM. After 5 min incubation, the solutions were combined together 
and incubated for 20 min. 500 μl of the DNA-Lipofectamine complexes were added 
to each well and left for 24 h before harvesting.  
2.2.3.3 Transfection of Cells for Knockdown with shRNA 
HEK293-TLR3 cells were seeded at 7.5x10
4 
cells/ml (3 ml) in 6-well plates and left 
overnight. 1 ml of media was removed from all wells to be transfected. 2 μg of 
plasmid DNA encoding shRNA targeting Pellino3 transcript
 was diluted in 250 μl of 
OptiMEM and mixed gently. A control shRNA was also used in the transfection. It 
was a non-targeting shRNA vector that can activate the RNA-induced silencing 
complex and the RNAi pathway, but does not target any human genes. In addition, 4 
μl of Lipofectamine 2000 was diluted into 250 μl of OptiMEM. After 5 min 
incubation the solutions were combined together and incubated for 20 min. 500 μl of 
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the DNA-Lipofectamine complexes were added to each well and left for 48 h. Cells 
were then subjected to treatment and harvesting or reconstituted (as indicated) by 
transient transfection outlined in 2.2.3.2.    
2.2.3.4 Transfection of Cells for Knockdown with siRNA 
HEK293-TLR3 cells were seeded at 7.5x10
4 
cells/ml (3 ml) in 6-well plates and left 
overnight. 1 ml of media was removed from all wells to be transfected. 20 nM of 
siRNA targeting TRAF6 transcript or GAPDH as a control was diluted in 250 μl of 
OptiMEM and mixed gently. In addition, 4 μl of Lipofectamine 2000 was diluted 
into 250 μl of OptiMEM. After 5 min incubation the solutions were combined 
together and incubated for 20 min. 500 μl of the DNA-Lipofectamine complexes 
were added to each well and left for 48 h. Cells were then subjected transient 
transfection outlined in 2.2.3.2.    
2.2.3.5 Retroviral Infection Assay 
2.2.3.5.1 Generation of Viral Particles 
HEK293T cells were seeded at 2x10
5 
and grown overnight to 70% confluence in a 
T175
2
 culture flask (25 ml). Cells were co-transfected with 8.5 μg of MCSV-EV 
plasmid or MCSV-mPeli3 or MCSV-mPeli3RING and with 8.5 μg of packaging (φ) 
vector using Lipofectamine 2000 as per manufactures instructions. In order to 
remove the transfection reagent and enhance retroviral production, the media was 
removed after 24 h and replaced with media containing 30% (v/v) FBS. The cells 
were then left for another 24 h and media containing the retrovirus harvested and 
subjected to centrifugation at 600 g for 6 min. The cell pellet was discarded and the 
supernatant again centrifuged. This supernatant constituted the cell free retrovirus 
used to infect MEF cells. 
2.2.3.5.2 Retroviral Infection of MEFs 
MEFs were seeded at the low density of 1x10
5
 cells/ml (25 ml) in a T175
2
 and 
allowed to adhere to the culture vessel, as the retrovirus only infects dividing cells. 
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The media was removed and replaced with 12.5 ml of retrovirus containing media 
for 6 hours and a further 12.5 ml of DMEM was then added to the flask and 
incubated for 48 h prior to experimental use.   
2.2.4 Biochemical Methods 
2.2.4.1 Protein Extraction 
In order to extract intracellular protein from adherent cells, 6-well plates were placed 
on ice and media removed. Cells were washed with 3 ml of ice cold PBS and 
removed. Cells were scraped in 1 ml ice cold PBS and added to a 1.5 ml tube. 
Samples were centrifuged at 6,500 g for 10 min and PBS removed. For semi-
adherent cells, the media containing the suspension cells was collected in a 15 ml 
tube.  Adherent cells were then scraped in 1 ml of ice cold PBS and added to the 15 
ml tube. Cells were centrifuged at 6,500 g for 10 min and PBS removed. Cell pellets 
were resuspended in 1 ml PBS and centrifuged at 6,500 g for 10 min and PBS 
removed. Regardless of cell type, pellets were then re-suspended in 90 μl cell lysis 
buffer and left on ice for 30 min. Samples were kept under near constant agitation by 
gently pipetting throughout the lysis process.  Protein lysates were then subjected to 
centrifugation at 12,000 g for 10 min. 80 μl of the supernatant which constitutes the 
soluble intracellular protein was added to a new 1.5ml tube and stored at -20°C. 
Prior to loading proteins lysates, samples were mixed with 4x sample buffer and 
boiled for 5 min. 
2.2.4.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
SDS-PAGE was conducted according to the method of Laemmli as modified by 
Studier (Laemmli, 1970, Studier, 1973). Samples and appropriate prestained (10-
180kDa) protein markers were loaded into separate wells. Electrophoresis was 
performed at 60V through a 5% polyacrylamide stacking gel and then through a 8-15% 
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polyacrylamide resolving gel at 80V for 1.5~2 h. The percentage gel was chosen 
based on the size of the proteins being electrophoresed.  
2.2.4.3 Immunoblotting 
Following separation by electrophoresis, the proteins were transferred 
electrophoretically to nitrocellulose membranes in a Hoefer TE 70 Semiphor semi-
dry transfer unit at 110mA for 1.5 h. 3 layers of Whatmann paper were placed on the 
bottom surface of the transfer unit followed by one layer of nitrocellulose. The 
resolving gel was then placed on top with care to avoid any air bubbles. Finally 3 
more layers of Whatmann paper were added and the unit closed. Following transfer, 
non-specific binding of antibody was blocked by incubating the nitrocellulose 
membranes at room temperature for 1 h with Blocking Buffer under gentle agitation. 
The membranes were then incubated under agitation at 4ºC overnight with the 
primary antibodies diluted in TBST containing 5% (w/v) skimmed milk powder or 
BSA as indicated in 2.1.3.1. The membranes were subsequently subjected to 3 x 5 
min washes in TBST. Membranes were then incubated in a secondary antibody 
specific for the primary antibody in question (anti-rabbit or anti-mouse) in TBST 
containing 5% (w/v) skimmed milk powder for 1 h in the dark at room temperature. 
The membranes were then washed a further 3 times for 5 min each in TBST in the 
dark. The immunoreactive bands were detected using Odyssey infrared imaging 
system from Licor Biosciences or using enhanced chemiluminescence development. 
2.2.4.4 Immunoprecipitation Analyses  
2.2.4.4.1 Co-Immunoprecipitation of Proteins 
 For overexpression co-immunoprecipitation assays, cells were transfected with 
expression constructs as described in 2.2.3.2. 24 h post transfection, cell were placed 
on ice and media removed. For endogenous co-immunoprecipitation assays, cells 
were seeded at 1x10
6 
cells/ml (10 ml) in petri dishes and left overnight prior to 
stimulation (as indicated). Cells were washed in 3 ml ice cold PBS and scraped in 1 
ml PBS and added to 1.5 ml tubes. Samples were centrifuged at 6,500 g for 10 min 
and PBS removed. Cell pellets were then re-suspended in 300 μl CoIP lysis buffer 
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and left on ice for 30 min. Samples were kept under near constant agitation by gently 
pipetting throughout the lysis process. Protein lysates were then subjected to 
centrifugation at 12,000 g for 10 min. 20 μl of this extract was removed and stored at 
-20°C and constituted whole cell lysate for loading and expression controls. For 
overexpression studies the remaining protein lysate was split into 2 tubes and the 
volume brought up to 1 ml in CoIP lysis buffer. Each tube was subjected to 
reciprocal co-immunoprecipitations using 1 μg of either anti-FLAG or anti-Myc 
antibody overnight at 4°C on a sample rocker. For endogenous interaction studies, 
the remaining protein lysate was immunoprecipitated with 1 μg of the antibody of 
interest overnight at 4°C on a sample rocker. Then 40 μl of protein A/G beads were 
added to each sample using pipettes with the top of each tip removed and samples 
were again left at 4°C overnight under constant agitation. Samples were centrifuged 
at 12,000 g for 1 min and supernatant removed. The pellets were washed with 1 ml 
CoIP lysis buffer and inverted several times. The samples were subjected to 3 more 
wash steps. Finally, all supernatant was removed from the pellet and 40 μl of 2x 
sample buffer was added to the beads and incubated at room temperature for 25 min. 
Samples were then boiled for 10 min and subjected to a brief vortex. Samples were 
then centrifuged at 12,000 g for 2 min and subjected to SDS-page as described in 
2.2.3.2 and immunoblotting as described in 2.2.3.3. 
2.2.4.4.2 Immunoprecipitation of Proteins to Investigate 
Post Translational Modifications  
For overexpression studies investigating post translational modifications (PTM) of 
proteins, cells were transfected with expression constructs as described in 2.2.3.2. 24 
h post transfection, cell were placed on ice and media removed. For investigation 
into stimulus induced PTMs of endogenous proteins, cells were seeded at 1x10
6
 
cells/ml (10 ml) in a cell culture petri dish and left overnight prior to stimulation. In 
some experiments cells were initially subjected to RNAi as described in 2.2.3.3. In 
rescue experiments cells were infected with retroviral constructs as described in 
2.2.3.5. Cells were stimulated as indicated and then placed on ice. For adherent cells, 
media was removed and washed in 3 ml ice cold PBS and scrapped in 1 ml PBS and 
added to 1.5 ml tubes. Samples were centrifuged at 6,500 g for 10 min and PBS 
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removed. For semi adherent cells, the media containing the suspension cells was 
collected in a 15 ml tube and the adherent cells were then scraped in 1 ml of ice cold 
PBS and added to the 15 ml tube. Cells were centrifuged at 4,200 g for 10 min and 
PBS removed. Cell pellets were re-suspended in 1 ml PBS and centrifuged at 6,500 g 
for 10 min and PBS removed. Cell pellets were then re-suspended in 200 μl IP lysis 
buffer and left on ice for 30 min. Samples were kept under near constant agitation by 
gently pipetting throughout the lysis process. Protein lysates were then subjected to 
centrifugation at 12,000 g for 10 min. 20 μl of this extract was removed and stored at 
-20°C and constituted whole cell lysate for loading and expression controls. To the 
remaining ~180 μl of protein lysis, 20 μl of 10% (w/v) SDS was added and samples 
left at room temperature for 5-10 min. The sample was then split into separate tubes 
and 900 μl of IP lysis buffer was added to dilute the SDS to ~0.1% (w/v) and 
samples returned to ice. Each tube was subjected to immunoprecipitation using 1 μg 
of the antibody of interest overnight at 4°C on a sample rocker. Then 40 μl of protein 
A/G beads were added to each sample using pipettes with the top of each tip 
removed and samples were again left at 4°C overnight under constant agitation. 
Samples were centrifuged at 12,000 g for 1 min and supernatant removed. The 
pellets were washed with 1 ml IP lysis buffer and inverted several times. The 
samples were subjected to 3 more wash steps. Finally, all supernatant was removed 
from the pellet and 40 μl of 2x sample buffer was added to the beads and incubated 
at room temperature for 25 min. Samples were then boiled for 10 min and subjected 
to a brief vortex. Samples were then centrifuged at 12,000 g for 2 min and subjected 
to SDS-page as described in 2.2.3.1.2 and immunoblotting as described in 2.2.3.1.2. 
2.2.4.4 Enzyme-Linked Immunosorbent Assay (ELISA)   
2.2.4.4.1 TNF-α, IL-6 and IP-10 ELISA 
Samples were collected and stored at -80ºC until ELISA analysis. 96-well NUNC 
“Maxisorb” plates were coated with 100 μl of goat anti-mouse TNF-α (0.8 μg/ml), 
rat anti-mouse IL-6 (2.0 μg/ml) or rabbit anti-mouse IP-10 (0.5 μg/ml) diluted in 
PBS and were incubated overnight at room temperature. Plates were washed three 
times with wash buffer (PBS with 0.05% (v/v) Tween-20) and dried by forcefully 
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inverting the plates on tissue paper. Plates were blocked for 2 h with reagent diluent 
(PBS containing 1% (w/v) filtered sterilised (0.2 μm) BSA). Plates were again 
washed three times and dried. Samples or standards (100 μl) diluted in reagent 
diluent (1:1) were added to each well. The concentrations of standards were between 
0 and 2000 pg/ml. Plates were incubated with samples or standards at 4°C overnight. 
100 μl of biotinylated goat anti-mouse TNF-α (200 ng/ml), anti-IL-6 (150 ng/ml) or 
rabbit anti-mouse IP-10 (0.25 μg/ml) diluted in reagent diluent was added to each 
well. Plates were incubated for 2 h and washed as before. Streptavidin-HRP 
conjugate (100 μl) diluted 1:200 in reagent diluent was added to each well. The 
plates were incubated in the dark for 20 min and then the wash step was repeated. 
100 μl TMB (1.25 mM/l) solution was added to each well and again plates were 
incubated in the dark for no longer than 20 min. 50 μl 1 N H2SO4 was used to stop 
the reaction and the OD was measured for each well at 450 nm and 590 nm using a 
ELx800TM microplate reader with Gen5 Data Analysis Software. The 
concentrations of TNF-α, IL-6 and IP-10 in each sample were extrapolated from a 
standard curve that related the OD of each standard to the known concentration. 
Standard samples were assayed in duplicate to generate the standard curve, while all 
samples were assayed in triplicate. Data analysis was performed using Graphpad 
Prism5 software.  
 
2.2.4.4.2 IFN-β ELISA 
Samples were collected and stored at -80ºC until ELISA analysis. 96-well NUNC 
“Maxisorb” plates were coated with 100 μl of rat anti-mouse IFN-β (0.1 μg/ml) 
diluted in PBS and were incubated overnight at room temperature. Plates were 
washed three times with wash buffer (PBS with 0.05% (v/v) Tween-20) and dried by 
forcefully inverting the plates on tissue paper. Plates were blocked for 2 h with 
reagent diluent (PBS containing 1% (w/v) filtered sterilised (0.2 μm) BSA). Plates 
were again washed three times and dried. Samples or standards (100 μl) diluted in 
reagent diluent (1:1) were added to each well. The concentrations of standards were 
between 0 and 5000 pg/ml. Plates were incubated with samples or standards at 4°C 
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overnight. 100 μl of unlabelled rabbit anti-mouse IFN-β (500 ng/ml) diluted in 
reagent diluent was added to each well. Plates were incubated for 2 h and washed as 
before. Anti-rabbit HRP-conjugate (100 μl) diluted 1:2000 in reagent diluent was 
added to each well. The plates were incubated for 1 h and then the wash step was 
repeated. 100 μl TMB (1.25 mM/l) solution was added to each well and again plates 
were incubated in the dark for no longer than 20 min. 50 μl 1 N H2SO4 was used to 
stop the reaction and the OD was measured for each well at 450nm and 590nm using 
a ELx800TM microplate reader with Gen5 Data Analysis Software. The 
concentrations of IFN-β in each sample were extrapolated from a standard curve that 
related the OD of each standard amount to the known concentration. Standard 
samples were assayed in duplicate to generate the standard curve, while all samples 
were assayed in triplicate. Data analysis was performed using Graph pad Prism5 
software.  
2.2.4.4.3 IFN-α ELISA 
Samples were collected and stored at -80ºC until ELISA analysis which was 
conducted using the IFN-α Platinum ELISA Kit from eBiosciences. Microwell plate 
strips coated with monoclonal antibody against murine IFN-α2/4 and were washed 
twice with the wash buffer  (300 μl) provided and dried on tissue. 50 μl of Assay 
buffer was added to all wells. 50 μl of standards ranging from 31.3 pg/ml to 2000 
pg/ml was added to designated wells. 50 μl of calibration buffer was added to act as 
a blank (0 pg/ml). 50 μl of supernatant was added to each sample well. Finally 50 μl 
of Biotin-Conjugate solution was added to all wells and the microwell plate sealed 
with an adhesive film and incubated for 2 h at room temperature at 400 RPM. After 
incubation, the plate was washed 4 times and 100 μl of the Streptavidin-HRP 
solution was added to each well and the plate re-sealed with a new adhesive strip. 
The plate was incubated at room temperature for 1 h at 400 RPM. The plate was then 
washed another 4 times and 100 μl of the substrate TMB solution was added to each 
well and incubates in the dark at room temperature for 30 min. The reaction was 
stopped by the addition of 100 μl Stop Solution. The OD was measured for each well 
at 450nm and 590nm using a ELx800TM microplate reader with Gen5 Data 
Analysis Software. The concentrations of IFN-β in each sample were extrapolated 
Chapter 2: Materials and Methods 
85 
 
from a standard curve that related the OD of each standard amount to the known 
concentration. Standard samples were assayed in duplicate to generate the standard 
curve, while all samples were assayed in triplicate. Data analysis was performed 
using Graph pad Prism5 software. 
2.2.4.5 Electro Mobility Shift Assay (EMSA)   
EMSA was used to detect the presence of DNA-binding proteins in nuclear extracts. 
NF-κB and PRDI/III Infrared Dye labelled oligonucleotides was purchased from 
Licor Biosciences and MWG respectively. 
2.2.4.5.1 Preparation of Sub-Cellular Fractions 
MEF cells were seeded at 5x10
5 
cells/ml (3 ml) or BMDCs were seeded at 1x10
6
 
cells/ml (3 ml) for generation of subcellular reactions. Following treatment, cells 
were washed with 1 ml of ice cold PBS and then scraped into 1 ml of hypotonic 
Buffer A. Following centrifugation at 4ºC at 16,000 RPM for 10 min the 
supernatants were removed and the cells were lysed for 10 min on ice in Buffer A 
containing 0.1% (w/v) Igepal (20 μl). Lysates were centrifuged at 21,000 g for 2 min. 
The resulting supernatants constituted cytosolic extracts and were stored at -20ºC in 
fresh 1.5 ml tubes. The remaining pellets were resuspended in 20 μl of Buffer B and 
incubated on ice for 20 min and kept under constant agitation. Samples were then 
centrifuged at 16,000 RPM for 10 min. The supernatants were then transferred to 50 
μl of Buffer C and were considered as the nuclear extracts. Protein concentrations 
were determined by the method of Bradford and assayed for translocation by western 
blotting (as described in 2.2.3.1 – 2.2.3.3) or assayed for DNA-binding activity as 
outlined in the following sections. 
2.2.4.5.2 Bradford Assay 
In order to determine the concentration of protein in nuclear extracts a Bradford 
assay was conducted as previously described (Bradford, 1976). BSA standards of a 
known protein concentration and samples were diluted in water (20 μl) and mixed 
with 180 μl of Bradford assay reagent and protein concentration determined by the 
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formation of a colorimetric product. The OD was measured for each well at 590nm 
using a ELx800TM microplate reader with Gen5 Data Analysis Software. The 
concentrations of protein in each sample were extrapolated from a standard curve 
that related the OD of each standard amount to the known concentration. Standard 
samples were assayed in duplicate to generate the standard curve, while all samples 
were assayed in triplicate. Data analysis was performed using Graph pad Prism5 
software. 
 
2.2.4.5.3 EMSA Reaction 
Nuclear extracts (5μg of protein), generated as described in section 2.2.3.4.1, were 
incubated with the following reaction mix: 
10x Binding Buffer  2 μl 
Poly (dI-dC)  1 μl 
25mM DTT 2 μl 
1% NP40 1 μl 
1mM MgCl2 1 μl 
IRDye labelled / non-labelled oligonucleotides 1 μl 
Nuclear extract (5 μg) + H20   12 μl 
 
NF-κB consensus oligonucleotide: 
 5’ - AGTTGAGGGGACTTTCCCAGGC - 3’ 
PRDI/III consensus oligonucleotide: 
5’ - GTAAATGACATAGGAAAACTGAAAGGGAGAAGTGAAAGTGG - 3’ 
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For competition assays, unlabelled oligonucleotides containing the consensus NF-κB 
were added for 10 min at room temperature, prior to addition of the IRDye labelled 
oligonucleotides. Incubations were performed in the dark for 30 min at room 
temperature. Reactions were stopped by adding 10X orange loading dye and placing 
reactions on ice prior to loading onto an native gel. 
 
2.2.4.5.4 Native Acrylamide Gel Electrophoreisis 
A native 5% Acrylamide Gel was prepared as follows 
H2O 39ml 
10x TBE 2.5ml 
30% Polyacrylamide 8.4ml 
10% APS 250μl 
TEMED 20μl 
The components were mixed well while minimizing bubble formation.  The gel was 
poured and allowed polymerize for 30-45 min. The gel was pre-run in 0.5X TBE for 
30 min at 70V.  The samples were added and subjected in the dark to electrophoresis 
for ~90 min at 70V in the non-denaturing 5% (w/v) polyacrylamide gel. Gels were 
then removed from the glass plates and visualised using Odyssey Infrared Imaging 
System from Licor Biosciences.  
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3.1 Prologue 
The initiation of the innate immune response is paramount to pathogenic 
identification and host protection. A family of PRRs known as the TLRs play a 
fundamental role in this process by both recognising and responding to specific 
pathogenic insults. Cell surface TLR1/2/4/5/6 have been shown to bind a vast array 
of microbial PAMPs ranging from gram positive and negative bacteria to fungal and 
parasitic motifs (McGettrick and O’Neill, 2010). In contrast, TLR7/8/9 are located 
on intracellular endosomes whereby they detect and respond to bacterial and viral 
nucleic acids (Blasius and Beutler, 2010). Interestingly, TLR3 a critical mediator of 
anti-viral defence against dsRNA species, is located on both endosome and cell 
surface membranes in a temporal and cell specific manner (Seya et al., 2009). Upon 
TLR-PAMP ligation, receptor dimerisation allows recruitment of the TIR adaptor 
proteins to instigate complex downstream signalling cascades which can be broadly 
categorised into the Myd88-dependent and TRIF-dependant pathways. Both 
pathways culminate in the transactivation of key transcription factor families, such as 
NF-κB, AP-1 and the IRFs leading to the co-ordinated induction of key mediators of 
host defence (Medzhitov et al., 1997b, Kyriakis et al., 1994, Medzhitov et al., 1998a, 
Sato et al., 2000). 
TLR3 is unique in the TLR family in that it alone does not require Myd88 to 
propagate downstream signalling (Oshiumi et al., 2003a). TLR3 exclusively recruits 
TRIF to its cytosolic TIR domain upon viral dsRNA ligation leading to TRIF 
phosphorylation by Burtons tyrosine kinase (BTK) (Lee et al., 2012). 
Phosphorylated TRIF can activate the NF-κB pathway in two distinct ways; a 
TRAF6-mediated pathway and a RIP1-dependent pathway. It has been reported that 
TRAF6 can associate with the N-terminus of activated TRIF, leading to TRAF6 
oligomersiation and activation of its E3 ubiquitin ligase activity (Sato et al., 2003, 
Ea et al., 2004). Polyubiquitinated TRAF6 on Lysine124 acts a signalling platform 
for the recruitment of a TAK1/TAB1/TAB2/TAB3 complex allowing TAK1 to 
become autophosphorylated (Jiang et al., 2003b, Kishimoto et al., 2000, Lamothe et 
al., 2007a). The formation of polyubiquitin chains by TRAF6’s E3 ligase domain 
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also serves to bring TAK1, a MAPKKK, into close proximity to its substrates IKKs 
and MKKs (Wang et al., 2001, Ea et al., 2004, Lamothe et al., 2007b). TAK1 
promotes phosphorylation of the IKKs which in turn localise to and phosphorylate 
IκBα (Zandi et al., 1998). Phosphorylation of IκBα leads to its K48-linked 
polyubiquitination and proteasomal degradation allowing NF-κB to translocate to the 
nucleus and initiate gene transcription (Brown et al., 1995). Recently however, a 
number of studies have reported contrasting roles for TRAF6 in TLR3 dependent 
NF-κB activation. TLR3-induced activation of NF-κB is completely abolished in 
TRAF6-deficient MEFs. However, TRAF6-deficient macrophages display normal 
NF-κB activity (Jiang et al., 2003b, Gohda et al., 2004). These discrepancies may be 
explained in part by cell type specific roles for TRAF6 and/or by functional 
redundancy with other members of the TRAF family, such as TRAF2 (Sasai et al., 
2010) . In addition, the role of TRAF6 in bridging TRIF to the NF-κB pathway may 
be mediated in full by the RIP1-dependent mechanism. Upon TLR3 dimerisation, 
RIP1 is recruited to TRIF’s C-terminus via a RIP homotypic interaction motif 
(Meylan et al., 2004). The adaptor protein TRADD binds RIP1 and is required for 
the recruitment of an E3 ligase to facilitate RIP1 polyubiquitination and subsequent 
interaction with the TAK1 complex to propagate NF-κB activation (Ermolaeva et al., 
2008, Cusson-Hermance et al., 2005). Although TRAF6 was originally proposed as 
the E3 ligase initiating RIP1 polyubiquitination, due to its cell type specific roles, 
other E3 ligases must be critical for this modification. Recently a member of the 
Pellino family of E3 ubiquitin ligases Pellino1 was shown to be vital for TRIF-
induced activation of NF-κB and pro-inflammatory cytokine production. Pellino1 
interacts with RIP1 and induces TRIF- dependent RIP1 polyubiquitination and NF-
κB pathway activation (Chang et al., 2009). As Pellino1 is required for NF-κB 
activation in both macrophages and MEFs, it indicates that the Pellino protein may 
be the key E3 ligase for TRIF dependent NF-κB signalling. 
In addition to inducing NF-κB and MAPK activity, TRIF-dependent signalling can 
also trigger the activation of the interferon regulatory factors IRF3 and IRF7. In 
TLR3 signalling the activation of IRF3 has been intensively investigated, with 
studies on IRF7 mainly restricted to TLR7/8/9 signalling. The TRIF dependent 
activation of IRF3 activation is independent of TRAF6 and RIP1 (Cusson-Hermance 
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et al., 2005, Jiang et al., 2004).  Instead, TRIF recruits both the adaptor protein 
NAP1 and the E3 ligase TRAF3 to propagate downstream activation of the non-
canonical IKKs, TBK1 and IKKi (Sasai et al., 2005, Hacker et al., 2006, Oganesyan 
et al., 2006). NAP1 is thought to directly facilitate the interaction of TBK1 and IKKi 
with the N-terminus of TRIF while K63-linked ubiquitination of TRAF3 has been 
proposed as a requirement for their downstream kinase activity. Activated TBK1 and 
IKKi can in turn bind to and phosphorylate IRF3/7 leading to their dimerisation, 
nuclear translocation and upregulation of anti-viral cytokines (Sharma et al., 2003, 
McWhirter et al., 2004b, Hiscott et al., 1999, Hemmi et al., 2004). IRF7 activation 
has been extensively investigated in specialised anti-viral response cells known as 
pDCs (Gilliet et al., 2008). Interestingly, pDCs sense viral nucleic acids by TLR7/9 
(Kadowaki et al., 2001, Kato et al., 2005). pDC activation of TLR7/9 results in the 
specific recruitment of the TIR adaptor protein Myd88  (Hemmi et al., 2003a). This 
causes MyD88 to complex with TRAF6 and IRF7 allowing TRAF6 to activate IRF7 
via K63-linked ubiquitination followed by nuclear translocation and type 1 IFN 
production (Kawai et al., 2004).  Therefore, although TRAF6’s role in NF-κB 
activation during anti-viral signalling is controversial its ability to activate IRF7, at 
least in pDCs, is undisputed. 
Type 1 IFN upregualtion by TLR3 is critical for host protection to a number of viral 
infections and requires the co-ordinated activation of NF-қB, AP-1 and IRF3/7 at the 
promoter of responsive genes. The best characterised example is the enhanceosome 
of the IFN-β promoter and contains at least four regulatory cis-elements: the positive 
regulatory domains (PRDs) I, II, III and IV. It is known that NF- қB binds to the 
PRDII element, AP-1 binds to PRDIV while IRF3 and IRF7 bind to the PRDI/III 
regions of the promoter (Du and Maniatis, 1992, Tanaka et al., 1993, Fujita et al., 
1989). Interestingly the PRDII and PRDIV domains have yet to be described for the 
IFN-α promoter partly explaining how IRF7 alone is a major driver of this cytokine 
by pDCs (Honda et al., 2005b). IFN-α exists as a family of structurally related 
cytokines while IFN-β is a single protein subtype (Bekisz et al., 2004). Interestingly, 
it is thought that IFN-α is functionally active as a monomer while the IFN-β 
functional unit is a dimer, however the biological significance of this is as yet 
unknown (Kempner and Pestka, 1986, Pestka et al., 1983, Pestka et al., 2004). 
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During initial TLR3 signalling both IFN-α4 and IFN-β are strongly upregulated and 
secreted from the cell and signal in an autocrine and paracrine fashion. This 
signalling is mediated by the type 1 IFNα/β receptor (IFNAR) which consists of two 
subunits known as IFN-αR1 and IFN-αR2c (Uze et al., 1990, Novick et al., 1994). 
IFN-αR1 is basally associated with tyrosine kinase 2 (Tyk2) while the IFN-αR2c is 
thought to interact with Janus kinase 1 (Jak1) (Domanski et al., 1997, Yan et al., 
1996). Ligand-induced receptor rearrangement and subunit dimerisation initiate 
tyrosine phosphorylation and activation of the associated kinases (Silvennoinen et al., 
1993, Kotenko et al., 2003). This in turn leads to tyrosine phosphorylation of a 
number of signal transducer and activator of transcription (STAT) proteins, 
including STAT1 and STAT3 (Matikainen et al., 1999). The activated STATs then 
form heterodimers or homodimers and translocate to the nucleus where they initiate 
transcription of IFN-stimulatory genes (ISGs) (Darnell, 1997). The formation of ISG 
factor 3 (ISGF3) complex includes activated STAT heterodimers and IRF9 allows 
for the induction of genes containing an IFN-stimulated response element (ISGE) 
(Fu et al., 1990, Schindler et al., 1992). Other combinations of STAT oligomers can 
also bind another response element known as the IFN-γ-activated site (GAS) element, 
that is present in the promoter of many ISGs (Ghislain et al., 2001). Type 1 IFN 
upregulation and activation of PKR leads to phosphorylation and termination of viral 
translation by initiation factor eIF2α upon dsRNA viral detection (Meurs et al., 1990, 
Balachandran et al., 2000). In addition, upregulation of 2',5'-oligoadenylate 
synthetase (OAS) and RNase L lead to direct degradation of viral mRNA (Zhou et 
al., 1993, Zheng et al., 2001). Upregualtion of chemokines such as interferon γ-
induced protein 10 (IP-10) can result in the recruitment of cytotoxic CD8
+
 T cells 
and cell death in virus infected cells represent another mechanism ISGs use to 
protect host homeostasis (Klein et al., 2005).  As TLR activation of type 1 IFNs can 
have dramatic consequences to the host, it is therefore critical the initial induction is 
controlled. 
It is clear that ubiquitination is an important mediator of TLR signal transduction. 
An emerging family of E3 ubiquitin ligases, the Pellino proteins, have recently been 
implicated in TLR signalling (Moynagh, 2009). The three mammalian Pellino 
proteins, Pellino1, Pellino2 and Pellino3 share an extremely high sequence 
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homology (Schauvliege et al., 2007). Each member of the Pellino family contains a 
N-terminal forkhead-associated (FHA) domain that recognises phosphothreonine 
residues and mediates association with IRAK proteins (Lin et al., 2008). In addition, 
each Pellino molecule contains a conserved C-terminal RING-like domain that 
confers the E3 ubiquitin ligase activity to the family (Schauvliege et al., 2006, Butler 
et al., 2007). Pellino1 is the only Pellino protein to be defined physiologically in 
TLR signalling using gene targeted studies. As mentioned above, Pellino1 is 
critically important for TRIF dependent activation of NF-κB during TLR3/4 
signalling (Chang et al., 2009). Reports on the functionality of the other Pellino 
proteins have been reliant on RNAi and overexpression approaches and have 
provisionally linked them to MAPK activation (Jensen and Whitehead, 2003a, 
Jensen and Whitehead, 2003b, Butler et al., 2005). In this thesis, the generation of a 
Peli3
–/–
mouse is described and physiological function of Pellino3 in TLR3 signalling 
is defined. 
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3.2 Results 
3.2.1 Design Strategy and Genotyping of a Peli3
–/–
 Mice 
To date, the function of Pellino3 in TLR signalling has remained elusive. Functional 
studies regarding Pellino3 have relied solely on overexpression and RNAi studies. In 
order to elucidate its physiological role in TLR immunobiology, Pellino3-deficient 
mice were generated according to the strategy outlined (Fig 3.1a). Using its 
proprietary technology, Taconic Artemis generated ES cells in which the Peli3 gene 
was flanked with loxP sites. A targeting vector was designed using BAC clones from 
the C57BL/6J RPCI-23 BAC library and transfected into the Taconic Artemis 
C57BL/6N Tac ES cell line. The constructed vector flanked exon3 of the Peli3 gene 
with the addition of a positive selection marker inserted into intron2. Generation of 
homologous recombinant clones were isolated using positive (Puromycin resistance) 
and negative (Thymidine kinase) selections and used to create chimeric mice by 
blastocyst injection. Highly chimeric males were chosen and mated with C57BL/6 
females. Their heterozygous progeny were identified by Southern blotting. 
Heterozygous mice with the targeted exon3 were bred with mice expressing Cre 
recombinase regulated by the ROSA26 locus (C57BL/6-Gt(ROSA)26Sor
tm16(Cre)Arte
).  
Upon recombination, exon3 of the Peli3 gene was deleted and caused a downstream 
frameshift in exons4-7. The Cre transgene was subsequently eliminated by mating 
the generated Peli3
(+/–)
 with WT C57BL/6 mice during colony expansion. 
In order to determine the genotype of the mice used in this study, PCR analysis of 
DNA isolated from murine ear punches was conducted (Fig. 3.1b). Genotyping PCR 
using WT (Peli3
(+/+)
) genomic DNA as a template resulted in the production of a 
large 1156 bp fragment when using primers (a + b) for the full length Peli3 gene 
spanning exon3. Genotyped DNA from heterozygous (Peli3
(+/–)
) animals also 
resulted in this large PCR product. However, the presence of a smaller 332 bp 
fragment detecting the recombined Peli3 allele was also observed. This smaller 
fragment was the only amplified product when using the Peli3-deficient (Peli3
–/–
)  
mice DNA as template. Primers (c + d) were used to distinguish heterozygous and 
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homozygous mice. Primer d was designed to target a part of the Peli3 gene sequence 
which was inside the loxP flanking region before exon3. Upon recombination this 
site was deleted. Genotyping PCR using this primer set resulted in a 210 bp fragment 
from both WT and heterozygote genomic DNA, but not from the Peli3-deficient 
DNA confirming the genotype of both alleles. For all reactions, DNase free water 
(H20) was used as a template as a negative control. As a positive control, primers 
were used to amplify the housekeeping gene HPRT. 
3.2.2 Lack of Pellino3 Expression in Peli3
–/– 
Murine Cells 
Semi-quantitative RT-PCR (Fig. 3.2a) was conducted on mRNA from MEFs, 
BMDMs and BMDCs using primers specific for either exon3 of Pellino3 or HPRT. 
The RT-PCR from the WT mice generated a PCR product in all 3 cell types. This 
band was completely absent in the Peli3-deficient cells. For this reaction, DNase free 
water was used as a template as a negative control. In addition, quantitative real-time 
RT-PCR (Fig. 3.2b) was performed to measure the levels of Pellino3 mRNA in the 
cell types used in this thesis. The total mRNA levels of each cell type were equalised 
to expression of HPRT mRNA and Pellino3 expression presented as a percentage of 
the indicated WT cells. A total abrogation of Pellino3 gene expression was evident in 
all cell types in Peli3
–/– 
mice samples. Taken together, these studies demonstrate that 
Pellino3 gene expression is absent in the Peli3
–/– 
mice. 
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Figure 3.1 Deletion of the murine Peli3 gene. 
 
(a) Strategy used to generate Peli3-deficient mice. Diagram shows the murine Peli3 
gene; the Peli3 targeting vector containing exon3 flanked by loxP sites, the positive 
selection marker (Puro) inserted into intron2 and a downstream Thymidine Kinase 
(TK) gene; the targeted Peli3 allele; and the Peli3 knockout allele after Cre 
recombination. Homologous recombinants in ES cells were isolated by Puro 
selection and used for blastocyst injection. Mice that were heterozygous for the 
targeted allele were bred with mice containing Cre recombinase regulated by the 
ROSA26 locus generating constitutive Peli3-deficient mice in which deletion of 
exon3 results in loss of function of the Peli3 gene by generating a frameshift in all 
downstream exons. Exons are numbered and regions targeted by genotyping primers 
are also indicated. (b) Genotyping by PCR analysis of genomic DNA from ear 
punches. Primers a and b differentiate the WT allele from the Peli3 knockout allele 
in heterozygous and homozygous mice based on different fragment size where 
primers c and d amplify a larger fragment for the WT allele and a shorter fragment 
for the knockout allele. Primers c and d detect only the WT Peli3 allele. Primers for 
HPRT were used to assess equal genomic DNA content in all reactions. Water was 
used as a negative control for the PCR reaction. 
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Figure 3.2 Expression of Pellino3 mRNA in cells isolated from WT and Peli3
–/– 
mice. 
 
Murine embryonic fibroblasts (MEF), bone marrow derived macrophages (BMDM) 
and bone marrow derived dendritic cells (BMDC) were isolated from WT and Peli3
–
/– 
mice. (a) cDNA was generated and semi-quantitative RT-PCR was performed 
using primers for exon3 of the Peli3 gene or a region of the house-keeping gene 
HPRT. Water was used as a negative control. (b) Real time PCR was performed to 
quantify the expression levels of the Pellino3 mRNA in the indicated cell types. All 
mRNA levels were normalised to HPRT expression. Pellino3 levels in Peli3
–/–
 cells 
are measured as a % of their WT counterparts.  
Peli3+/+ Peli3–/–
H2O MEF BMDM BMDC MEF BMDM BMDC
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3.2.3 Loss of Pellino3 Fails to Affect TLR-induced 
Expression of TNF-α 
The role of Pellino3 in TLR signalling was initially explored by comparing the 
expression of TLR-responsive genes in cells from WT and Pellino3-deficient mice. 
BMDMs (Fig. 3.3a) and BMDCs (Fig. 3.3b) from WT and Peli3
–/– 
 mice were 
stimulated for 6 h with ligands for TLR2/6, Pam2CSK; TLR2/1, Pam3CSK; TLR2 
and Dectin-1, Zymosan; TLR3, Poly(I:C); TLR4, LPS; TLR5, Flagellin; TLR7/8, 
CLO97; and TLR9, CpG type B and mRNA levels assessed for the pro-
inflammatory cytokine TNF-α by quantitative real-time PCR. Each TLR agonist 
induced expression of TNF-α in all cell types from WT and Peli3–/– mice. However, 
no differences in cytokine upregulation were detected in cells deficient in Pellino3 
compared to that of WT cells. 
Although TNF-α mRNA expression was comparable between the WT and Pellino3-
deficent cells after 6 h TLR stimulation (Fig. 3.3), it was important to confirm 
Pellino3 had no role in TNF-α protein production and secretion. To this end, 
BMDMs (Fig. 3.4a), BMDCs (Fig. 3.4b) and MEFs (Fig. 3.4c) were stimulated with 
the TLR ligands as indicated for 24 h. Again all ligands triggered TNF-α production 
in each cell type and no differences in TNF-α induction were observed between cells 
derived from WT and Peli3
–/–
 mice. These results indicate Pellino3 is dispensable for 
TLR-induced expression of TNF-α. 
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Figure 3.3 Effect of Pellino3-deficiency on TLR-induced expression of TNF-α 
mRNA. 
 
Quantitative real-time PCR of TNF-α  expression in cells from (a) BMDMs or (b)  
BMDCs isolated from WT and Peli3
–/– 
mice and left untreated (UT) or stimulated 
with Pam2CSK (10 ng/ml), Pam3CSK (10 ng/ml), Zymosan (5 μg/ml), Poly(I:C) (10 
μg/ml), LPS (10 ng/ml), Flagellin (1 μg/ml) or CLO97 (1 μg/ml) or CpG (3 μM) for 
6 h. Data are presented as a fold relative to WT UT, normalised to HPRT expression 
and as the mean +/- S.E.M. of three independent experiments and were subjected to 
paired two-tailed Student's t-test. 
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Figure 3.4 Effect of Pellino3-deficiency on TLR-induced production of TNF-α. 
 
ELISA of TNF-α production in media from (a) BMDMs or (b) BMDCs isolated 
from WT and Peli3
–/– 
mice and left untreated (UT) or stimulated with Pam2CSK (10 
ng/ml), Pam3CSK (10 ng/ml), Zymosan (5 μg/ml), Poly(I:C) (10 μg/ml), LPS (10 
ng/ml), Flagellin (1 μg/ml), CLO97 (1 μg/ml) or CpG (3 μM) for 24 h. ELISA of 
TNF-α production in media from (c) MEFs isolated from WT and Peli3–/– mice and 
left untreated (UT) or stimulated with Pam2CSK (100 ng/ml), Pam3CSK (100 ng/ml), 
Zymosan (5 μg/ml), Poly(I:C) (25 μg/ml), LPS (100 ng/ml), Flagellin (5 μg/ml), 
CLO97 (5 μg/ml) or CpG (5 μM) for 24 h. Higher concentrations of the each TLR 
ligand was used in MEF cells as they are not as responsive to TLR activation as 
professional innate immune cells. Data are presented as the mean +/- S.E.M. of least 
three independent experiments and were subjected to paired two-tailed Student's t 
test. 
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3.2.4 Loss of Pellino3 Fails to Affect TLR-induced 
Expression of IL-6 
A potential role for Pellino3 in TLR-induced expression of IL-6 was next examined 
with a view to assessing if the lack of an involvement of Pellino3 in TNF expression 
extended to other pro-inflammatory cytokines. BMDMs (Fig. 3.5a) and BMDCs (Fig. 
3.5b) from WT and Peli3
–/– 
were stimulated for 6 h with the indicated TLR agonists 
and levels of IL-6 mRNA expression assessed by quantitative real-time PCR. Each 
TLR ligand induced an upregulation of IL-6 expression in cells from WT and 
Pellino3-deficent animals. However, no significant differences in IL-6 mRNA were 
observed between WT and Pellino3-deficent cells.  
In order to confirm Pellino3 had no role in TLR production of IL-6 protein, BMDMs 
(Fig. 3.6a), BMDCs (Fig. 3.6b) and MEFs (Fig. 3.6c) were stimulated with the TLR 
ligands as indicated for 24 h. TLR stimulation with all ligands resulted in increased 
Il-6 production in all cell types. Once again however, Pellino3-deficiency had no 
effect on the pro-inflammatory cytokines expression when compared to WT cells. 
Taken together these results indicate Pellino3 is dispensable during TLR induction of 
IL-6 and strongly suggests it has no role in pro-inflammatory cytokine expression 
during TLR signalling. 
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Figure 3.5 Effect of Pellino3-deficiency on TLR-induced expression of IL-6 
mRNA. 
 
Quantitative real-time PCR of TNF-α expression in cells from (a) BMDMs or (b)  
BMDCs isolated from WT and Peli3
–/– 
mice and left untreated (UT) or stimulated 
with Pam2CSK (10 ng/ml), Pam3CSK (10 ng/ml), Zymosan (5 μg/ml), Poly(I:C) (10 
μg/ml), LPS (10 ng/ml), Flagellin (1 μg/ml) or CLO97 (1 μg/ml) or CpG (3 μM) for 
6 h. Data are presented as a fold relative to WT UT, normalised to HPRT expression 
and as the mean +/- S.E.M. of three independent experiments and were subjected to  
paired two-tailed Student's t-test. 
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Figure 3.6 Effect of Pellino3-deficiency on TLR-induced production of IL-6. 
 
ELISA of IL-6 production in media from (a) BMDMs or (b) BMDCs isolated from 
WT and Peli3
–/– 
mice and left untreated (UT) or stimulated with Pam2CSK (10 
ng/ml), Pam3CSK (10 ng/ml), Zymosan (5 μg/ml), Poly(I:C) (10 μg/ml), LPS (10 
ng/ml), Flagellin (1 μg/ml), CLO97 (1 μg/ml) or CpG (3 μM) for 24 h. ELISA of 
TNF-α production in media from (c) MEFs isolated from WT and Peli3–/– mice and 
left untreated (UT) or stimulated with Pam2CSK (100 ng/ml), Pam3CSK (100 ng/ml), 
Zymosan (5 μg/ml), Poly(I:C) (25 μg/ml), LPS (100 ng/ml), Flagellin (5 μg/ml), 
CLO97 (5 μg/ml) or CpG (5 μM) for 24 h. Higher concentrations of the each TLR 
ligand was used as MEFs are not as responsive to TLR activation as professional 
innate immune cells. Data are presented as the mean +/- S.E.M. of three independent 
experiments and were subjected to paired two-tailed Student's t test. 
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3.2.5 Loss of Pellino3 Leads to Enhanced TLR3-induced 
Expression of IFN-β 
Another critically important consequence for host immunity during TLR signalling 
is the activation of anti-viral type 1 IFNs. TLR3, TLR4, TLR7/8 and TLR9 are the 
predominant TLR family members that drive expression of type 1 IFNs while other 
TLRs have either limited or no ability to induce expression. Therefore, BMDMs (Fig. 
3.7a) and BMDCs (Fig. 3.7b) from WT and Peli3
–/– 
were stimulated for 24 h with 
ligands for TLR3, TLR4, TLR7/8, and TLR9, and their ability to induce IFN-β 
production was measured by ELISA. In addition, MEFs from WT and Peli3
–/– 
mice 
were stimulated with Poly(I:C) for 24 h and IFN-β levels were also assessed by 
ELISA (Fig. 3.7c). Each of the ligands triggered IFN-β upregulation in the WT cells 
and in all cases, except the TLR3 ligand Poly(I:C), the levels of induction of IFN-β 
were comparable in the Peli3
–/–
 cells. However, there was a significant augmentation 
of Poly(I:C)-induced expression of IFN-β induction in the Peli3–/– cells. This data 
indicates that Pellino3 is a specific regulator of TLR3-induced IFN-β in multiple cell 
types.  
Studies were next performed to assess if the specific effects of Pellino3 on IFN-β 
expression manifested at the level of transcriptional regulation of the IFN-β 
expression. BMDMs (Fig. 3.8a) and BMDCs (Fig. 3.8b) from WT and Peli3
–/– 
mice 
were thus stimulated with the ligands for TLR3, TLR4, TLR7/8 and TLR9 and 
measured for IFN-β mRNA expression by quantitative real-time PCR analysis. As 
was the case for protein levels of IFN-β, Peli3–/– cells showed greater induction of  
IFN-β mRNA in response to Poly(I:C), relative to WT cells suggesting that the 
ability of Pellino3 to modulate TLR3-induced expression of IFN-β is occurring at the 
transcriptional level. 
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Figure 3.7 Effect of Pellino3-deficiency on TLR-induced production of IFN-β. 
 
ELISA of IFN-β production in media from (a) BMDMs or (b) BMDCs isolated from 
WT and Peli3
–/– 
mice and left untreated (UT) or stimulated with Poly(I:C) (10 μg/ml), 
LPS (10 ng/ml), CLO97 (1 μg/ml) or CpG (3 μM) for 24 h. ELISA of IFN-β  
production in media from MEFs (c) isolated from WT and Peli3
–/– 
mice and left 
untreated (UT) or Poly(I:C) (25 μg/ml) for 24 h. Data are presented as the mean +/- 
S.E.M. of at least three independent experiments and were subjected to paired two-
tailed Student's t test. *, p < 0.05 
NT Poly(I:C) LPS CLO97 CpG
0
500
1,000
1,500
2,000
WT
Peli3
–/–
*
IF
N
- 
 (
p
g
/m
l)
UT Poly(I:C) LPS CLO97 CpG
0
1,000
2,000
3,000
WT
Peli3
–/–
*
IF
N
- 
 (
p
g
/m
l)
a 
b 
c 
UT Poly(I:C)
0
500
1,000
1,500
2,000
2,500
WT
Peli3
–/–
*
IF
N
- 
 (
p
g
/m
l)
Chapter 3: Results 
106 
 
 
 
Figure 3.8 Effect of Pellino3-deficiency on TLR-induced expression of IFN-β 
mRNA.
 
 
Quantitative real-time PCR of IFN-β expression in cells from (a) BMDMs or (b) 
BMDCs isolated from WT and Peli3
–/– 
mice and left untreated (UT) or stimulated 
with Poly(I:C) (10 μg/ml), LPS (10 ng/ml), CLO97 (1 μg/ml) or CpG (3 μM) for 6 h. 
Data are presented as a fold relative to WT UT, normalised to HPRT expression and 
as the mean +/- S.E.M. of three independent experiments and were subjected to 
paired two-tailed Student's t test. **, p < 0.01; ***, p < 0.001. 
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3.2.6 Loss of Pellino3 Leads to Enhanced TLR3-induced 
Expression of IFN-α 
Given that IFN- is another type 1 IFN whose expression is transcriptionally 
regulated by a mechanism similar to IFN-β, the loss of Pellino3 affect on the 
expression of IFN-α was next examined. BMDMs (Fig. 3.9a), BMDCs (Fig. 3.9b) 
and MEFs (Fig. 3.9c) were isolated from WT and Peli3
–/–
 mice stimulated for 24 h 
with Poly(I:C) and levels of IFN-α2/4 were measured by ELISA. Poly(I:C)-induced 
modest expression levels of  IFN-α in all 3 cell types from WT mice but the 
corresponding cells from  Pellino3-deficient mice showed much stronger induction 
of IFN-α protein production. 
To confirm if Pellino3 was again targeting the transcriptional regulation of this type 
1 IFN, and if it was again a TLR3 restricted phenomena, BMDMs (Fig. 3.10a) and 
BMDCs (Fig. 3.10b) from WT and Peli3
–/–
 mice were stimulated with the ligands for 
TLR3, TLR4, TLR7/8, CLO97 and TLR9 for 6 h and mRNA measured by 
quantitative real-time PCR. In BMDMs from WT mice, all ligands induced IFN-α4 
transcription with Poly (I:C) being the most efficacious. In addition, the Poly(I:C)-
induced transcription of IFN-α4 was further enhanced in BMDMs from Peli3–/– mice. 
The ligands for TLR4, TLR7/8 and TLR9-induced low levels of IFN-α transcript in 
cells from WT mice but unlike Poly(I:C), the levels of IFN-α4-induced by these 
other ligands were the same in BMDMs from WT and Pellino3-deficent cells. The 
selective effects of Pellino3-deficiency on TLR3-induced IFN-α were also observed 
in BMDCs. In the latter cells, Poly(I:C) was most efficacious  in inducing  IFN-α4 
transcription in cells from WT mice and again this was further  increased in the 
Pellino3-deficient cells. As before, LPS and CLO97-induced IFN-α4 transcription in 
WT BMDCs and the levels of induced transcripts were similar in cells from Peli3
–/–
 
mice. Taken together, these findings highlight Pellino3 as specific negative regulator 
of type 1 IFNs during TLR3 signalling, likely mediating its inhibitory effects via 
regulation of gene transcription.  
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3.2.7 Pellino3 Limits Bioactive Type 1 IFN Secretion in 
Response to TLR3 Signalling 
Given that loss of Pellino3 leads to enhanced expression of type 1 IFNs in response 
to TLR3 stimulation it was important to confirm that these IFNs were bioactive. To 
this end, BMDMs (Fig. 3.11a), BMDCs (Fig. 3.11b) and MEFs (Fig. 3.11c) from 
WT and Peli3
–/–
 mice were stimulated with the TLR3 ligand Poly(I:C) for 24 h. 
Conditioned media from cells were incubated with a bioactive type 1 IFN blue 
sensor cell assay in which increased IFN signalling is measured as increased 
secretion of the reporter gene SEAP under the control of the ISG54 promoter. 
Secreted SEAP levels were measured quantitatively upon addition of Quanti-blue 
substrate and absorbance measured at 630 nm. In all 3 cell types, TLR3 activation 
resulted in an upregulation of bioactive type 1 IFNs and a further augmentation was 
detected in supernatants from Pellino3-deficent cells compared to their WT cell 
counterparts.  
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Figure 3.9 Effect of Pellino3-deficiency on TLR3-induced production of IFN-α. 
 
ELISA of IFN-α production in media from (a) BMDMs or (b) BMDCs isolated from 
WT and Peli3
–/– 
mice and left untreated (UT) or stimulated with Poly(I:C) (10 μg/ml). 
ELISA of IFN-α production in media from (c) MEFs isolated from WT and Peli3–/– 
mice and left untreated (UT) or with Poly(I:C) (25 μg/ml) for 24 h. Data are 
presented as the mean +/- S.E.M. of at least three independent experiments and were 
subjected to paired two-tailed Student's t test. *, p < 0.05; **, p < 0.01. 
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Figure 3.10 Effect of Pellino3-deficiency on TLR-induced expression of IFN-α 
mRNA. 
 
Quantitative real-time PCR of IFN-α expression in cells from (a) BMDMs or (b) 
BMDCs isolated from WT and Peli3
–/– 
mice and left untreated (UT) or stimulated 
with Poly(I:C) (10 μg/ml), LPS (10 ng/ml), CLO97 (1 μg/ml) or CpG (3 μM) for 6 h. 
Data are presented as a fold relative to WT UT, normalised to HPRT expression and 
as the mean +/- S.E.M. of three independent experiments and were subjected to 
paired two-tailed Student's t test. *, p < 0.05; **, p < 0.01. 
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Figure 3.11 Effect of Pellino3-deficiency on TLR3-induced production of 
bioactive type 1 IFN. 
 
Bioactive type 1 IFN blue sensor cell assay of media from (a) BMDMs or (b) 
BMDCs isolated from WT and Peli3
–/– 
mice and left untreated (UT) or stimulated 
with Poly(I:C) (10 μg/ml). Bioactive type 1 IFN blue sensor cell assay in media from 
MEFs (c) isolated from WT and Peli3
–/– 
mice and left untreated (UT) or stimulated 
with Poly(I:C) (25 μg/ml) for 24 h. Data are presented as the absorbance at 630 nm 
and are the mean +/- S.E.M. of three independent experiments and were subjected to 
paired two-tailed Student's t test. *, p < 0.05; ***, p < 0.001. 
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3.2.8 Pellino3 Regulates TLR3-induced Production of IP-10 
In addition to type 1 IFNs, a number of other soluble mediators play fundamental 
roles in the clearance of viral pathogens. The chemokine IP-10 is thought to play an 
essential role in recruitment of various effector cells to limit viral replication during 
infection. The expression of IP-10 is also regulated by mechanisms similar to type 1 
IFNs. BMDMs (Fig. 3.12a), BMDCs (Fig. 3.12b) and MEFs (Fig. 3.12c) were 
stimulated with TLR3, TLR4, TLR7/8 and TLR9 ligands for 24 h and IP-10 levels 
assessed by ELISA. Each stimulation resulted in an increase in IP-10 production in 
the different cells types. Similar levels of the chemokine were observed in response 
to TLR4, TLR7/8 and TLR9 stimulations between WT and Pellino3-deificent cells, 
however, a specific augmentation in IP-10 production was detected in Pellino3-
defienct cells upon TLR3 activation compared to WT cells. 
 
 To ensure Pellino3 was targeting IP-10 production in a similar fashion to that of the 
type 1 IFNs, the effect of Pellino3 deficiency on IP-10 transcription was next 
investigated. BMDMs (Fig. 3.13a) and BMDCs (Fig. 3.13b) from WT and Peli3
–/– 
were stimulated with the ligands for TLR3, TLR4, TLR7/8 and TLR9 for 6 h and 
mRNA was extracted. Real-time PCR analysis for IP-10 indicated that Pellino3 was 
once again selectively targeting the transcription of the anti-viral gene during TLR3 
signalling as the Poly(I:C) stimulated cells deficient in Pellino3 showed significant 
augmentation in IP-10 expression relative to WT cells. This data taken together 
strongly indicate that Pellino3 is specifically targeting the TLR3 antiviral signalling 
pathway. 
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Figure 3.12 Effect of Pellino3-deficiency on TLR-induced production of IP-10. 
 
ELISA of IP-10 production in media from (a) BMDMs or (b) BMDCs isolated from 
WT and Peli3
-/- 
mice and left untreated (UT) or stimulated with Poly(I:C) (10 μg/ml), 
LPS (10 ng/ml), CLO97 (1 μg/ml) or CpG (3 μM) for 24 h. ELISA of IP-10  
production in media from (c) MEFs isolated from WT and Peli3
-/- 
mice and left 
untreated (UT) or stimulated with Poly(I:C) (25 μg/ml), LPS (100 ng/ml), CLO97 (5 
μg) or CpG (5 μM)  for 24 h. Data are presented as the mean +/- S.E.M. of at least 
three independent experiments and were subjected to paired two-tailed Student's t 
test. *, p < 0.05. 
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Figure 3.13 Effect of Pellino3-deficiency on TLR-induced expression of IP-10. 
 
Quantitative real-time PCR of IP-10 expression in cells from (a) BMDMs or 
BMDCs (b) isolated from WT and Peli3
–/– 
mice and left untreated (UT) or 
stimulated with Poly(I:C) (10 μg/ml), LPS (10 ng/ml), CLO97 (1 μg) or CpG (3 μM) 
for 6 h. Data are presented as a fold relative to WT UT, normalised to HPRT 
expression and as the mean +/- S.E.M. of three independent experiments and were 
subjected to paired two-tailed Student's t test. *, p < 0.05. 
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3.2.9 Pellino3 does not Regulate the Expression of Type 1 
IFNs in Response to TLR Stimulation in pDCs.  
A subset of dendritic cells, the pDCs are known to be specialised and rapid 
producers of type 1 IFNs in response to viral infections. Interestingly, the pDCs 
detect viral RNA and DNA using only endosomal TLR7/8 and TLR9 and have no 
expression of TLR3. As Pellino3 is a specific regulator of TLR3-induced anti-viral 
signalling, it was of importance to investigate if Pellino3 could mediate its regulatory 
effects in cells that respond to viral PAMPs by producing type 1 IFNs in a TLR3- 
independent manner. To this end, cells from WT and Peli3
–/– 
mice bone marrow was 
driven to both a BMDC (with GM-CSF) and pDC (with FLT3L) cell lineage for 9 
days. After polarisation, the pDC cells were subject to a negative selection 
enrichment process using antibodies conjugated to magnetic beads that label non 
pDC cells for retention in a magnetic column allowing a purified population of pDC 
cells to be obtained. Flow cytometry analysis (Fig. 3.14a) was used to assess the 
purity of cell populations. Live viable cells which stained negative for 7aad and 
positive for the pan DC marker CD11c were gated upon and used for dot plots 
provided. Cells that stained positive for CD11b and negative for CD45R (lower right 
quadrant) were considered BMDCs. With purity of 98.1% and 94.8% in the WT and 
Peli3
–/–
 cells respectively, after GM-CSF-induced polarisation, it indicates that the 
absence of Pellino3 has no effect on the percentage of BMDCs generated by GM-
CSF. Cells that stained CD11b negative and CD45R positive (upper left quadrant) 
were considered pDCs. The enriched cell population from WT and Peli3
–/– 
pDCs 
were also comparable with purities of 90.5% and 88.4% respectively. Using these 
enriched pDC populations, WT and Peli3
–/– 
(Fig. 3.14b) pDCs were stimulated with 
the ligands for TLR3, TLR4, and TLR9 and their ability to produce IL-6, IP-10, 
IFN-β and IFN-α was measured by ELISA. In line with other published reports, 
TLR3 and TLR4 stimulation failed to induce cytokines in the pDCs. Stimulation of 
TLR9 in WT pDCs resulted in robust induction of IL-6, IP-10, IFN-β and IFN-α 
with WT and Pellino3-deficent cells displaying comparable levels of cytokine 
production. This data indicates Pellino3 regulation of type 1 IFNs is specific to 
TLR3 signalling. 
Chapter 3: Results 
116 
 
 
UT Poly(I:C) LPS CpG
0
2,000
4,000
6,000
8,000
WT
Peli3
–/–
IF
N
- 
 (
p
g
/m
l)
UT Poly(I:C) LPS CpG
0
2,000
4,000
6,000
8,000
WT
Peli3
–/–
IF
N
- 
 (
p
g
/m
l)
UT Poly(I:C) LPS CpG
0
1,000
2,000
3,000
4,000
5,000
WT
Peli3
–/–
IP
-1
0
 (
p
g
/m
l)
UT Poly(I:C) LPS CpG
0
200
400
600
WT
Peli3
–/–
IL
-6
 (
p
g
/m
l)
 
Figure 3.14 Effect of Pellino3-deficiency on expression of TLR-responsive 
induced cytokines in pDCs. 
 
(a)  Generation of BMDCs and pDCs. BMDCs and pDCs were generated from bone 
marrow cells in the presence of GM-CSF (10 ng/ml) or FLT3L (10 ng/ml) 
respectively for 9 days with media changed at 3 day intervals. The pDCs were 
subject to magnetic bead enrichment prior to flow cytometry analysis. Dot plots 
shown are gated on CD11c positive cells that are viable and stained 7aad negative. 
CD11b positive and CD45R negative cells were considered BMDCs while CD11b 
negative and CD45R positive cells were considered pDCs. (b) ELISA of IL-6, IP-10, 
IFN-β and IFN-α production in media from pDCs isolated from WT and Peli3–/– 
mice and left untreated (UT) or stimulated with Poly(I:C) (10 μg/ml), LPS (10 ng/ml) 
or CpG (3 μM) for 24 h. Data are presented as the mean +/- S.E.M. of three 
independent experiments and were subjected to paired two-tailed Student's t test. 
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3.2.10 Pellino3 does not Target the MDA5 Pathway 
Given that Poly(I:C) can potentially stimulate both TLR3 and the cytosolic receptor 
MDA-5, studies next probed which receptor pathway was being targeted  by Pellino3 
in its modulation of cell responsiveness to Poly(I:C). BMDMs from WT and Peli3
–/– 
mice were stimulated directly with Poly(I:C) to favour TLR3 activation or subjected 
to liposome-mediated  transfection with Poly(I:C), to facilitate its delivery to the 
cytosolic MDA5 receptors (Fig. 3.15a). Both delivery methods induced IFN-β in the 
WT BMDMs, and this was further enhanced in Pellino3-deficient cells when the 
Poly(I:C) was directly applied to the cells but  not when transiently transfected. This 
further supported the earlier proposal that Pellino3 is targeting the TLR3 pathway. 
This was further validated by showing that responses to Poly(I:C) in the present 
models were mediated by TLR3 and not Mda-5 (Fig. 3.15b). Thus immortalised 
BMDMs derived from WT, TRIF- and MAVS-deficient mice were treated with 
Poly(I:C). Quantitative real-time PCR for IFN-β revealed a loss of induction only in 
the TRIF-deficient cells with strong activation in WT and Mavs
–/– 
macrophages. 
Given that TRIF is a critical adaptor for TLR3 and MAVS critical for MDA5 signal 
propagation, these data confirm that the presently used direct application of Poly(I:C) 
to cells is activating the TLR3 pathway and not Mda-5 and by extension the 
regulatory effects of Pellino3 on Poly(I:C) signalling are due to targeting of the 
TLR3 pathway. 
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Figure 3.15 Differential effects of Pellino3-deficiency on TLR3 and MDA5 
signalling. 
 
(a) ELISA of IFN-β protein in media from BMDMs from WT and Peli3–/– mice and 
left untreated (UT), stimulated with Poly(I:C) (5 μg/ml) or transfected with Poly(I:C) 
(5 μg/ml) for 24 h. (b) Quantitative real-time PCR of IFN-β mRNA expression in 
immortalised WT, Trif
–/–
 and Mavs
–/–
 BMDMs untreated (UT) or stimulated with 
Poly(I:C) (25 μg/ml) for 6 h. Data are presented as a fold relative to WT UT, 
normalised to HPRT expression and as the mean +/- S.E.M. of three independent 
experiments and were subjected to paired two-tailed Student's t test. **, p < 0.01; 
***, p < 0.001; ns, not significant. 
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3.2.11 Pellino3 Expression is TLR3 Responsive 
As a number of negative regulators of innate immune signalling are functionally 
upregulated by the signals they inhibit, it was important to investigate if Pellino3 
expression was TLR3 responsive. Immortalised BMDMs derived from WT, TRIF
–/–
, 
TBK1
–/–
 and MAVS
–/– 
were stimulated with Poly(I:C)  for 6 h and mRNA extracted 
(Fig. 3.16a). Poly(I:C)-induced the expression of Pellino3 mRNA in WT BMDMs 
however, its upregulation was significantly reduced in the TRIF
–/– 
and TBK1
–/– 
BMDMs. Interestingly, cells deficient in MAVS, the critical adaptor for MDA5 
signalling, had no significant impact on Poly(I:C)-induced levels of Pellino3 mRNA 
suggesting that Pellino3 mRNA expression is specifically regulated by TLR3 
signalling. Given that Poly(I:C) is a synthetic analogue of viral dsRNA, the role of a 
live virus in upregulating Pellino3 expression was next explored. EMCV was chosen 
as during its infection cycle it generates dsRNA and TLR3 signalling has been 
shown to be important for host protection (Hardarson et al., 2007b). Immortalised 
BMDMs derived from WT, TRIF
–/–
, TBK1
–/–
 and MAVS
–/– 
were infected with live 
EMCV for 25 h and mRNA extracted (Fig. 3.16b). EMCV infection caused potent 
upregulation of Pellino3 mRNA in WT iBMDMs. Again, the absence of TRIF or 
TBK1 leads to significant abrogation of viral-induced Pellino3 expression. 
Importantly, MAVS deficiency had no significant effect on Pellino3 upregulation. 
As EMCV infection activates TLR3 and MDA5, this data strongly indicates that 
Pellino3 is targeting the TLR3 pathway during EMCV infection. 
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Figure 3.16 TLR3 induces Pellino3 expression in a TRIF pathway-dependent 
manner 
 
Quantitative real-time PCR of Pellino3 expression in immortalised BMDMs and left 
(a) untreated (UT) or stimulated with Poly(I:C) (25 μg/ml) for 6 h or (b) left 
uninfected (UI) or infected with live EMCV (250 PFU) for 25 h. Data are presented 
as a fold relative to WT UT, normalised to HPRT expression and as the mean +/- 
S.E.M. of three independent experiments and were subjected to paired two-tailed 
Student's t test. *, p < 0.05; ns, not significant. 
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3.2.12 Pellino3 Negatively Regulates EMCV-induced 
Expression of IFN-β 
Although EMCV is capable of driving Pellino3 expression, it was important to 
demonstrate that Pellino3 could also negative regulate the anti-viral response during 
a live EMCV infection. BMDMs (Fig. 3.17a) and MEFs (Fig. 3.17b) were isolated 
from WT and Peli3
–/– 
mice and were infected with live EMCV for 25 h and IFN-β 
production measured by ELISA. EMCV infection resulted in a potent upregulation 
of IFN-β in WT and Pellino3-deficent cells. EMCV induction of IFN-β was 
significantly enhanced in the Pellino3-deficient cells compared to that of WT cells. 
The transcription of IFN-β mRNA in BMDMs (Fig. 3.17c) and MEFs (Fig. 3.17d) 
from WT and Peli3
–/– 
mice was also upregulated by EMCV infection. Again a 
further enhancement of the cytokine was evident in cells from Pellino3-deficent mice 
compared to WT cells. Together, this data indicates that Pellino3 can not only 
control Poly(I:C)-induced IFN-β but also plays a physiological role in regulating the 
expression of IFN-β in response to live viral challenge. 
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Figure 3.17 Effect of Pellino3-deficiency on EMCV-induced expression of IFN-β. 
 
ELISA of IFN-β protein in media from (a) BMDMs or (b) MEFs isolated from WT 
and Peli3
–/– 
mice and left uninfected (UI) or infected with live EMCV (250 PFU). 
Quantitative real-time PCR of IFN-β expression in cells from (c) BMDMs or (d) 
MEFs isolated from WT and Peli3
–/– 
mice and left UI or infected with EMCV (250 
PFU) for the indicated times. Data are presented as a fold relative to WT UT, 
normalised to HPRT expression and as the mean +/- S.E.M. of three independent 
experiments and were subjected to paired two-tailed Student's t test . *, p < 0.05; **, 
p < 0.01. 
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3.2.13 Pellino3 is a Negative Regulator of EMCV-induced 
IFN-α 
To investigate if EMCV-induced other type 1 IFNs and if they were similarly 
regulated by Pellino3, BMDMs (Fig. 3.18a) and MEFs (Fig. 3.18b) were isolated 
from WT and Peli3
–/– 
mice and were infected with live EMCV (250 PFU) for 25 h 
and IFN-α2/4 production measured by ELISA. Infected cells displayed a robust 
upregulation of IFN-α production in both WT and Pellino3-deficent cells. EMCV 
induction of IFN-α was significantly enhanced in the Pellino3-deficient cells 
compared to WT cells. Real-time PCR analysis investigating the transcription of 
IFN-α4 in WT and Peli3–/– mice BMDMs (Fig. 3.18c) and MEFs (Fig. 3.18d) 
revealed a similar phenotype in response to EMCV infection In BMDMs and MEFs 
significant augmentation of IFN-α4 mRNA levels was evident in Pellino3-deficent 
cells after 25 h infection compared to their WT counterparts. Therefore, Pellino3 has 
the ability to regulate other type 1 IFNs in response to viral infection. 
3.2.14 Pellino3 Negatively Regulates EMCV-induced 
Bioactive type 1 IFN Secretion 
In order for type 1 IFNs to mediate protection from EMCV virus, they must be able 
to functionally upregulate ISGs to help control viral replication. To this end, 
BMDMs (Fig. 3.19a) and MEFs (Fig. 3.19b) from WT and Peli3
–/–
 mice were 
infected with live EMCV for 25 h and supernatants measured for expression of 
bioactive type 1 IFNs. Conditioned media from cells were incubated with the 
bioactive type 1 IFN blue sensor cell assay. EMCV infected cells displayed an 
increase in secreted bioactive type 1 IFNs. However, the levels of bioactive type 1 
IFNs was further augmented in cells deficient in Pellino3 compared to WT cells 
highlighting Pellino3 as a functional regulator of type 1 IFN signalling in response to 
EMCV infection. 
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Figure 3.18 Effect of Pellino3-deficiency on EMCV-induced expression of IFN-α. 
 
ELISA of IFN-α protein in media from (a) BMDMs or (b) MEFs isolated from WT 
and Peli3
–/– 
mice and left uninfected (UI) or infected with live EMCV (250 PFU). 
Quantitative real-time PCR of IFN-α expression in cells from (c) BMDMs or (d) 
MEFs isolated from WT and Peli3
–/– 
mice and left UI or infected with EMCV (250 
PFU) for the indicated times. Data are presented as a fold relative to WT UT, 
normalised to HPRT expression and as the mean +/- S.E.M. of three independent 
experiments and were subjected to paired two-tailed Student's t test . *, p < 0.05; **, 
p < 0.01. 
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Figure 3.19 Effect of Pellino3-deficiency on EMCV-induced production of 
bioactive type 1 IFN. 
 
Bioactive type 1 IFN blue sensor cell assay of media from (a) BMDMs or (b) MEFs 
isolated from WT and Peli3
–/– 
mice and left untreated (UT) or infected with EMCV 
(250 PFU) for 25 h. Data are presented as the absorbance at 630 nm and are the 
mean +/- S.E.M. of three independent experiments and were subjected to paired two-
tailed Student's t test. *, p < 0.05; **, p < 0.01. 
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3.2.15 Pellino3 is a Negative Regulator of EMCV-induced 
IP-10 Expression 
Investigation into IP-10 was again employed to investigate if Pellino3 affected other 
EMCV-responsive genes that are regulated in a manner similar to type 1 IFNs. 
BMDMs (Fig. 3.20a) and MEFs (Fig. 3.20b) were isolated from WT and Peli3
–/– 
mice and infected with live EMCV for 25 h and IP-10 production measured by 
ELISA. EMCV-induced production of IP-10 in both WT and Pellino3-deficent cells 
however, EMCV induction of IP-10 was significantly enhanced in the Pellino3-
deficient cells compared to WT cells. Real-time PCR analysis investigating the 
transcription of IP-10 in WT and Peli3
–/– 
mice BMDMs (Fig. 3.20c) and MEFs (Fig. 
3.20d) revealed a similar phenotype. In BMDMs and MEFs significant augmentation 
of IP-10 mRNA levels were evident in cells lacking Pellino3 expression compared to 
WT cells after 25 h infection. Therefore, Pellino3 has the ability to regulate other 
cytokines that share similar transcription factor regulation profiles to the type 1 IFNs. 
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Figure 3.20 Effect of Pellino3-deficiency on EMCV-induced expression of IP-10. 
 
ELISA of IP-10 protein in media from (a) BMDMs or (b) MEFs isolated from WT 
and Peli3
–/– 
mice and left uninfected (UI) or infected with live EMCV (250 PFU). 
Quantitative real-time PCR of IP-10 expression in cells from (c) BMDMs or (d) 
MEFs isolated from WT and Peli3
–/– 
mice and left UI or infected with EMCV (250 
PFU) for the indicated times. Data are presented as a fold relative to WT UT, 
normalised to HPRT expression and as the mean +/- S.E.M. of three independent 
experiments and were subjected to paired two-tailed Student's t test . *, p < 0.05; **, 
p < 0.01. 
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3.2.16 Loss of Pellino3 Fails to Affect EMCV-induced TNF-
α Production 
To investigate whether Pellino3 was a specific regulator of viral-induced anti-viral 
cytokines or if it could also regulate the pro-inflammatory cytokine TNF-α, BMDMs 
(Fig. 3.21a) and MEFs (Fig. 3.21b) were isolated from WT and Peli3
–/– 
mice and 
were infected with live EMCV for 25 h and TNF-α production measured by ELISA. 
EMCV-induced a modest activation of TNF-α in WT cells and this was also 
observed in cells from the Peli3
–/–
 animals. EMCV infection induced the 
transcription of TNF-α in BMDMs (Fig. 3.21c) and MEFs (Fig. 3.21d) from WT and 
Peli3
–/– 
mice, however no significant differences in the cytokine production were 
observed between WT and Pellino3-deficent cells. In BMDMs, EMCV-induced a 
time dependent increase in TNF-α mRNA expression until 10 h infection which 
began to be downregulated by 25 h. In MEFs, a time dependent increase in transcript 
was measured up until 25 h. This data indicates that EMCV regulation may undergo 
differential regulation in a cell type and temporal manner; however Pellino3 plays no 
role in these processes. The data to this point has provided definitive evidence that 
Pellino3 is a key and specific mediator of TLR3- and viral-induced type 1 IFNs in 
cells isolated ex-vivo from Pellino3 knockout mice. 
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Figure 3.21 Effect of Pellino3-deficiency on EMCV-induced TNF-α. 
 
ELISA of TNF-α production in media from (a) BMDMs or (b) MEFs isolated from 
WT and Peli3
–/– 
mice and left uninfected (UI) or infected with live EMCV (250 
PFU). Quantitative real-time PCR of TNF-α expression in cells from (c) BMDMs or 
(d) MEFs isolated from WT and Peli3
–/– 
mice and left UI or infected with EMCV 
(250 PFU) for the indicated times. Data are presented as the mean +/- S.E.M. of at 
least three independent experiments and were subjected to paired two-tailed 
Student's t test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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3.2.17 Absence of Pellino3 Enhances Host Protection 
against EMCV Infection 
The physiological and pathological relevance of these regulatory effects of Pellino3 
in the context of an in vivo EMCV infection model was then investigated. Two lethal 
doses, 250 PFU (Fig. 3.22a left panel) and 50 PFU (Fig.3.22a right panel) of EMCV 
were injected intra-peritoneally into WT and Peli3
–/– 
mice. The higher infection 
challenge had a lethal effect on all WT mice by 7 d while 60% of the Peli3
–/– 
mice 
survived up until the end point of the experiment, 12 d. The lower dose of the virus 
triggered lethality in 50% of the WT mice with all the Peli3
–/– 
mice surviving till the 
experimental end point. In order to assess what was happening physiologically 
during the infection, another cohort of animals were infected with 50 PFU for 4 days 
and sacrificed. An increased heart to body weight ratio, a hallmark of EMCV 
infection and associated with lethality was evident in the WT mice but not in the 
Peli3
–/– 
mice (Fig. 3.22b). A blinded pathological examination of heart tissue from 
EMCV-infected animals by microscopy revealed histopathological changes with 
random multifocal mononuclear interstitial infiltrates and myofiber nuclear 
karyolysis and myofiber cell loss accompanied by mild edema (Fig. 3.22c). Such 
pathological alterations from control mice were not detected in infected Peli3
–/– 
mice. 
The enhanced protection from the pathological and lethal effects of EMCV infection 
in Peli3
–/– 
mice was associated with a lower viral load in cardiac tissue, as assessed 
by mRNA expression of the EMCV replicase gene (Fig. 3.22d). Indeed, this was 
consistent with increased IFN-β expression in Peli3–/– mice hearts infected with the 
virus; which presumably facilitated the increased viral clearance and host protection. 
The increase in viral clearance was not associated with a stronger pro-inflammatory 
response as no significant differences in TNF-α mRNA were detectable between WT 
and Peli3
–/– 
mice. Taken together, Pellino3 plays a critical physiological and 
regulatory role in controlling type 1 IFN production in response to viral infection. 
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Figure 3.22 Pellino3-deficiency leads to enhanced host protection against 
EMCV infection. 
 
(a) Survival rates of age-matched and sex-matched wild-type (WT; n = 7) 
and Peli3
−/−
 (n = 7) mice after intraperitoneal injection with 250 PFU or 50 PFU of 
EMCV virus or with PBS as a vehicle control (P = 0.005, Kaplan-Meier analysis). 
Moribund mice were killed. Surviving mice were killed 12 d or 14 d after infection. 
(b) Heart/body weight ratios (c) and heart samples stained with hematoxylin and 
eosin from WT and Peli3
−/−
 mice after intraperitoneal injection with EMCV (50 
PFU). UT, untreated. Original magnification, ×40 (top) and ×200 (bottom). 
Quantitative PCR of mRNA expression for (d) EMCV replicase, (e) IFN-β and (f) 
TNF-α in heart tissue from WT and Peli3−/− mice 4 d after intraperitoneal injection 
with 50 PFU EMCV (n = 3 mice each group). Error bars, S.E.M. (n = 3 experiments). 
*, p < 0.05; ** p < 0.01 (paired Student's t-test). (Data provided by Dr. Jakub 
Siednieko. Histological analysis conducted by Dr. John J. Callanan. Data adapted 
from Siednienko, Jackson et al., 2012). 
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3.2.18 Pellino3
 
does not Regulate Secondary type 1 IFN-
induced Signalling 
Studies next progressed to probe the mechanism underlying the negative regulatory 
effects of Pellino3 on the TLR3 pathway. Given that the initial induction of type 1 
IFNs by TLR3 can feed forward to enhance further expression of type 1 IFNs and 
related genes, it was important to exclude a role for Pellino3 in regulating this 
secondary induction of type 1 IFN signalling.  As type 1 IFN signalling results in the 
activation of the STAT proteins leading to up regulation of ISGs, the role for 
Pellino3 in STAT1 and STAT3 activation was conducted. BMDCs from WT and 
Peli3
–/– 
mice were stimulated with recombinant murine IFN-α4 for the indicated 
times (Fig. 3.23). Protein lysates were generated and probed for phosphorylation of 
STAT1 and STAT3. Activation was strongly induced after 15 m and 30 m 
stimulation, with dephosphorylation occurring upon longer exposure to the cytokine 
stimulus. These phosphorylation kinetics were identical in cells from both the WT 
and Peli3
–/– 
dendritic cells indicating a lack of a role for Pellino3 in this signalling 
pathway. This highlights that Pellino3’s role in the regulation of type 1 IFN 
expression is likely to be solely restricted to targeting the primary and direct phase of 
TLR3 signalling.  
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Figure 3.23 Effect of Pellino3-deficiency on IFN-α-induced phosphorylation of 
STAT1 and STAT3 in BMDCs. 
 
BMDCs were isolated from WT and Peli3
–/– 
mice and were left untreated (0) or 
treated with recombinant murine IFNα4 (1 μg/ml) for the indicated times. Cell 
lysates were generated and subjected to immunoblot analysis for phosphorylated (p-) 
STAT1 and p-STAT3. Lysates were also probed for the levels of total STAT1, 
STAT3 and β-actin to act as a loading control. Data are representative of 2 
independent experiments.  
 
 
 
 
 
p-STAT1 
STAT1 
p-STAT3 
STAT3 
β-actin 
      IFNα4        0        15’     30’    1.5h   3h     6h         0       15’    30’   1.5h    3h    6h  
Peli3–/–  WT 
Chapter 3: Results 
134 
 
3.2.19 Pellino3 does not Contribute to TLR3-induced 
Activation of MAPKs or AP-1 
Previous work on Pellino3 had indicated it may have a role in the MAPK p-38 
activation and AP-1-induced transcription factor activity (Jensen and Whitehead, 
2003c, Butler et al., 2005) . Given that AP-1 binds the PRDIV of the IFN-β promoter 
and that TRIF-dependent phosphorylation of p38 leads to the stabilisation of IFN-β 
mRNA (Johnsen et al., 2012, Wathelet et al., 1998), the role of Pellino3 in MAPK 
and AP-1 activation was next explored. BMDMs (Fig. 3.24) and BMDCs (Fig. 3.25) 
from WT and Peli3
–/– 
mice were stimulated with Poly(I:C) for the indicated times. 
TLR3 activation resulted in increased phosphorylation of p38, ERK and JNK at 30 
min and 45 min post stimulation. Interestingly however, the activated MAPK levels 
showed comparable levels in both WT and Pellino3-deficent cells. Since activation 
of MAPKs also results in phosphorylation the of transcription factor c-JUN, a 
member of the AP-1 family, its phosphorylation status was next investigated. 
Phosphorylation of c-Jun occurred after 45 m stimulation and was maintained until 3 
h post activation. Once again however, no differences in c-JUN activation were 
observed in the absence of Pellino3.  These findings indicate that any regulatory 
effects of Pellino3 in the TLR3 pathway are not mediated by targeting the activation 
of MAPKs or AP-1. 
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Figure 3.24 Effect of Pellino3-deficiency on TLR3-induced activation of MAPK 
and AP-1 pathways in BMDMs. 
 
BMDMs were isolated from WT and Peli3
–/– 
mice and were left untreated (0) or 
treated with Poly(I:C) (25 μg/ml) for the indicated times. Cell lysates were generated 
and subjected to immunoblot analysis for p-p38, p-ERK and p-JNK. Lysates were 
also probed for the levels of total p38, ERK, JNK and β-actin to act as a loading 
control. Data are a representative of 3 independent experiments.  
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Figure 3.25 Effect of Pellino3-deficiency on TLR3-induced activation of MAPK 
and AP-1 pathways in BMDCs. 
 
BMDCs were isolated from WT and Peli3
–/– 
mice and were left untreated (0) or 
treated with Poly(I:C) (25 μg/ml) for the indicated times. Cell lysates were generated 
and subjected to immunoblot analysis for p-p38, p-ERK and p-JNK. Lysates were 
also probed for the levels of total p38, ERK, JNK and β-actin to act as a loading 
control. Data are a representative of 3 independent experiments.  
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3.2.20 NF-κB activation is not Regulated by Pellino3 during 
TLR3 Signalling 
TLR3-induced expression of type 1 IFNs requires the coordinated activation of a 
number of transcription factors. The NF-κB family of transcription factors have been 
shown to bind to the PRDII of the IFN-β promoter and induce cytokine transcription 
in response to viral stimuli (Mesplede et al., 2003). The canonical NF-κB pathway 
was next assessed as a potential target for the regulatory effects of Pellino3. As 
activation of IKKs lead to the phosphorylation and subsequent degradation of the 
NF-κB cytosolic sequestering protein IκBα (Zandi et al., 1998), their 
phosphorylation kinetics were investigated as an index of NF-κB activation. 
BMDMs (Fig. 3.26) and BMDCs (Fig. 3.27) were stimulated with Poly(I:C) for 
indicated times. The absence of Pellino3 did not affect the capacity of Poly(I:C) to 
induced the phosphorylation of the IKKs. Robust phosphorylation of IKKα/β can be 
seen in both WT and Pellino3-deficent cells 30 min post stimulation, with 
phosphorylated kinase still evident at 3 h. Phosphorylation of their downstream 
substrate IκBα is also unaffected by Pellino3-deficency. After IκBα phosphorylation 
it is known to be K48-linked polyubiquitinated and targeted for 26S proteasomal 
degradation (Alkalay et al., 1995). This is demonstrated by the decrease in total IκBα 
protein abundance seen after 30 m stimulation. However, both the degradation and 
re-synthesis of IκBα is again unaffected in Pellino3-deficent cells. Recently, the NF-
κB subunit p65 has been shown to play a vital role in viral-induced IFN-β production 
(Bartlett et al., 2012), however, although phosphorylation of p65 at serine 536 is 
strongly induced by TLR3 activation there is no phenotypic difference between WT 
and Pellino3-deficent cells. Whilst Pellino3 fails to regulate upstream regulatory 
pathways that control NF-κB, it was important to assess if it could affect the binding 
of NF-κB to its DNA recognition motif.  Nuclear extracts were generated from 
BMDCs from WT and Peli3
–/– 
mice, previously stimulated with Poly(I:C) and 
subjected to EMSA analysis.  In WT cells Poly(I:C)-induced a time dependant 
increase in the amount of nuclear NF-κB that could bind with a labelled NF-κB 
consensus site oligonucleotide  (Fig. 3.28). This pattern was also observed in 
Pellino3-deficient cells indicating that Pellino3 does not target NF-κB in the TLR3 
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pathway. In order to ensure specificity of the NF-κB-oligonucleotide binding 
reaction, a non-labelled form of the same oligonucleotide successfully competed 
with the labelled oligonucleotide for binding to the nuclear extracts.  
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Figure 3.26 Effect of Pellino3-deficiency on TLR3-induced activation of the NF-
κB pathway in BMDMs. 
 
BMDMs were isolated from WT and Peli3
–/– 
mice and were left untreated (0) or 
treated with Poly(I:C) (25 μg/ml) for the indicated times. Cell lysates were generated 
and subjected to immunoblot analysis for p-IKKα/β, p-IκBα and p-p65. Lysates were 
also probed for the levels of total IKKβ, IκBα, p65 and β-actin to act as a loading 
control. Data are a representative of 3 independent experiments.  
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Figure 3.27 Effect of Pellino3-deficiency on TLR3-induced activation of the NF-
κB pathway in BMDCs. 
 
BMDCs were isolated from WT and Peli3
–/– 
mice and were left untreated (0’) or 
treated with Poly(I:C) (25 μg/ml) for the indicated times. Cell lysates were generated 
and subjected to immunoblot analysis for p-IKKα/β, p-IκBα and p-p65. Lysates were 
also probed for the levels of total IKKβ, IκBα, p65 and β-actin to act as a loading 
control. Data are a representative of 3 independent experiments.  
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Figure 3.28 Effect of Pellino3-deficiency on TLR3-induced binding of NF-κB to 
DNA 
 
BMDCs were isolated from WT and Peli3
–/– 
mice and left untreated (0) or treated 
with Poly (I:C) (25 μg/ml) for the indicated times. Nuclear extracts (5 μg protein) 
were incubated with an IR-labelled oligonucleotide containing the NF-κB-binding 
consensus site and subjected to native PAGE. The specificity of the NF-κB-DNA 
binding reaction was confirmed by the absence of the complex when the nuclear 
extract from WT BMDCs (treated with Poly (I:C) for 90 min) was pre-incubated 
with unlabelled competitor (C) oligonucleotide. The labelled oligonucleotide probe 
(P) was also run alone as a negative control. Data are a representative of 3 
independent experiments. 
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3.2.21 Pellino3 does not Affect TBK1 or IRF3 Activation by 
TLR3 
Another critical component in type 1 IFN production by TLR3 is the activation of 
the IRF transcription factors.  IRF3 and its upstream kinase TBK1 are absolutely 
required for type 1 IFN and related gene expression, as deficiency in either lead to 
signal abrogation during TLR3 signalling (McWhirter et al., 2004a). Therefore, their 
phosphorylation kinetics was next examined in response to Poly(I;C). BMDMs (Fig. 
3.29) and BMDCs (Fig. 3.30) from WT and Pellino3-deficent mice were stimulated 
with Poly(I:C) for the indicated times and protein lysates generated. Western blot 
analysis of WT cells revealed that Poly(I:C)-induced time dependent 
phosphorylation of TBK1 after 30 min stimulation displaying some reduction by 3 h. 
However, this pattern was also observed in Pellino3-deficient cells excluding TBK1 
as a target for Pellino3. TBK1 is well known to phosphorylate and activate IRF3. So 
to investigate if Pellino3 may function downstream of TBK1, Poly(I:C)-induced 
phosphorylation of IRF3 phosphorylation was next explored. After 45 min Poly(I:C) 
stimulation, BMDMs and BMDCs from WT and Pellino3-deficent mice exhibited 
comparable levels of IRF3 phosphorylation. Phosphorylated levels peaked between 1 
h and 1.5 h and were returning to basal levels by 3 h. These data indicated that 
Pellino3 does not target the activation of IRF3 in the TLR3 pathway.  
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Figure 3.29 Effect of Pellino3-deficiency on TLR3-induced activation of the 
IRF3 pathway in BMDMs. 
 
BMDMs were isolated from WT and Peli3
–/– 
mice and were left untreated (0) or 
treated with Poly(I:C) (25 μg/ml) for the indicated time. Cell lysates were generated 
and subjected to immunoblot analysis for p-TBK1 and p-IRF3. Lysates were also 
probed for the levels of total TBK1, IRF3 and β-actin to act as a loading control. 
Data are a representative of 3 independent experiments.  
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Figure 3.30 Effect of Pellino3-deficiency on TLR3-induced activation of the 
IRF3 pathway in BMDCs. 
 
BMDCs were isolated from WT and Peli3
–/– 
mice and were left untreated (0) or 
treated with Poly(I:C) (25 μg/ml) for the indicated time. Cell lysates were generated 
and subjected to immunoblot analysis for p-TBK1 and p-IRF3. Lysates were also 
probed for the levels of total TBK1, IRF3 and β-actin to act as a loading control. 
Data are a representative of 3 independent experiments.  
 
 
 
 
 
 
 
 
Poly(I:C)        0       30’     45’    1h    1.5h    3h         0      30’    45’    1h     1.5h    3h  
WT Peli3–/–  
p-TBK1 
TBK1 
p-IRF3 
IRF3 
β-actin 
Chapter 3: Results 
145 
 
3.2.22 Pellino3 Negatively Regulates TLR3-induced Binding 
of Proteins to the PRDI/III Region of the IFN-β Promoter 
Although IRF3 activation was not affected by Pellino3-deficiency, it was possible 
that Pellino3 may be targeting IRF7.  The PRDI/III site of the IFN-β promoter is 
recognised by both IRF3 and IRF7 and is critically important in the upregulation of 
the anti-viral cytokine and so we next used EMSA analysis to assess the effects of 
Pellino3-deficiency on TLR3-induced binding of proteins to the PRDI/III motif. 
MEFs were isolated from WT and Peli3
–/– 
mice and stimulated with Poly(I:C) for the 
indicated times and nuclear fractions generated. Incubation of the nuclear fraction 
from Poly(I:C)-treated WT cells with a labelled oligonucleotide containing the 
PRDI/III motif from the IFN-β promoter revealed modest DNA binding in extracts 
after 3 h stimulation (Fig. 3.31). Interestingly, DNA-protein interaction was evident 
earlier at 1.5 h in the Pellino3-deficient cells, with further augmentation seen at 3 h 
compared to the WT cells. In order to ensure specificity of the reaction, a non-
labelled oligonucleotide was pre-incubated for 15 m with the Peli3
–/– 
3 h stimulated 
nuclear fraction prior to labelled oligonucleotide incubation. The absence of detected 
DNA protein binding in this competitor (C) sample is indicative of a specific PRD 
I/III DNA interaction. This increase in IRF PRDI/III association seen in cells 
isolated from Peli3
–/– 
mice suggested that Pellino3 was somehow targeting the IRF 
binding to the PRDI/III domain of the IFNB promoter. 
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Figure 3.31 Effect of Pellino3-deficiency on TLR3-induced binding of IRF3/7 to 
DNA 
 
MEFs were isolated from WT and Peli3
–/– 
mice and left untreated (0) or treated with 
Poly (I:C) (25 μg/ml) for the indicated times. Nuclear extracts (5 μg protein) were 
incubated with an IR-labelled oligonucleotide containing the IRF3/7-binding 
consensus site and subjected to native PAGE. The specificity of the IRF-DNA 
binding reaction was confirmed by the absence of the complex when the nuclear 
extract from Peli3
–/– 
cells (treated with Poly (I:C) for 3 h) was pre-incubated with 
unlabelled competitor (C) oligonucleotide. The labelled oligonucleotide probe (P) 
was also run alone as a negative control. Data are a representative of 3 independent 
experiments. 
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3.2.23 Pellino3 Negatively Regulates Poly(I:C)-induced 
Phosphorylation of IRF7  
Given that IRF3 and IRF7 can both bind to the PRDI/III region of IFN-β promoter, 
and Pellino3-deficiency does not affect IRF3 activation, the regulatory effect of 
Pellino3 on IRF7 was next examined. Unfortunately, no commercially available 
phospho-specific antibody for IRF7 is available to detect endogenous 
phosphorylated-IRF7 and so an indirect approach was used in which IRF7 was 
immunoprecipitated and probed for phosphorylation using an anti-phospho-serine 
antibody. BMDCs from WT and Peli3
–/– 
mice were stimulated with Poly(I:C) for the 
indicated times (Fig. 3.32). In order to dissociate any protein-protein interactions, 
cell lysates were generated and 10% SDS added followed by sample boiling for 5 
min. The SDS was diluted to 1% and endogenous IRF7 was then 
immunoprecipitated using an anti-IRF7 antibody. The enriched lysate which should 
only contain IRF7 and its covalent modifications and lysates were probed for the 
presence of phosphorylated serine residues. Poly(I:C)-induced a modest time 
dependent increase in IRF7 phosphorylation in WT cells which was substantially 
higher in the absence of Pellino3. Although IRF7 protein levels can be upregulated 
by type 1 IFN signalling, immunoblotting for total IRF7 revealed no difference in 
the protein abundance in this experimental model. This suggested that Pellino3 may 
regulate the phosphorylation of IRF7.  
3.2.24 Pellino3 Specifically Inhibits IRF7 Nuclear 
Translocation 
As phosphorylation of IRF7 is a prerequisite for its nuclear translocation, the ability 
of Pellino3 to regulate this process was next examined. Nuclear fractions were 
isolated from BMDCs from WT and Peli3
–/– 
mice after Poly(I:C) stimulation for the 
indicated durations (Fig. 3.33). In both WT and Pellino3-deficent cells, Poly(I:C)-
induced a time dependent nuclear translocation of IRF7 however, the levels of 
nuclear IRF7 were further augmented in the Pellino3-deficent cells compared to the 
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WT controls. In order to confirm Pellino3 primarily targeted IRF7 and not IRF3, 
IRF3’s translocation was also examined.  However, the Poly(I:C)-induced nuclear 
localisation of IRF3 was comparable in both WT and  Peli3
–/– 
cells suggesting that 
Pellino3 specifically targets IRF7 and not IRF3 in the TLR3 pathway.  
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Figure 3.32 Effect of Pellino3-deficiency on TLR3-induced phosphorylation of 
IRF7 in BMDCs. 
 
BMDCs were isolated from WT and Peli3
–/– 
mice and were left untreated (0) or 
treated with Poly(I:C) (10 μg/ml) for the indicated times. Cell lysates were generated 
and subjected to immunoprecipitation (IP) with an anti-IRF7 antibody and 
immunoblotted (IB) for phosphorylated serine residues (p-Ser) on IRF7. 
Immunoprecipitated samples and whole cell lysates were also immunoblotted for 
total IRF7 and β-actin to act as a loading control. The arrows indicate the heavy 
chain (HC) of the IP antibody and the serine phosphorylated form of IRF7 (p-IRF7). 
Data are a representative of 3 independent experiments.  
 
 
 
 
Figure 3.33 Effect of Pellino3-deficiency on TLR3-induced nuclear 
translocation of IRF3 and IRF7. 
 
BMDCs were isolated from WT and Peli3
–/– 
mice and left untreated (0) or treated 
with Poly(I:C) (25 μg/ml) for the indicated times. Nuclear fractions were subjected 
to immunoblotting using antibodies against IRF7, IRF3 and Fibrillarin (loading 
control). Data are representative of 3 individual experiments. 
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3.2.25 Pellino3 Negatively Regulates TLR3-induced 
Polyubiquitination of IRF7 
The mechanism by which Pellino3 was targeting the IRF7 pathway was next 
explored. As loss of Pellino3 had no effect on the upstream kinase for IRF7 and 
Pellino3 is itself an E3 ligase, the polyubiquitination of IRF7 was investigated in 
Pellino3-deficient cells. In order to examine this modification, the same 
immunoprecipitation approach as described in 3.2.20 was employed but probed for 
ubiquitination. MEFs (Fig. 3.34a) and BMDCs (Fig. 3.34b) isolated from WT and 
Peli3
–/– 
mice were stimulated with Poly(I:C) for the indicated times. In MEFs from 
WT mice, Poly(I:C)-induced a ubiquitination of IRF7 after 30 m stimulation. This 
was further augmented and sustained in cells from Peli3
–/–
 mice. In addition, the 
ubiquitinated IRF7 appears more abundant in the Pellino3-deficient cells at all time 
points. In BMDCs, again IRF7 polyubiquitination occurs earlier in cells from 
Pellino3-deficent mice and the intensity of the ubiquitination appears greater than 
what is observed in cells from WT mice after Poly(I:C) treatment. It has previously 
been reported that IRF7 polyubiquitination is a prerequisite for activation of IRF7 
(Ning et al., 2008a), indicating that this increased ubiquitination of IRF7 in Pellino3-
deficient cells may facilitate the augmented responses to Poly(I:C) and EMCV in  
Peli3
–/– 
mice. 
3.2.26 Pellino3 Inhibits TLR3-induced TRAF6-IRF7 
Interaction 
As there is increased polyubiquitination of IRF7 in the absence of Pellino3, 
investigation into the E3 ligase responsible was conducted. As TLR7/8 signalling in 
pDC results in TRAF6-mediated activation of IRF7 (Kawai et al., 2004) and TRAF6 
has been shown to directly interact with and ubiquitinate IRF7 (Ning et al., 2008a), 
the effects of Pellino3-deficiency on TRAF6-IRF7 interaction was next explored. 
BMDCs were isolated from WT and Peli3
–/– 
mice and stimulated with Poly(I:C) for 
the indicated times. Cell lysates were generated and samples were 
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immunoprecipitated with an antibody for IRF7. Samples were then probed for the 
presence of co-precipitating TRAF6 protein. TLR3 activation induced interaction 
between IRF7 and TRAF6 in a time-dependent manner in BMDCs from WT mice 
(Fig. 3.35). Interestingly, this interaction was increased in the absence of Pellino3 
suggesting that Pellino3 regulates the ubiquitination of  IRF7 by modulating the 
interaction of IRF7 with its E3 ubiquitin ligase TRAF6. 
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Figure 3.34 Effect of Pellino3-deficiency on TLR3-induced IRF7 
polyubiquitination. 
 
(a) MEFs and (b) BMDCs were isolated from WT and Peli3
–/– 
were left untreated (0) 
or treated with Poly(I:C) ((a) 25 μg/ml or (b) 10 μg/ml) for the indicated time. Cell 
lysates were generated and subjected to immunoprecipitation (IP) with an anti-IRF7 
antibody and immunoblotted (IB) for polyubiquitinated IRF7. Immunoprecipitated 
samples and whole cell lysates were also immunoblotted for total IRF7 and β-actin 
to act as a loading control. Data are a representative of 3 independent experiments.  
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Figure 3.35 Effect of Pellino3-deficiency on TLR3-induced TRAF6 and IRF7 
interaction 
 
BMDCs were isolated from WT and Peli3
–/– 
were left untreated (0’) or treated with 
Poly(I:C) (10 μg/ml) for the indicated time. Cell lysates were generated and 
subjected to immunoprecipitation (IP) with an anti-IRF7 antibody and immunobloted 
IB) for TRAF6. Immunoprecipitated samples and whole cell lysates were also 
probed for the levels of total IRF7 and β-actin to act as a loading control. The arrows 
indicate the heavy chain (HC) of the IP antibody and the total IRF7 protein. Data is a 
representative of 3 independent experiments. 
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3.2.27 TRAF6 Mediates TLR3-induced Cytokine 
Production 
The data presented above suggests that TRAF6-mediated IRF7 polyubiquitination 
may be an important target for Pellino3 and for manifesting its regulatory effects on 
the TLR3 pathway. However, such a model would require demonstration of an 
important mediatory role for TRAF6 and its E3 ligase activity in the TLR3 pathway 
that regulates type 1 IFN expression. MEFs from WT, Peli3
–/–
, Traf6
–/– 
mice were 
thus stimulated with Poly(I:C) for 6 h and mRNA extracted. Real-time quantitative 
PCR for IFN-β confirmed, as before, that Pellino3 negatively regulates TLR3-
induced IFN-β (Fig. 3.36a). Interestingly, a complete loss of TLR3-induced IFN-β 
mRNA expression was exhibited in the Traf6
–/– 
MEFs highlighting an indispensable 
role for TRAF6 in TLR3 signalling. In order to confirm previous reports that TRAF6 
is essential for TLR3-induced pro-inflammatory cytokine production by the NF-κB 
pathway in MEFs, real time quantitative PCR for IL-6 was also conducted (Fig. 
3.36b). Investigation of Traf6
–/– 
in TLR3 activation of IL-6 mRNA expression, 
confirmed previous studies that implicate TRAF6 as an essential mediator of TLR3 
activation of the NF-κB pathway in MEFs (Fig. 3.36b). As seen in BMDMs and 
BMDCs previously (Fig. 3.6), Pellino3-deficiency had no effect on Poly(I:C)-
induced IL-6 transcription in MEFs. Taken together, these results indicate that in 
MEFs, TRAF6 plays a key role in both pro-inflammatory and anti-viral signalling 
pathways in response to dsRNA. 
3.2.28 TRAF6-E3 Ligase Activity is essential for TLR3 
Signal Transduction 
We next assessed if the E3 ligase activity of TRAF6 is  critically important in TLR3-
induced cytokine expression. In order to investigate this, Traf6
–/–
 MEFs were 
reconstituted with 3 μg of DNA encoding the expression constructs for WT TRAF6 
or a point mutant in the RING domain of TRAF6
(C70A) 
which abolishes its ability to 
conjugate polyubiquitin chains. As a control, Traf6
–/–
 MEFs were also transfected 
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with 3 μg of non-protein coding DNA. Reconstituted cells were stimulated with 
Poly(I:C) for 6 h and mRNA extracted. Real time PCR analysis for IFN-β showed 
that the WT TRAF6 construct could rescue TLR3-induced IFN-β whereas the point 
mutant failed to (Fig. 3.37a). In addition, real-time PCR analysis for IL-6 revealed a 
similar requirement for the E3 ligase functionality of TRAF6 (Fig. 3.37b). These 
results are consistent with a TLR3 signalling model in which TRAF6-induces 
ubiquitination of IRF7 thus promoting IFN-β expression.  
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Figure 3.36 Differential effects of Pellino3- and TRAF6-deficiency on TLR3-
induced cytokine production in MEFs. 
 
Quantitative real-time PCR of (a) IFN-β and (b) IL-6 expression in cells from MEFs 
isolated from WT , Peli3
–/– 
 and Traf6
–/–
 mice and left untreated (UT) or stimulated 
with Poly(I:C) (25 μg/ml) for 6 h. Data are presented as a fold relative to WT UT, 
normalised to HPRT expression and as the mean +/- S.E.M. of three independent 
experiments and were subjected to paired two-tailed Student's t test. *, p < 0.05; ***, 
p < 0.001. 
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Figure 3.37 TLR3 induction of cytokines is dependent on the E3 ligase activity 
of TRAF6 in MEFs.  
 
Traf6
–/–
 MEFS were transfected with either an empty vector (EV) or an expression 
construct encoding WT TRAF6 (TRAF6) or a RING domain mutant (TRAF6
(C70A)
). 
Quantitative real-time PCR analysis of (a) IFN-β and (b) IL-6 mRNA expression in  
untreated (UT) cells or cells stimulated with Poly(I:C) (25 μg/ml) for 6 h. Data are 
presented as a fold relative to WT UT, normalised to HPRT expression and as the 
mean +/- S.E.M. of three independent experiments and were subjected to paired two-
tailed Student's t test. **, p < 0.01; ***,  p < 0.001, ns, not significant. 
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3.2.29 Pellino3 Interacts with TRAF6 during TLR3 
Signalling 
Given that Pellino3 can regulate the interaction of TRAF6 with IRF7 and subsequent 
ubiquitination, the ability of Pellino3 to target TRAF6 was next assessed. Initially, 
HEKT cells stably expressing TLR3 on their surface were transfected with 1 μg of 
plasmid DNA encoding a non-protein coding empty vector (EV), and/or expression 
constructs encoding Myc-tagged Pellino3 and/or FLAG-tagged TRAF6. Cell lysates 
were then split and co-immunoprecipitated with either an anti-Myc or an anti-FLAG 
antibody. Reciprocal co-interactions studies demonstrated that Pellino3 and TRAF6 
could indeed interact when both proteins are overexpressed (Fig. 3.38a). However, 
although overexpression studies play a fundamental role in identify interacting 
proteins, they do not indicate if interactions are physiologically relevant at 
endogenous concentrations or during specific signalling events. In order to address 
this shortfall, the human derived astrocytoma cell line U373, which naturally 
expresses TLR3, was stimulated with Poly(I:C) for various times and subjected to 
co-immunopreciptiation analysis to characterise the interaction of endogenous forms 
of Pellino3 and TRAF6. Co-immunoprecipitation using an anti-TRAF6 antibody and 
immunoblotting for Pellino3 revealed a stimulus and time dependent interaction of 
the proteins peaking at 30 min to 1.5 h which diminishes by 3 h activation (Fig. 
3.38b). Therefore, Pellino3 interacts with TRAF6 during TLR3 signalling.  
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Figure 3.38 TLR3 promotes the interaction of Pellino3 with TRAF6 
 
(a) HEKT-TLR3 cells were transfected with empty vector (EV) or expression 
constructs encoding Pellino3-Myc (Peli3) and/or TRAF6-FLAG. Cell lysates were 
generated, divided in two and immunoprecipitated with an anti-Myc or anti-FLAG 
antibody. Immunoprecipitated (IP) samples and whole cells lysates were subjected to 
immunoblot (IB) analysis for presence of Myc-tagged, FLAG-tagged proteins. β-
actin was used as a loading control. (b) U373 cells were left untreated (0) or 
stimulated with Poly(I:C) (25 μg/ml) for the indicated time. Cell lysates were 
generated and subjected to immunoprecipitation using an anti-TRAF6 antibody. 
Immunoprecipitated samples and whole cells lysates were subjected to immunoblot 
analysis for presence of Pellino3 (Peli3), TRAF6 and β-actin was used as a loading 
control. Data are a representative of 3 independent experiments. 
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3.2.30 Pellino3 is Required for TLR3-induced TRAF6 
Ubiquitination 
To investigate the functional consequence of the above interaction, Pellino3 was 
explored as a potential E3 ligase for TRAF6 in the TLR3 pathway. MEFs isolated 
from WT and Peli3
–/– 
mice were stimulated for the indicated times with Poly(I:C) 
and cell lysates generated. Immunoprecipitation for TRAF6 and immunoblotting 
analysis revealed that TLR3 did indeed induce TRAF6 polyubiquitination in WT 
cells (Fig. 3.39a). Interestingly however, this modification was nearly completely 
abrogated in the absence of Pellino3. In order to confirm this in a human model 
system, HEK293 cells stably expressing TLR3 were transfected with shRNA 
encoding either a nontargeting control shRNA or shRNA specific for Pellino3 
mRNA transcript. Modest knockdown was achieved and was sufficient to lead to a 
complete loss of TLR3-induced TRAF6 polyubiquitination in the human cells (Fig. 
3.39b).  These findings suggest that the Pellino3 acts as a key mediator of TRAF6 
ubiquitination during TLR3 signalling. 
3.2.31 Reconstitution of TLR3-induced Polyubiquitination 
of TRAF6 in Pellino3-deficient Cells 
Although transgenic knockout models represent the gold standard in the 
determination of a proteins physiological function, they are not without significant 
drawbacks. One such limitation was recently highlighted in which deletion by 
recombination of Caspase1
 
resulted in the deletion of the adjacent gene Caspase11 
(Kayagaki et al., 2011). In order to investigate if the loss of TRAF6 
polyubiquitination was a direct result of Pellino3-deficiency or if it was due a non-
intentional genetic alteration of the mouse genome, MEFs from WT and Peli3
–/– 
mice were isolated and infected with a MSCV encoding either a non-protein coding 
empty vector (EV) or a Myc-tagged murine Pellino3 expression construct. WT and 
Peli3
–/–
 cells previously exposed to MSCV-EV were stimulated with Poly(I:C) for 
the indicated times. As observed previously, TLR3 activation caused TRAF6 
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polyubiquitination in a stimulus dependant manner in WT cells and TRAF6 
polyubiquitination was lost in Peli3
–/– 
cells (Fig. 3.40a). The exposure to MSCV-EV 
had no effect on either cell type. However, pre-exposure of cells to MSCV-Pellino3 
had a profound effect on TLR3-induced TRAF6 ubiquitination. Ectopic expression 
of Pellino3 lead to basal ubiquitination of TRAF6 in WT cells, indicating the 
increase in Pellino3 protein levels can lead to TRAF6 modification. Upon TLR3 
activation, an increase in this ubiquitination is evident. Importantly, in the Pellino3-
deficient cells virally reconstituted with Pellino3, the stimulus induced 
polyubiquitination of TRAF6 is restored. Taken together, Pellino3 protein expression 
is a critical mediator of TRAF6 polyubiquitination in the TLR3 pathway. 
3.2.32 The E3 Ligase Activity of Pellino3 is Required for 
TLR3-induced Ubiquitination of TRAF6 
The previous findings confirm that Pellino3 is required for TLR3-induced TRAF6 
polyubiquitination. To investigate if this was reliant on Pellino3’s intrinsic E3 ligase 
activity, MEFs from Peli3
–/– 
mice were isolated and exposed to MSCV encoding an 
empty vector or an expression construct encoding either Myc-tagged WT murine 
Pellino3 or a Myc-tagged double point mutant form of Pellino3 that lacks a 
functional RING-like domain. Cells were then left untreated or stimulated with 
Poly(I:C)) for 1.5 h and TRAF6 was immunoprecipitation and immunoblotted using 
an anti-ubiquitin antibody conducted. Again the WT Pellino3 reconstitution was 
sufficient to rescue TLR3-induced TRAF6 ubquitination (Fig. 3.41). However, the 
RING-like domain mutant construct of Pellino3 failed to facilitate TLR3-induced 
TRAF6 polyubiquitination. This data provides strong evidence suggesting that 
Pellino3’s E3 ligase activity is essential for TLR-induced TRAF6 polyubiquitination. 
 
Chapter 3: Results 
162 
 
 
 
 
Figure 3.39 Pellino3 is required for TLR3-induced ubiquitination of TRAF6. 
 
(a) MEFs were isolated from WT and Peli3
–/– mice and left untreated (0) or 
stimulated with Poly(I:C) (25 μg/ml) for the indicated time. Cell lysates were 
generated and subjected to immunoprecipitation (IP) with an anti-TRAF6 antibody. 
IP samples and whole cell lysates were subjected immunoblot analysis (IB) for 
ubiquitin, TRAF6 and β-actin as a loading control. (b) HEK293-TLR3 cells were 
transfected with either a shRNA expression construct targeting Pellino3 (Peli3 
shRNA) or a scrambled control targeting no transcript (Ctrl shRNA) and left 
untreated (0) or stimulated with Poly(I:C) (25 μg/ml) for the indicated time. Cell 
lysates were generated and subjected to IP with an anti-TRAF6 antibody. 
Immunoprecipitated samples and whole cell lysates were subjected to immunoblot 
analysis for the presence of ubiquitin, TRAF6, Pellino3 and β-actin as a loading 
control. Data is representative of 3 independent experiments. 
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Figure 3.40 Reconstitution of TLR3-induced ubiquitination of TRAF6 
ubiquitination in Peli3
–/– 
MEFs  
 
MEFs from WT and Peli3
–/– 
mice were infected with Mouse Stem Cell Virus 
(MSCV) containing (a) an empty vector (EV) or (b) Myc-tagged murine Pellino3 
(mPellino3) expression construct. Cells were then left untreated (0) or stimulated 
with Poly(I:C) (25 μg/ml) for the indicated times. Cell lysates were generated and 
subjected to immunoprecipitation (IP) with an anti-TRAF6 antibody. 
Immunoprecipitated samples and whole cell lysates were subjected immunoblotting 
(IB) for ubiquitin, TRAF6, Myc-Pellino3 (Peli3) and β-actin as a loading control. 
Data is representative of 3 independent experiments. 
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Figure 3.41 TLR3-induced ubiquitination of TRAF6 ubiquitination is 
dependent on the E3 ligase activity of Pellino3 
 
MEFs from Peli3
–/– 
mice were infected with Mouse Stem Cell Virus (MSCV) 
containing an empty vector (EV), myc-tagged murine WT Pellino3 (Peli3) 
expression construct or myc-tagged murine Pellino3 mutant construct containing a 
non-functional RING-like domain (RING). Cells were then left untreated (0) or 
stimulated with Poly(I:C) (25 μg/ml) for 1.5 h. Cell lysates were generated and 
subjected to immunoprecipitation (IP) with an anti-TRAF6 antibody. 
Immunoprecipitated samples and whole cell lysates were subjected immunoblotting 
(IB) for ubiquitin, TRAF6, Myc-Pellino3 (Peli3) and β-actin as a loading control. 
Data is representative of 3 independent experiments. 
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3.2.33 Pellino3 E3 Ligase Activity Inhibits TLR3-induced 
Type 1 IFN Production 
We next exploited the above reconstitution models to assess if reconstitution of 
TRAF6 ubiquitination by ectopic Pellino3 in Pellino3-deficient cells was associated 
with negative regulatory effects on TLR3-induced expression of IFN-β. To this end, 
MEFs from Peli3
–/– 
mice were left uninfected or infected with MSCV encoding an  
empty vector non-protein coding DNA or an expression construct for either Myc-
tagged WT murine Pellino3 or a Myc-tagged mutant form of Pellino3 that lacks a 
functional RING-like domain. Cells were stimulated with Poly(I:C) for 6 h. To 
investigate if exposure of cells to MSCV-induced IFN-β mRNA expression, cells 
were left uninfected and infected with MSCV for 4 days prior to TLR3 stimulation 
and IFN-β mRNA levels examined (Fig.3.42a). Real-time PCR analysis revealed 
Poly(I:C)-induced IFN-β levels were comparable between cells not exposed to and 
pre-exposed to MSCV indicating that MSCV infection was having no effect on the 
experimental model of TLR3 signalling. Reintroduction of Pellino3 into the 
Pellino3-deficienct cells lead to a significant inhibition of Poly(I:C)-induced 
expression of  IFN-β mRNA (Fig. 3.42a)  and bioactive type 1 IFNs (Fig. 3.42b). As 
with TRAF6 ubiquitination, the RING-like domain mutant of Pellino3 failed to have 
a regulatory effect on IFN-β expression (Fig. 3.42a) or induction of bioactive type 1 
IFNs (Fig. 3.42b). In order to investigate this effect in a human system, HEK293 
cells stably expressing TLR3 were transfected with shRNA encoding either a 
nontargeting control shRNA or shRNA specific for Pellino3 mRNA transcript. 
Knockdown of Pellino3 lead to augmented Poly(I:C)-induced expression of IFN-β 
compared to control knockdown cells (Fig. 3.42). Overexpression of Pellino3 in 
Pellino3 knockdown cells was sufficient to regulate the Poly(I:C)-induced  levels of 
IFN-β relative to those observed in control knockdown cells whereas overexpression 
of the RING-like domain mutant was ineffective in inhibiting TLR3-iduced IFN-β 
expression. Taken together, this data is consistent with a TLR3 signalling model in 
which Pellino3 mediates ubiquitination of TRAF6, blocking the interaction of 
TRAF6 with IRF7 and reducing ubiquitination of the latter to downregulate type 1 
IFN production. 
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3.2.34 Polyubiquitination of TRAF6 Inhibits TRAF6-
induced IRF7 Polyubiquitination 
Exploration into whether ubiquitination of TRAF6 affects its capacity to ubiquitinate 
IRF7 was next undertaken. HEK293 cells stably expressing TLR3 were transfected 
with 1 μg of DNA encoding the expression constructs for either WT TRAF6, a 
mutant in the RING domain of TRAF6
(C70A) 
which has lost its ability to conjugate 
polyubiquitin chains or a TRAF6
(K124R)
 mutation in its primary ubiquitination site in 
the presence or absence of IRF7. As a control, cells were also transfected with 1 μg 
of non-protein coding empty vector. As both IRF7 and TRAF6 constructs were 
FLAG-tagged, IRF7 was immunoprecipitated selectively with and anti-IRF7 
antibody and protein-protein interactions were disrupted as previously described. As 
expected, coexpression of WT TRAF6 with IRF7 led to an induction of 
polyubiquitination of the transcription factor. The point mutant in the TRAF6 RING 
domain resulted in a complete loss of IRF7 polyubiquitination highlighting TRAF6 
as a key E3-ubiquitin ligase of IRF7. Interestingly however, mutation of the key 
TRAF6 ubiquitination site for its role in NF-κB-mediated signalling had no such 
negative affect on IRF7 ubiquitination. In fact, the lysine mutant of TRAF6 exhibits 
an enhanced ability to polyubiquitinate IRF7 compared to WT TRAF6. These 
finding highlight a novel difference in TRAF6 functionality between the different 
signalling pathways and suggests that polyubiquitination of TRAF6 may act as a 
negative regulatory signal for IRF7 activation. 
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Figure 3.42 Pellino3 E3 ligase activity inhibits TLR3-induced type 1 IFN 
production. 
 
(a) Quantitative real-time PCR of IFN-β expression in MEF cells from Peli3–/– mice 
were left uninfected (UI) or retrovirally infected with Mouse Stem Cell Virus 
(MSCV) encoding an empty vector (EV), myc-tagged murine WT Pellino3 (Peli3) 
expression construct or a myc-tagged murine Peli3 mutant construct containing a 
non-functional RING-like domain (Peli3 RING). Cells were then left untreated (UT) 
or stimulated with Poly(I:C) (25 μg/ml) for 6 h. (b) Bioactive type 1 IFN blue sensor 
cell assay from media from MEF cells isolated from WT and Peli3
–/– 
mice which 
were retrovirally infected with Mouse Stem Cell Virus (MSCV) encoding an empty 
vector (EV), murine WT Pellino3 (Peli3) expression construct or murine Pellino3 
mutant construct containing a non-functional RING-like domain (Peli3 RING). Cells 
were left untreated (UT) or stimulated with Poly(I:C) (25 μg/ml) for 24 h. (c) 
Quantitative real-time PCR of IFN-β expression  in HEK293-TLR3 cells transfected 
with either a shRNA expression construct targeting Pellino3 (Peli3 shRNA) or a 
scrambled control targeting no transcript (Ctrl shRNA). Cells were then transfected 
with either a non-protein coding empty vector (EV) or with WT Pellino3 (Peli3) 
expression construct or a Pellino3 mutant construct containing a non-functional 
RING-like domain (Peli3 RING). Subsequently, cells were left untreated (UT) or 
stimulated with Poly(I:C) (25 μg/ml) for 6 h. For real-time PCR data are presented as 
a fold relative to WT UT, normalised to HPRT expression and as the mean +/- 
S.E.M. of three independent experiments and were subjected to paired two-tailed 
Student's t test. For type 1 bioassy data are presented as the absorbance at 630 nm 
and are the mean +/- S.E.M. of three independent experiments and were subjected to 
paired two-tailed Student's t test. *, p < 0.05 **, p 0.01; ***, p < 0.001; ns, not 
significant. 
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3.2.35 TRAF6 Polyubiquitination during TLR3 Signalling 
Inhibits IFN-β Expression 
In order to investigate if Pellino3 meditated TRAF6 polyubiquitination is the 
mechanism by which Pellino3 limits TLR3-induced type 1 interferon production, 
HEK293 cells stably expressing TLR3 were subjected to TRAF6-specific 
knockdown and then reconstituted with ectopic WT TRAF6 or  a point mutant of 
TRAF6 (K124R) that is refractory to ubiquitination. Cells were stimulated with 
Poly(I:C) for 6 h and the mRNA extracted. Knockdown of TRAF6 led to a near 
complete loss in Poly(I:C)-induced IFN-β highlighting TRAF6’s key role in the type 
1 IFN pathway (Fig. 3.44a). WT TRAF6 partially rescued TLR3-induced IFN-β but 
the RING mutant of TRAF6 showed greater efficacy in this endeavour suggesting 
that the ubiquitination of TRAF6 is a negative signal in the context of activation of 
TLR3-induced expression of type 1 IFNs. In order to investigate this mutant in pro-
inflammatory signalling, TLR3-induced IL-6 was also examined (Fig. 3.44b). Again, 
TRAF6 knockdown led to a significant decrease in IL-6 expression and this was 
completely rescued with reconstitution of WT TRAF6. In line with previous studies, 
the TRAF6 mutant failed to rescue IL-6 protein levels indicating TRAF6 
polyubiquitination is a positive signal with respect to TLR3-induced expression of 
pro-inflammatory cytokines.  
These data further our mechanistic understanding of not only Pellino3’s 
physiological role in TLR signalling but also highlights a novel pathway in TLR3-
induced type 1 IFN production. TLR3 signalling leads to an upregulation of Pellino3 
and its interaction with TRAF6. Pellino3’s E3 ligase actively facilitates TLR3-
induced polyubiquitination of TRAF6. This modification acts as a regulatory signal 
inhibiting TRAF6-IRF7 interaction and IRF7 polyubquitination. Loss of IRF7 
polyubiquitination results in downregulation of type 1 IFN gene expression. 
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Figure 3.43 TRAF6 ubiquitinates IRF7. 
 
HEKT-TLR3 cells were transfected with empty vector (EV), or expression 
constructs encoding a FLAG-tagged TRAF6 (WT), a FLAG-tagged TRAF6 mutant 
construct containing a non-functional RING-like domain (TRAF6
(C20A)
), a FLAG-
tagged TRAF6 mutant construct that is refractory to ubiquitination (TRAF6
(K124)
) 
and/or a FLAG-tagged IRF7 expression construct. Cell lysates were generated and 
subjected to immunoprecipitation with an anti-IRF7 antibody. Immunoprecipitated 
(IP) samples and whole cell lysates were subjected immunoblotting (IB) for 
ubiquitin, IRF7, FLAG and β-actin as a loading control. Data is representative of 3 
independent experiments. 
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Figure 3.44 Differential effects of ubiquitination of TRAF6 on TLR3-induced 
expression of IFN-β and IL-6.  
 
HEK293-TLR3 cells were left untransfected (Mock) or transfected with siRNA 
targeting GAPDH or TRAF6. Cells were subsequently transfected with a non-protein 
coding empty vector (EV) or an expression constructs encoding WT TRAF6 
(TRAF6) or an expression construct encoding a TRAF6 mutant construct that is 
refractory to ubiquitination (TRAF6
(K124R)
). Cells were left untreated (UT) or 
stimulated with Poly(I:C) (25 μg/ml) for 6 h and subjected to quantitative real-time 
PCR analysis for (a) IFN-β and (b) IL-6.  Data are presented as a fold relative to WT 
UT, normalised to HPRT expression and as the mean +/- S.E.M. of three 
independent experiments and were subjected to paired two-tailed Student's t test. *, p 
< 0.05; **, p < 0.01; ns, not significant. 
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4.1 Discussion 
The rapid initiation of type 1 IFNs by innate immune cells represents a key defence 
strategy to mediate viral eradication from the host. Recognition of the nucleic acids 
present in the viral genome or generated during viral replication has evolved as the 
major mechanism that innate immunity employs to trigger the type 1 IFN protective 
response.  Central to this detection and response are the PRRs. TLRs ligate viral 
motifs and instigate downstream signalling cascades to activate specific transcription 
factors to induce expression of these anti-viral mediators. However, type 1 IFNs, if 
left unchecked, can mediate a number of deleterious outcomes to the host. It is now 
well established that elevated serum levels of IFNs are found in patients with 
autoimmune diseases such as SLE and rheumatoid arthritis, with increased levels 
correlating with disease activity (Hooks et al., 1979). Furthermore, IFN-α/β therapies 
can also directly induce autoimmune phenotypes which include SLE-like disorders 
(Ronnblom et al., 1991).  Recently, a mechanistic understanding of how aberrant 
type 1 IFNs mediate these pathologies has begun to be realised. Elevated type 1 IFNs 
can break peripheral tolerance by the activation of immature DCs which in turn can 
present self-antigen from dying host cells initiating the auto-reactive B and T cells 
that characterise disorders like SLE (Blanco et al., 2001). A strict balance between 
the beneficial viral clearance properties of type 1 IFNs must be weighed against the 
acute and chronic pathologic conditions associated with this dysregulated production. 
Therefore, tight regulation of TLR-induced type 1 IFNs is crucial to prevent 
detrimental levels of cytokine accumulation after viral clearance. For this reason, 
investigation and mechanistic understanding of the regulatory signalling circuitry 
activated by TLRs is a vital prerequisite to potential medical intervention to both 
viral infection and host autoimmunity. 
The aim of this study was to characterise the physiological role of Pellino3  in TLR 
signalling. In order to achieve this goal, the generation of a gene targeted disruption 
of the murine Peli3 gene was commissioned. Deletion of the third protein coding 
exon of Peli3 results in a frameshift in its remaining downstream exons resulting in a 
Pellino3-deficient animal. Peli3
–/– 
mice were viable, developmentally normal and 
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displayed no obvious immuno-deficiencies when housed in specific pathogen free 
housing. Furthermore, to date, there is no evidence of the spontaneous induction of 
autoimmune disease as exhibited in Peli1
–/– 
mice (Chang et al., 2011), found to occur 
in Pellino3-deficient animals. This important observation highlights non-redundant 
roles for the highly conserved mammalian Pellino proteins in control of the adaptive 
immune response. The data provided in this thesis indicates that Pellino3 has no role 
in TLR induction of pro-inflammatory cytokines but plays a key regulatory role in 
controlling TLR3-dependent induction of type 1 IFNs in response to viral dsRNA 
and live viral infection. Pellino3 upregulation during TLR3 signalling facilitates its 
interaction with TRAF6, an essential signal for TRAF6 polyubiquitination. In this 
novel auto-regulatory signalling network, polyubiquitinated TRAF6 can no longer 
bind to or catalyse IRF7 modification thereby terminating the type 1 IFN response.  
Prior to this work, the role of Pellino3 in the innate immune responses was 
investigated using overexpression and RNAi studies. Such approaches implicated 
Pellino3 in contrasting roles in both positive and negative regulatory functions in 
inflammatory signal activation of NF-қB and the MAPKs (Xiao et al., 2008, Butler 
et al., 2005). However, studies into the Pellino proteins in a physiologically setting 
had been restricted to Pellino1. Pellino1 was originally shown to play a critical role 
in TRIF-dependent activation of NF-қB and subsequent pro-inflammatory cytokine 
production during TLR activation (Chang et al., 2009). Interestingly, Pellino3 also 
functions in the TRIF-dependent signalling cascade. However, Pellino3 has no effect 
on pro-inflammatory cytokine expression and instead mediates regulation of TRIF-
dependent signal activation of the type 1 IFNs, the other arm of the TLR3 response. 
Pellino3 was found to specifically function in the TLR3 sub-pathway that induces of 
type 1 IFNs and genes such as IP-10 that are similarly regulated at the transcriptional 
level. The observation that Pellino3 negatively regulates TRIF-mediated induction of 
IFN-β is in agreement with a recent study involving oxLDL derived from 
atherosclerotic lesions (Tzieply et al., 2012). In this study oxLDL signals via the 
scavenger receptor-A1 (SR-A1) and leads to IRAK-induced activation of Pellino3 
and ubiquitination of TANK resulting in inhibition of TBK1-mediated activation of 
IRF3. Such findings in conjunction with the present study highlight a role for 
Pellino3 in a regulatory system that controls production of type 1 IFNs. As type 1 
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IFNs have been implicated in promoting atherosclerosis (Goossens et al., 2010), 
experimental investigation into models of this disorder in the Pellino3-deficient mice 
may provide genetic evidence for a role for Pellino3 in non-viral, and TLR3-
dependent regulation of type 1 IFNs through distinct intracellular mechanisms. This 
is a very interesting concept in light of the fact that Pellino1 facilitates IRF3 
activation of IFN-β in response to RLR receptor RIG-I activation (Enesa et al., 2012). 
One could speculate that the Pellino molecules may act in synchronism to control the 
magnitude and temporal kinetics of a type 1 IFN response. Therefore, investigation 
into the interplay between these two non-redundant family members may further our 
understanding of anti-viral signalling by dsRNA recognition. Although the upstream 
kinases of Pellino1 have been identified as TBK1 and IKKε (Goh et al., 2012), and 
TBK1 is required for Pellino3 upregulation, the role of upstream kinases for Pellino3 
phosphorylation is still unknown in TLR3 signalling. This deficit in our 
understanding of TLR3 signalling requires further attention as phosphorylation is 
known to enhance Pellino protein E3 ligase activity (Ordureau et al., 2008). One 
potential kinase that may serve this purpose is IRAK1, as it has been shown to 
phosphorylate Pellino proteins in vitro (Ordureau et al., 2008). In addition, a recent 
report has indicated that IRAK1 can inhibit TLR3 activation of type 1 IFNs and 
although IRAK1 has other targets and can also inhibit pro-inflammatory cytokine 
production, Pellino3 phosphorylation may be one of the mechanisms it employs to 
inhibit TLR3 signalling (Bruni et al., 2013). Other potential avenues of investigation 
into how Pellino1 and Pellino3 mediate antagonistic control of type 1 IFN may be 
explored with inspection of the primary structure of Pellino3. Pellino3 contains an 
additional 27 aa leader sequence at its N terminus not on either Pellino1 or Pellino2, 
and otherwise Pellino3 exhibits high sequence homology with the other family 
members (~82% aa identity without the leader sequence). The role for this additional 
sequence is still unknown and it may facilitate Pellino3-specific interactions with 
substrates, kinases, E2 ubiquitin conjugating enzymes or influence its expression, 
protein stability or cellular localisation. The delineation of the function of this leader 
sequence will represent a further appreciation of the role of Pellino3 in 
immunobiology. 
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Recently, Pellino1 has also been implicated in the activation of the MAPK pathways 
in the CNS by TLR2 and TLR4 signalling (Xiao et al., 2013). RNAi and 
overexpression studies have also implicated a requirement for Pellino3 in TLR2 and 
TLR4-induced activation of p38 MAPK signalling (Mellett et al., 2011, Butler et al., 
2005). However, experimental evidence provided here indicates that Pellino3 has no 
function in pro-inflammatory cytokine production in response to the TLR2 and 
TLR4 agonists; Pam2CSK, Pam3CSK, Zymosan and LPS. In addition, Pellino3-
deficiency has no adverse effect on TLR3-induced activation of MAPK pathways 
questioning its role, if any, of Pellino3 in MAPK signalling. These discrepancies 
may again in part be explained by the high sequence homology between the two 
family members. Overexpression of Pellino3 may force its interaction with upstream 
proteins and mediate ubiquitination of Pellino1’s substrates; however in a 
endogenous physiological environment, Pellino3 may not be recruited to the given 
signalling intermediate. Additionally, RNAi although very specific may also lead to 
knockdown of very similar transcripts, like that which are present between Pellino1 
and Pellino3 and careful selection of the interfering sequence is vital for specific 
knockdown (Schwarz et al., 2006, Ui‐Tei et al., 2004). Therefore, it is possible that 
some of the roles attributed to Pellino3 by overexpression and RNAi approaches 
may in fact be facilitated by Pellino1 and may explain why Pellino3-deficiency in 
vivo has no effect on NF-қB and MAPK activation during TLR signalling. In 
addition, during RNAi knockdown of Pellino proteins, some functional 
compensation may be exhibited by the other family members obscuring the 
individual proteins functions. 
In order to define if the augmentation of type 1 IFNs exhibited in the Peli3
–/– 
mice 
during anti-viral signalling, played a physiologically relevant role in vivo, mice were 
infected with EMCV, a small non-enveloped single stranded RNA virus that 
produces dsRNA during replication and is recognised by TLR3 (Carocci and 
Bakkali-Kassimi, 2012). EMCV infection primarily targets the heart and brain of the 
host and TLR3-induced expression  of type 1 IFNs is known to protect against 
EMCV as TLR3-deficient animals are more susceptibility to EMCV-induced 
lethality and have higher viral titres and increased pathological damage in their 
cardiac tissue upon EMCV infection (Hardarson et al., 2007a). Conversely, Peli3
–/– 
Chapter 4: Discussion 
176 
 
mice displayed increased survival and EMCV clearance from the heart. In addition, 
Peli3
–/– 
mice did not exhibit the pathological alterations seen in the hearts of control 
animals and this collated to decreased inflammation but increased IFN-β expression 
in the knockout animals. Such findings are consistent with Pellino3 playing a critical 
role in the control of TLR3-induced type 1 IFN production and this increased 
production facilitating enhanced viral elimination from the murine host. Interestingly, 
the major organs of EMCV infection are the heart and brain, two tissues with the 
highest expression of Pellino3 mRNA (Jensen and Whitehead, 2003b). It could be 
speculated that viruses such as EMCV have shaped Pellino3 evolutionary 
conservation in the mammalian genome, by controlling aberrant and even harmful 
levels of type 1 IFN during and after viral infection by orchestrating host 
homeostasis and resolution of the anti-viral immune response. 
Although TLR3 signalling is critical for resistance against EMCV, a member of the 
RLR pathway MDA-5, can also recognise EMCV and Poly(I:C) dsRNA in vivo and 
plays a significant role in type 1 IFN production and anti-viral protection (Gitlin et 
al., 2006, Kato et al., 2006). Therefore, it cannot be ruled out that the increased type 
1 IFN exhibited in the Pellino3-deficient animals may in part be facilitated by 
Pellino3 negatively regulating the MDA-5 pathway. However, in our experimental 
models, both Poly(I:C) and EMCV-induced the expression of Pellino3 mRNA in a 
TRIF-dependent manner. Interestingly, both activators could still induce 
upregulation of Pellino3 mRNA in the absence of the essential MDA-5 adaptor 
MAVS, indicating that TLR3- and TRIF-dependent signalling was responsible for 
Pellino3 upregulation and negative feedback inhibition. As direct application of 
Poly(I:C) is used throughout this study, it was important to distinguish which PRR 
was being triggered by this mode of stimulation. Although both MDA-5 and TLR3 
can also recognise Poly(I:C), MDA-5 requires direct delivery of the dsRNA into the 
cytosol where the receptor is present. Importantly, although transfected Poly(I:C) 
induces IFN-β production in WT cells, no further augmentation is induced in Peli3–/– 
cells. This suggests that Pellino3 does not regulate MDA-5 signalling. In addition, 
direct treatment of Poly(I:C) activates cell surface TLR3 and in the case of 
intracellular TLR3, the dsRNA is internalised by the Clathrin-mediated endocytic 
pathway for endosomal delivery whereby it bypasses the cytosolic MDA-5 (Itoh et 
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al., 2008). Furthermore, direct application of Poly(I:C) upregulates type 1 IFN 
production in a TRIF-dependent manner. Deficiency of MAVS has no effect on 
exogenously administrated Poly(I:C)-induced IFN-β. These data provide strong 
evidence that TLR3-mediated type 1 IFN production is targeted by Pellino3. It was 
also considered that the increased survival of Pellino3-deficient mice in vivo may be 
due to a secondary role of Pellino3 in inhibiting type 1 IFN signalling. This however 
does not seem to be the case as IFN-α4-induced phosphorylation of STAT1 and 
STAT3 displayed similar activation kinetics in BMDCs stimulated ex vivo from WT 
and Pellino3-deficent mice. Although this does not completely rule out an effect of 
Pellino3 on IFNAR signalling during the complexities of an in vivo viral infection, it 
does suggest a non-essential role for Pellino3. Taken together, this data reaffirms that 
Pellino3 is targeting the TLR3 proximal pathway specifically and mediates a 
physiological relevant role during lethal viral infection. 
The data presented in this thesis illustrates a novel negative regulatory system 
whereby Pellino3 is upregulated during TLR3 signalling in order to terminate type 1 
IFN production. In this model, Pellino3 functions by negatively regulating IRF7 
ubiquitination, nuclear translocation and activation. Interestingly, although IRF7 is 
the key mediator of type 1 IFNs in pDCs, Pellino3 deficiency had no effect on TLR 
–signalling in this specialised anti-viral cell type. However, as pDC do not express 
TLR3 or signal through TRIF and instead only utilise Myd88 dependent signalling 
(Honda et al., 2005a), it is plausible that Pellino3 is not upregulated in this cell type 
during TLR activation and therefore cannot mediate negative regulation of the 
pathway. Interestingly, during TLR3 signalling the absence of Pellino3 had no effect 
on TBK1 activation or IRF3 phosphorylation. However, levels of IRF7 
polyubiquitination were greatly increased in the absence of Pellino3 giving rise to 
two hypotheses. The first was that Pellino3 was acting as a direct DUB enzyme for 
IRF7 with Pellino3-mediated deubiquitination of IRF7 serving to inhibit its 
transcriptional activity. However there is no evidence to suggest that Pellino3 
exhibits DUB activity. The other potential mechanism by which Pellino3 negatively 
regulated IRF7 polyubiquitination was by interfering with the E3 ligase that 
ubiquitinates IRF7. IRF7 is reported to be the master regulator of type 1 IFN in 
TLR7/9 signalling in pDCs (Honda et al., 2005a), with TRAF6 E3 ligase activity 
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being essential for the IRF7 antiviral response (Kawai et al., 2004). Although 
TRAF6s role in TLR3-induced NF-қB and MAPK activation is still a matter of 
contention (Gohda et al., 2004, Sato et al., 2003), it stood to reason that TRAF6 may 
serve a specific function for IRF7 similar to that displayed during intracellular 
TLR7/9 signalling. Furthermore, TRAF6 polyubiquitination and activation of IRF7 
was also reported to be induced by the Epstein-Barr virus LMP1. During LMP1 
activation, polyubiquitination of the last 3 lysine residues of IRF7 by TRAF6 was 
shown to be a prerequisite for IKKε mediated phosphorylation and activation of 
IRF7 transcriptional activity (Ning et al., 2008b). The present investigations into 
TRAF6 and IRF7 during TLR3 signalling reveal that a stimulus dependent 
interaction between the E3 ligase and the type 1 interferon transcription factor indeed 
occurred upon dsRNA recognition. Importantly, Pellino3 serves as a potent negative 
regulator of this interaction as increased association is evident in Pellino3-deficient 
cells. Taken together, such findings explain not only the increased ubquitination and 
activity of IRF7 but also the increased serine phosphorylation observed in TLR3 
activated Pellino3-deficient cells. Interestingly, the naturally occurring Thogoto virus 
encodes a virulence factor known as the ML protein that also inhibits the TRAF6-
IRF7 interaction to circumvent host immunity (Buettner et al., 2010). This highlights 
the critical nature of TRAF6 mediated IRF7 activation for type 1 IFN production. It 
is therefore not surprising that a physiological regulatory mechanism has co evolved 
to target this intersection to limit TLR3 mediated signalling.  
In order for Pellino3 to negatively regulate type 1 IFN by modulating TRAF6 
activation of IRF7, it would therefore have to be assumed that TRAF6 is required for 
TLR3 activation of type 1 IFNs. As TRAF6s role in TLR3 signalling is still 
somewhat unclear, it was important to confirm the published observations that 
TRAF6 is essential for Poly(I:C) and EMCV-induced type 1 IFN production (Konno 
et al., 2009). TRAF6-deficient cells displayed a complete loss of TLR3 induction of 
IFN-β expression in line with this previous report. In addition, ablated TLR3-
induced IFN-β expression could be rescued by reconstitution of WT TRAF6 but not 
the C70A E3 ligase dead TRAF6 mutant. These data indicate that TRAF6 and its E3 
ligase activity is vital for TLR3 induction of IFN-β. In confirmation with the seminal 
description of Pellino3, Pellino3 and TRAF6 interaction was observed in an artificial 
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overexpression system (Jensen and Whitehead, 2003c). A critical finding in this 
study demonstrated that under physiological relevant signalling conditions, TLR3 
activation results in Pellino3 association with TRAF6 in a stimulus dependent 
manner. Importantly, this interaction is crucial for TRAF6 polyubiquitination and 
absence of Pellino3 results in a complete abrogation of TLR3-induced TRAF6 
modification. As TRAF6 polyubiquitination can be rescued by retroviral 
reconstitution with WT Pellino3 but not an E3 ligase activity dead mutant, it 
provides strong evidence that Pellino3 acts as an E3 ubiquitin ligase for TRAF6 
during TLR3 signalling. Furthermore, Pellino3s E3 ligase activity is the critical 
mediator of its negative regulatory effects on type 1 IFN production. This indicates 
that Pellino3 polyubiquitination of TRAF6 serves to inhibit TRAF6 activation of 
IRF7. Therefore it is possible that Pellino3 may act as the direct E3 ligase for TLR3-
dependent TRAF6 polyubiquitination or Pellino3 may polyubiquitinate another E3 
ligase critical for TRAF6 polyubiquitination. However, this does not preclude the 
possibility that Pellino3 may function to facilitate TRAF6 auto-ubiquitination. 
Interestingly, TRAF-interacting protein with a forkhead-associated domain (TIFA) 
has been shown to play a vital role in TRAF6s ability to autophosphorylate and 
undergo oligomerisation, properties classically associated with TRAF6’s intrinsic 
ability to activate the TAK1-IKK complex in NF-қB signalling (Lamothe et al., 
2007a, Baud et al., 1999). TIFA interaction with TRAF6 is dependent on the formers 
FHA domain, and results in the recruitment of the E2 ligases Ubc13–Uev1A that 
promote TRAF6 catalytic activity (Ea et al., 2004). As Pellino3 also contains a FHA 
domain, it may associate with TRAF6 and function in similar manner to TIFA 
during TLR3 stimulation. Alternatively, it is possible that TLR3 stimulation results 
in the formation of a Pellino3, TRAF6 and TIFA complex whereby Pellino3 
mediates polyubiquitination of TIFA or an associated protein to facilitate TIFA 
dependent TRAF6 auto-ubiquitination. It is interesting that Pellino3-induced 
polyubiquitination of TRAF6 acts as a negative regulatory signal without inducing 
TRAF6 proteasomal degradation. Recently Pellino1 has been shown to bind TRAF3 
and mediate its K48-linked polyubiquitination to allow TLR-induced MAPK 
activation (Xiao et al., 2013). It is intriguing that both Pellino proteins are involved 
in TRIF-dependent signalling and TRAF protein modification in different TLR 
pathways and the elucidation of the signalling events or cell type restrictions that 
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mediate these phenomena will be fascinating. Importantly, a number of critical 
functions of the Peli proteins may be hidden due to functional redundancy within the 
proteins and the generation of double and triple knockout animals may reveal why 3 
highly related proteins have been so highly conserved throughout mammalian 
evolution.   
Although the exact molecular interactions require further interrogation, what is 
certain is that Pellino3 E3 ligase activity facilitates TRAF6 polyubiquitination and 
this acts a negative regulatory mechanism preventing TRAF6 activation of IRF7. As 
polyubiquitination of TRAF6 is classically associated with its ability to activate 
downstream signalling cascades by the formation of a signalling complex involving 
TAK1 and IKK, the above findings are highly original. Emerging data in the field is 
indicating that TRAF6 can also activate NF-қB in some cases in the absence of auto-
ubquitination and it can also catalyse the formation of free polyubiquitin chains to 
serve this signalling platform purpose (Walsh et al., 2008, Xia et al., 2009). It is 
likely that polyubiquitinated TRAF6 cannot bind IRF7 to high affinity as loss of 
TRAF6 polyubiquitination is associated with increased IRF7 interaction. 
Alternatively, oligomerisation of TRAF6 may mask the IRF7 binding site preventing 
its association and activation of the transcription factor. By employing a cell-based 
overexpression ubiquitination assay, it is clear that TRAF6-induced 
polyubiquitination of IRF7 is critically dependent on TRAF6 E3 ligase activity but 
not on TRAF6’s own posttranslational modification. In fact, TRAF6s own 
polyubquitination site (K124) serves as a negative regulatory site for TLR3-induced 
IFN-β, while this same site is essential for TLR3-mediated activation of the NF-қB 
responsive classic pro-inflammatory cytokine IL-6. These findings also give rise to 
the model that the auto-ubiquitination of TRAF6 may serve as a signalling 
divergence point for TLR activation of pro-inflammatory and anti-viral cytokine 
production.  
In conclusion, the generation of Pellino3-deficient mice has elucidated a specific and 
non-redundant physiological role for Pellino3 in TLR biology. Upon TLR3 
recognition of viral dsRNA, type 1 IFNs are produced to combat viral infection. 
Although vital for host protection and viral clearance, type 1 IFNs must be tightly 
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controlled as excessive production can directly lead to chronic and acute 
autoimmune disease. This thesis describes the identification of a novel auto-
regulatory mechanism employed by TLR3 during anti-viral signalling. TLR3 
upregulates Pellino3 to inhibit type 1 IFN transcription. Pellino3 specifically counter 
regulates TLR3 activation of IRF7. In order to control this process, Pellino3 
facilitates polyubiquitination of TRAF6, a modification that prevents TRAF6 
association with and activation of IRF7 (summarised in Fig. 4.1). These findings 
suggest that Pellino3 may be a critically important and protective protein utilised to 
defend the body against type 1 IFN-mediated autoimmunity. In order to build upon 
these findings, investigation into Pellino3s functionality in patients with autoimmune 
disorders in conjugation with experimental disease models in the knockout mice is 
required. Such exploration could provide important and potential clinically relevant 
insight into the role of the Pellino3 in the physiological regulation of viral and 
autoimmune disease. 
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Fig. 4.1 Pellino3 regulates TLR3-induced type 1 IFN 
Yellow circles marked with a “p” inside represent phosphorylation events, green 
circles with “Ub” represents K63-linked ubiquitination while red circles with “Ub” 
represent K48-linked ubiquitination. Straight Blue arrows represent TRIF-dependent 
signalling. Straight red arrows indicate Pellino3 signalling. Straight green arrows 
represent nuclear translocation. The stripped blue arrow indicates possible TRIF 
signalling. A red “X” indicates Pellino3 inhibition of TLR3-induced IFNβ.
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